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Galectins-1, -3 and -9, are endowed with many immune-regulatory properties, 
with galectins-1 and -9 largely regarded as anti-inflammatory and galectin-3 as 
pro-inflammatory. Expression levels increase in activated adaptive immune 
cells, with peak expression often correlating with peak inflammation. Galectin 
actions are not only determined by their expression levels but also target tissue 
permissibility to galectin binding, which is in turn determined by the profile of 
specific carbohydrate residues, namely N-acetyllactosamine, recognised by 
these lectins. How expression levels and actions are modulated in innate 
immune cells during inflammation has not been systematically characterised. 
This study therefore set out to delineate the effects of inflammation on 
neutrophil glycophenotype, as well as elucidate the temporal and spatial 
modulation of galectins during resolving inflammation. 
The neutrophil glycophenotype was modulated during trafficking with decreased 
levels of all terminal glycan residues assessed. However, this did not correlate 
with galectin binding permissibility suggesting this is not a useful indicator in this 
model. The overall change in glycosylation may theoretically be a consequence 
of rapid modulation of cell surface glycoproteins by activated neutrophils (i.e. 
CD62L shedding) rather than the actions of specific glycosylation enzymes as 
demonstrated in T- and endothelial cells.  
Assessment of galectin levels in leukocytes over a 96h zymosan-induced 
resolving peritonitis demonstrated alterations both spatially and temporally with 
increased galectin-3 expression in neutrophils at the inflammatory site 
compared to the periphery and a peak expression at 24h adding supporting 
evidence that modulation of galectin expression allows delineation of galectin 
responses by neutrophils. This study also demonstrated a novel pro-resolution 
effect of galectin-3 with defective resolution observed in galectin-3 null mice.  
In conclusion this work demonstrated that neutrophil permissibility for galectins-
1, -3 and -9 binding is more likely a consequence of the exposure to galectins at 
specific time points in the resolving inflammatory response rather than due to a 
modulation of the glycophenotype upon activation. This study also 
3 
demonstrated that as well as an important role in the induction of an 
inflammatory response galectin-3 is involved in resolution, a novel finding which 
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GM-CSF Granulocyte-macrophage colony-stimulating factor 
GPCR G protein coupled receptor 
HAEC Human aortic endothelial cell 
HBSS Hanks buffered saline solution 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMVEC Human microvascular endothelial cells 
HRP Horseradish peroxidase 
hrTNF human recombinant tumour necrosis factor-α 
HUVEC Human umbilical vein endothelial cell 







JAM Junctional adhesion molecule 
kDa Kilodalton 
LacNAc N-acetyllactosamine 
LAD Leukocyte adhesion deficiency 
LBG Ligand binding groove 
LEL Lycopersicon esculentum lectin 
LFA Lymphocyte function-associated antigen 
Lgals Lectins, galactoside-binding 
LPS Lipopolysaccharide 
Mac Macrophage-1 antigen 
MAL II Maackia amurensis lectin II 
Man Mannose 
19 
MAPK Mitogen-activated protein kinase 
MCP Monocyte-chemotactic protein 
MerTK Mer receptor tyrosine kinase 
MFI Median fluorescence intensity 
MGAT N-acetylglucosaminyltransferase 
MHC Major histocompatibility complex II 
MMP Matrix metalloproteinase 
MPO Myeloperoxidase 
mRNA Messenger ribonucleic acid 
NADPH Nicotinamide adenine dinucleotide phosphate 
NeuNAc N-acetylneuraminic acid 
NOD Non-obese diabetic 
OSGE O-sialogycoprotein endopeptidase 
PAF Platelet-activating factor 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PECAM Platelet-endothelial cell adhesion molecule 
PerCP Peridinin chlorophyll 
PFA Paraformaldehyde 
PHA-L Phaseolus vulgaris leucoagglutinin 
PMN Polymorphonuclear cell 
PNA Peanut agglutinin 
Poly(I:C) Polyinosinic-polycytidylic acid 
ppGalNAcT Polypeptide N-acetylgalactosaminyltransferase 
Pro Proline 
PS Phosphatidylserine 
PSGL P-selectin glycoprotein ligand 
RCA120 Ricinus communis Agglutinin 120 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute 
Sc subcutaneous 
SEM Standard error mean 
Ser serine 
SNA Sambucus nigra agglutinin 
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SNARE Soluble NSF attachment protein receptor 
SSC Side scatter 
ST3GalT α2,3-sialyltransferase-IV 
ST6Gal α2,6-sialyltransferase-1 
TAE Tris-acetate EDTA 
TGF Transforming growth factor 
Thr Threonine 
Tim T cell immunoglobulin domain and mucin domain 
TLR Toll-like receptor 
TMB 3,3,5,5-tetramethylbenzidine 
TNF Tumour necrosis factor-α 
TRPV1 
Transient receptor potential cation channel subfamily 5 member 
1 
Tyr Tyrosine 
UDP Uridine diphosphate 
UEA Ulex europaeus agglutinin I 
VAMP Vesicle-associated membrane protein 
VCAM Vascular cell adhesion molecule 
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1 Introduction 
1.1 Glycobiology  
Glycosylation is one of the most important post-translational modifications of proteins 
with more than 50% of all mammalian proteins being glycosylated (van Kooyk et al., 
2013). Approximately 10% of the expressed mammalian genome encodes enzymes 
that play a role in the glycosylation process; these include glycosyltransferases and 
glycosidases that add and remove monosaccharides from glycoconjugates respectively 
(Haslam et al., 2008). It was initially believed that glycosylation was restricted to 
eukaryotes however in 1976 Mescher and Strominger discovered a glycoprotein on the 
cell surface of Halobacterium salinarum and this provided the first evidence for 
glycoproteins in other kingdoms of life (Mescher and Strominger, 1976). Glycosylation 
has since been identified in ancient organisms including archaea indicating that it is an 
evolutionarily conserved process and thus is of importance for many facets of life 
(Jarrell et al., 2010).  
The expression of glycosylation enzymes is regulated by the genome however the 
glycophenotype (the total expression of glycoconjugates on the surface of a cell) is 
considered a secondary gene product as glycan chains are modified post-
translationally and can be affected by availability of monosaccharides (Grigorian et al., 
2007, Lis and Sharon, 1993).  
Glycan chains are frequently attached to cell surface proteins or lipids where they form 
glycoproteins and glycolipids respectively; their production is post-translational allowing 
cells of the same type to express different glycophenotypes dependent on the cellular 
environment. Thus unlike protein production, the glycoprotein status of a cell cannot be 
predicted by mRNA expression. This project focuses on the expression and regulation 
of glycoproteins on cells of the immune system with particular focus on those targeted 
by specific galectins, a family of proteins with known immunomodulatory functions.  
Glycoproteins can be subdivided into two groups based on the amino acid in the 
protein chain to which they are bound; N-glycans are attached via an asparagine (Asn) 
residue while O-glycans are attached via a serine or threonine (Ser/Thr) residue. It is 
important to distinguish between the two as each has different binding permissibility for 
lectins.  
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1.1.1 N-Glycan Biosynthesis 
N-glycan formation begins in the rough endoplasmic reticulum where, on the 
cytoplasmic side, two N-acetylglucosamine (GlcNAc) residues are added to a dolichol 
molecule via a uridine diphosphate (UDP)-GlcNAc donor by N-acetylglucosaminyl 
phosphate transferase (GlcNAc-1-phosphotransferase). Five mannose (Man) residues 
are added to the GlcNAc residues by mannosyltransferase enzymes via a guanosine 
diphosphate (GDP)-Man donor. The molecule is then translocated to the lumen of the 
endoplasmic reticulum where a further 4 mannose residues are added by 
mannosyltransferase enzymes via a lipid intermediate, dolichol-P-Man. Finally 
glucosyltransferases add three glucose (Glc) residues to the end of the structure 
(Burda and Aebi, 1999, Kornfeld and Kornfeld, 1985) Figure 1.1. 
 
Figure 1.1: Schematic for the formation of a dolichol-linked precursor molecule in N-glycan 
biosynthesis. On the cytoplasmic side of the endoplasmic reticulum two N-acetylglucosamine 
residues are added followed by five mannose residues. The molecule is then translocated to the 
lumen where four more mannose residues and three glucose residues are added. Adapted from 
(Taylor and Drickamer, 2003). 
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The dolichol precursor molecule is transferred to an Asn residue on a polypeptide by 
an oligosaccharyltransferase enzyme. The Asn molecule is selected based on certain 
criteria: the amino acid sequence must follow the sequence Asn-X-Ser/Thr where X 
can be any amino acid except proline and the asparagine residue must lie in the 
correct position of the three-dimensional protein structure (Kornfeld and Kornfeld, 
1985).  
The first stage of processing is the removal of the three glucose residues and this is 
performed by glucosidases I and II, followed by up to four of the Man residues as 
shown in Figure 1.2. 
 
Figure 1.2: Processing of N-glycans following transfer to an asparagine residue on a polypeptide. 
Glucose residues are removed followed by up to 4 mannose residues depending on the type of N-
glycan being generated. Adapted from (Taylor and Drickamer, 2003). 
The glycoprotein is then translocated to the Golgi apparatus for the final processing to 
take place at which stage the N-glycan produced can be high mannose, hybrid or 
complex type depending on the extent of processing. High mannose N-glycans are 
those that have between five and nine Man residues and no further extensions. 
Complex N-glycans have all but three Man residues removed and each branch is 
extended with GlcNAc via N-acetylglucosaminyltransferase I (MGAT1). These can be 
subdivided into bi-, tri-, or tetra-antennary depending on the number of branches on the 
core structure and these branches can all be extended by N-acetyllactosamine chains 
(galactose bound to GlcNAc – LacNAc); extension usually continues until the chain is 
capped with a sialic acid residue that prevents further elongation. Fucosyltransferases 
also modify complex N-glycans and are important for the generation of sialyl Lewis x 
motifs. Hybrid N-glycans are formed when a GlcNAc is added onto the core structure 
containing three mannose residues, which can be extended but no further processing 
takes place as shown in Figure 1.3 (Kornfeld and Kornfeld, 1985).  
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Figure 1.3: Schematic of the three types of N-glycans: high mannose, hybrid and complex. High 
mannose structures can be modified by N-acetylglucosaminyltransferase 1 to form hybrid structures 
and these can be further modified by mannosidase II and N-acetylglucosaminyltransferase 2 
enzymes to form bi, -tri-, and tetra-antennary complex type N-glycans. Hybrid and complex N-glycans 
can be extended with LacNAc chains. Adapted from (Taylor and Drickamer, 2003). 
1.1.2 O-Glycan Biosynthesis 
O-glycans are generated in a different manner to the N-glycans with each 
monosaccharide added to a glycan chain individually without the production of a 
precursor molecule. Initially an N-acetylgalactosamine (GalNAc) residue is added to 
the protein at a serine or threonine residue by polypeptide N-
acetylglucosaminyltransferase (ppGalNAcT) using UDP-GalNAc as a donor. The 
glycoprotein is then elongated using a variety of enzymes to form one of four core 
structures which each have different binding preferences.  
Core 1 O-glycans are generated by addition of a single galactose (Gal) residue to the 
basal structure by core 1 1,3-galactosyltransferase (T-synthase) and this can be 
further modified by core 2 1,6-N-acetylglucosaminyltransferases (C2GlcNAcT) which 
adds a GlcNAc molecule to the basal structure of the core 1 O-glycan to form a core 2 
structure. Core 3 O-glycans are generated from the initial basal structure but via the 
addition of a GlcNAc by C3GlcNAcT and this can be further modified by C4GlcNAcT, 
which adds a second GlcNAc residue to the core 3 O-glycan as shown in Figure 1.4. 
Each of the core structures can be elongated with LacNAc chains and these are 
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commonly terminated by the addition of sialyl Lewis x motifs by the actions of 
sialyltransferases and fucosyltransferases (Van den Steen et al., 1998). 
 
Figure 1.4: Core 1-4 O-glycan structures and the enzymes used to produce them. Core 1 O-glycans 
are generated by addition of galactose to the core structure, core 2 O-glycans are built onto the core 
1 O-glycans, core 3 O-glycans are generated by the addition of N-acetylglucosamine to the core 
structure and core 4 O-glycans are built onto core 3 O-glycans. Adapted from (Taylor and Drickamer, 
2003). 
1.2 Inflammation 
Inflammation is a physiological process designed to protect against infection or trauma 
by recruiting leukocytes from the circulation with the aim of destroying invading 
pathogens, repairing damaged tissue and restoring homeostasis to the area. This is 
accomplished via the sequential recruitment of leukocytes known as the leukocyte 
adhesion cascade, a term coined to explain the main stages of trafficking: capture and 
rolling, firm adhesion and transmigration (Butcher, 1991).  
Initially neutrophils are captured from the bloodstream and begin to roll on the 
endothelium via interactions of selectins with their glycoconjugate counter-receptors. 
Selectins are a family of calcium-dependent lectins that interact with terminal sialyl 
Lewis x motifs (NeuNAc-2,3-Gal-1,4-(Fuc-1,3)-GlcNAc) expressed on leukocyte 
glycoconjugates (Walz et al., 1990, Lowe et al., 1990). P-selectin and E-selectin are 
up-regulated on the endothelium following activation with pro-inflammatory cytokines 
released from resident macrophages and dendritic cells at the inflammatory site in 
response to injury or infection while L-selectin is constitutively expressed on leukocytes 
(Jung and Ley, 1999, Yang et al., 1999, Patel and McEver, 1997). The selectin-sialyl 
Lewis x interaction, along with secondary stimulation by chemokines released from the 
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inflammatory site and presented at the endothelium, leads to activation of integrins on 
the neutrophil surface, which interact with their respective ligands on the endothelium 
to promote firm adhesion (von Andrian et al., 1991, Laudanna and Bolomini-Vittori, 
2009, Chesnutt et al., 2006). Once adherent neutrophils utilise a range of cell adhesion 
molecules, including platelet-endothelial cell adhesion molecule (PECAM)-1, 
endothelial cell-selectin adhesion molecule (ESAM)-1 and junctional adhesion 
molecule (JAM)-A to traverse the endothelial barrier and travel to the site of 
inflammation (Williams et al., 2011, Woodfin et al., 2009).  
Once at the site of inflammation neutrophils play an important role in pathogen killing 
via phagocytosis, bacteria are detected by pattern recognition receptors such as toll-
like receptors (TLRs) expressed on the neutrophil cell surface and endocytosed into 
phagosomes inside the neutrophil (van Kessel et al., 2014). Following this endocytotic 
process neutrophil nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
becomes activated resulting in increased superoxide generation within the phagosome, 
due to the limited space within the phagosome the concentration of superoxide 
reaches approximately 20μM. Primary granule release into the phagosome also occurs 
leading to concentrations of myeloperoxidase (MPO) in the millimolar range; this MPO 
catalyses the conversion of hydrogen peroxide to hypochlorous acid and the highly 
acidic environment inside the granule is responsible for pathogen killing (Winterbourn 
and Kettle, 2013).  
Aside from the well-organised mechanism of killing pathogens in phagosomes 
neutrophils also release their primary granule contents, including defensins, neutrophil 
elastase and MPO, into the extracellular environment to destroy invading pathogens; 
these mediators are not specific to microbial cells and thus cause damage to the host 
tissue if left unimpeded (Borregaard et al., 1993). To prevent damage to the host a 
second set of phagocytic leukocytes are recruited, the monocytes, which can be 
subdivided into two groups. Classical monocytes release cytokines to destroy any 
pathogens not removed by the neutrophils and are involved in cellular immunity; these 
are considered pro-inflammatory. Non-classical monocytes differentiate into 
macrophages at the inflammatory site and these phagocytose damaged tissue and 
apoptotic neutrophils to allow the tissue to return to homeostasis and are thus 
considered to facilitate/drive resolution (Gordon, 2003, Gordon and Taylor, 2005). 
Recent studies have shown that after a mild inflammatory stimulus the resolution 
phase is followed by population of the inflammatory site with a second wave of 
monocytes composed of monocyte-derived macrophages and tissue resident 
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macrophages; these cells act as a bridge between the innate and adaptive immune 
system before homeostasis can be restored (Newson et al., 2014).  
1.2.1 Mechanisms of Neutrophil Degranulation 
As described in the previous chapter neutrophil degranulation is essential to the 
inflammatory response and consequently is a tightly controlled process. Secretory 
vesicles, tertiary and secondary granules are required for trafficking to an inflammatory 
site and thus require release from the cell via exocytosis while primary granules are 
predominantly released into phagosomes for pathogen killing therefore a mechanism 
needs to be in place to control the release of granules.  
One of the mechanisms in place for controlling sequential release of granules is their 
sensitivity to intracellular calcium flux; secretory vesicles are the most sensitive while 
primary granules are least sensitive however the downstream pathways following this 
activation have yet to be elucidated (Borregaard and Cowland, 1997, Kanaho et al., 
2013).  
Another mechanism by which granule release is controlled is via the binding of vesicle-
associated membrane proteins (VAMPs) expressed on the granule surface to SNARE 
(soluble NSF attachment protein receptor) complexes expressed on the cell 
membrane. Granules contain different VAMPs to allow sequential release; secretory 
vesicles express VAMP-2, tertiary granules express both VAMP-2 and VAMP-7, while 
secondary and primary granules express VAMP-7 only. These proteins bind to SNARE 
complexes composed of soluble NSF associated proteins (SNAPs) and syntaxin-4 
resulting in pore formation and release of the granule either from the cell or into a 
phagosome (Lacy, 2006).  
1.3 Glycosylation in Inflammation 
Glycosylation is of particular importance to the inflammatory process as the 
glycophenotype of an immune cell is crucial to its recruitment, activation and removal 
from inflammatory sites. The effect of glycosylation on leukocyte trafficking has been 
extensively studied using genetically manipulated mice and this has provided a 
framework for the identification of the roles of glycans on immune cells during 
inflammation.  
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1.3.1 Capture and Rolling 
Glycosylation is important at all stages of leukocyte trafficking, especially during 
capture and rolling as these stages are dependent on interactions between selectins 
and sialyl Lewis x motifs expressed on cell surface glycoproteins (Figure 1.5). 
 
Figure 1.5: The role of glycosylation enzymes in neutrophil capture and slow rolling. Neutrophil 
tethering and rolling is mediated by interactions between P-selectin expressed on the endothelium in 
response to inflammatory stimulation and tyrosine sulphated Core 2 O-glycans on PSGL-1 
constitutively expressed on the neutrophil. The expression of the core 2 O-glycans is dependent on 
the actions of ppGalNAcT-1, T-synthase, C2GnT-1, ST3Gal-IV and FucT-VII. Neutrophil slow rolling is 
mediated by interactions between E-selectin expressed on the endothelium in response to 
inflammatory stimulation and N-glycans expressed on CD44/ESL-1, Core 1 O-glycans expressed on 
unknown glycoproteins and Core 2 O-glycans expressed on glycolipids and PSGL-1. Slow rolling is 
dependent on the actions of T-synthase, ST3Gal-IV, FucT-VII and FucT-IV. Loss of the enzymes 
involved at either stage lead to a partial or complete loss of neutrophil trafficking. (Wright and 
Cooper, 2014). 
The initial capture and rolling of leukocytes from the circulation relies on the interaction 
between P-selectin on activated endothelial cells and sialyl Lewis x motifs on 
constitutively expressed P-selectin glycoprotein ligand (PSGL)-1 on leukocytes. Mice 
lacking ppGalNAcT, the enzyme responsible for initiating O-glycan synthesis, 
demonstrate a significantly lower level of capture and rolling compared to wild type 
controls indicating that sialyl Lewis x expressed by PSGL-1 is displayed on core 2 O-
CHAPTER 1: INTRODUCTION 
30 
glycans (Block et al., 2012, Tenno et al., 2007). Similarly mice deficient in C2GlcNAcT-
1 (responsible for core 2 extension) have severely reduced P-selectin-dependent 
leukocyte rolling (Sperandio et al., 2001).  
The importance of β4GalT-1 (which is essential for extending core 2 O-glycans) is 
highlighted by null mice, which have reduced neutrophil recruitment in models of 
zymosan-induced dermatitis and skin wound healing due to defective selectin ligand 
biosynthesis (Asano et al., 2003, Mori et al., 2004).  
Finally sialyl Lewis x motifs are capped with sialic acid and fucose, generated by the 
actions of 2,3-sialyltransferase-IV (ST3GalT-IV) and 1,3-fucosyltransferase-VII 
(FucT-VII) and deletion of either of these enzymes results in mice which have 
significantly reduced leukocyte capture and rolling compared to wild types controls in 
inflamed cremaster models using intravital microscopy (Ellies et al., 2002, Malý et al., 
1996). As glycosylation is imperative for leukocytes to elicit their roles in inflammation a 
large amount of biological redundancy is innate in the system with many enzymes 
capable of compensating in case of loss of one, thus complete inhibition of the 
recruitment pathway usually requires the knock down of multiple enzymes. For 
example although FucT-IV mice have no deficiency in capture and rolling compared to 
wild type mice the remaining response seen in FucT-VII null mice is completely 
abolished in double null mutants (FucT-VII/FucT-IV) suggesting that the FucT-IV 
enzyme can compensate for FucT-VII loss but does not act constitutively (Homeister et 
al., 2001). Fucosylation is of particular importance to leukocyte trafficking as 
demonstrated in patients suffering from leukocyte adhesion deficiency (LAD)-II; these 
patients have a genetic defect in the gene encoding the GDP-fucose transporter and 
thus do not generate selectin ligands. The disease manifests with recurrent bacterial 
infections, persistent leukocytosis and mental and growth retardation (Etzioni et al., 
1992, Frydman et al., 1992, Price et al., 1994).  
Once leukocytes have begun to roll on the endothelium in a P-selectin-dependent 
manner they need to decrease their velocity in order for adhesion and transmigration to 
begin and this is mediated by the interactions of E-selectin with its counter-receptors. 
E-selectin binds PSGL-1 in much the same manner as P-selectin but knock-down of 
PSGL-1 is unable to completely abolish E-selectin-dependent rolling suggesting the 
lectin is able to bind other receptors (Yang et al., 1999). E-selectin also binds to 
fucosylated N-glycans on CD44 and E-selectin ligand (ESL)-1 as removal of O-glycans 
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from myeloid cells using O-sialoglycoprotein endopeptidase (OSGE) does not abolish 
E-selectin-dependent rolling (Katayama et al., 2005, Levinovitz et al., 1993).  
Recent evidence has also demonstrated a role for core 1 O-glycans as E-selectin 
ligands as mice lacking T-synthase, the key enzyme responsible for the formation of 
core 1 O-glycans, in haematopoietic cells show significant reductions in E-selectin-
dependent neutrophil recruitment to the peritoneum in response to thioglycollate 
injection. These mice had a significantly diminished response when compared to the 
C2GlcNAcT-1 null mice suggesting core 1 O-glycans are also E-selectin ligands (Yago 
et al., 2010). 
1.3.2 Firm Adhesion 
E-selectin-dependent slow rolling induces the intermediate activation of integrins on the 
leukocyte surface including Mac-1 (CD11b/CD18) and LFA-1 (CD11a/CD18), full 
activation of the integrins is stimulated by the interactions between chemokine 
receptors on the leukocyte surface and chemokines that are released from activated 
endothelial cells or presented on the surface of endothelial cells following their release 
from other cellular sources (von Andrian et al., 1991, Rot, 1992, Alon and Ley, 2008). 
Chemokines are presented to leukocytes by the endothelium on glycosaminoglycans 
(GAGs) such as heparan sulphate; GAGs are also found in the extracellular matrix and 
this allows formation of an immobilised chemokine gradient that can be followed by the 
leukocytes to the site of inflammation (Patel et al., 2001).  
Chemokine receptors themselves are glycosylated and this increases the binding 
affinity of the chemokine for the receptor, for example 2,6-linked sialic acid is required 
for chemokine binding to CCR5 and CXCR4 (Bannert et al., 2001, Zhou and Tai, 
1999). The role of sialylation has been further investigated using ST3GalT-IV null mice, 
which have decreased CXCR2-mediated firm adhesion as assessed by intravital 
microscopy of the cremasteric microcirculation in mice (Frommhold et al., 2008). The 
ST3GalT-IV null mice also have decreased recruitment of both neutrophils and 
monocytes to the peritoneal cavity in response to CCL2 when compared to wild type 
mice (Döring et al., 2014). As well as altering chemokine affinity, glycosylation of 
chemokine receptors also protects them from proteolytic removal from the cell thus 
prolonging the effect of the chemokine (Ludwig et al., 2000). 
Activated integrins on the PMN surface bind to members of the Ig superfamily on the 
endothelial cell surface including ICAM-1 and VCAM-1. These receptors are 
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themselves glycosylated and N-glycans play important roles in the process of firm 
adhesion. Human ICAM-1 has eight sites that are permissible for N-glycosylation and 
importantly the extent of processing affects the binding of integrins. For example, 
treatment of human umbilical vein endothelial cells (HUVECs) with 
deoxymannojirimycin (DMJ), an inhibitor of mannosidase I that blocks N-glycans from 
being processed past high mannose type, results in increased neutrophil adhesion 
(Bloom et al., 1996). This effect is due to Mac-1 binding preferentially to ICAM-1 with 
simple high mannose N-glycans; it has also been demonstrated that LFA-1 binds to 
ICAM-1 with large complex N-glycans (Diamond et al., 1991). VCAM-1 contains seven 
potential N-glycosylation sites and is decorated with 2,6-linked sialic acid however the 
sialylation of VCAM-1 does not affect VCAM-1-dependent leukocyte adhesion under 
flow conditions and the role of this glycosylation has yet to be determined (Hanasaki et 
al., 1994, Abe et al., 1999) Figure 1.6.  
 
Figure 1.6: The role of glycosylation enzymes in neutrophil firm adhesion. Neutrophil firm adhesion is 
mediated by interactions between integrins expressed by leukocytes and their ligands on the 
activated endothelium. Slow rolling on E-selectin promotes the intermediate activation of the integrin 
molecules and these are fully activated by interactions between chemokines, which are immobilised 
on endothelial glycosaminoglycans, and their GPCR receptors. GPCR receptors require modification 
by ST6GalT-IV to bind chemokines. Once fully active the integrins bind to ICAM-1 and VCAM-1 that 
are N-glycosylated. Loss of enzymes at either stage leads to a partial loss of neutrophil trafficking. 
(Wright and Cooper, 2014). 
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1.3.3 Transmigration 
Transmigration is mediated by a number of adhesion molecules including ESAM-1, 
JAM-A, PECAM-1 and vascular endothelial (VE)-cadherin and although studies have 
shown that many of these are glycosylated it is not yet clear whether this directly 
affects leukocyte trafficking (Figure 1.7).  
 
Figure 1.7: The role of glycosylation enzymes in neutrophil transmigration. Neutrophil transmigration 
is mediated by interactions between cell adhesion molecules expressed on the leukocyte and the 
endothelium including PECAM-1, ESAM-1 and JAM-A. Of these PECAM-1 requires modification by 
ST6Gal-1 to be retained at the cell surface. VE-cadherin is required to disassemble in order for 
trafficking to take place and is known to be glycosylated however it is unclear how this affects 
trafficking. (Wright and Cooper, 2014). 
PECAM-1 is expressed by both the endothelium and leukocytes and forms homophilic 
interactions to initiate the transmigration stage of trafficking (Piali et al., 1995). The 
expression of PECAM-1 on endothelial cells in ST6Gal-1 null mice is reduced when 
compared to wild type cells suggesting sialylation is important for surface retention of 
the adhesion molecule and thus may play an indirect role in trafficking (Kitazume et al., 
2010).  
VE-cadherin is expressed on endothelial cells and forms zipper-like cell-cell 
interactions that maintain vascular integrity during homeostasis and thus prevent 
trafficking; VE-cadherin is required to disassemble in order for leukocytes to pass 
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through the endothelial cells during inflammation (Shapiro et al., 1995). There are 
seven potential N-glycosylation sites on VE-cadherin, all of which are in the 
extracellular domain; these are predominantly sialylated and fucosylated biantennary 
complex N-glycans with some expression of sialylated hybrid-type N-glycans (Suzuki et 
al., 1991, Breviario et al., 1995, Geyer et al., 1999). Studies using bacterially-produced 
VE-cadherin suggested the protein forms trimers at the cell surface however this was 
recently demonstrated to be an artefact caused by a lack of glycosylation and it is now 
believed that the high level of sialylation provides the protein with a negative charge 
thus preventing association with molecules on the same cell and promoting association 
with molecules on opposing cells to maintain the “zipper-like” structure (Legrand et al., 
2001, Bibert et al., 2002, Brasch et al., 2011).  
1.3.4 Modulation of the Glycophenotype during 
Inflammation 
It is known that the glycophenotype of the endothelium is fluid during inflammation and 
is modulated upon pro-inflammatory stimulation, such as tumour necrosis factor (TNF)-
α and disturbed flow, and this leads to an increase in the expression of 
hypoglycosylated N-glycans that are predominantly high-mannose structures (Chacko 
et al., 2011). This modulation has been shown to promote an increase in the local 
adhesion of monocytes under flow and thus the glycophenotype of the endothelium 
has been proposed to act as a “zip code” for directing specific recruitment of 
leukocytes in different vascular beds in response to inflammatory stimuli (Renkonen et 
al., 2002).  
The modulation of the endothelial glycophenotype also impacts the binding of lectins 
such as galectins that have a role in leukocyte trafficking. Treatment of the endothelium 
with immunosuppressive cytokines (such as interleukin (IL)-10 and transforming growth 
factor (TGF)-β) leads to increased expression of complex tri- and tetra-antennary N-
glycans with poly-LacNAc chains and decreased expression of α2,6-linked sialic acid 
residues; this glycophenotype is permissive for the binding of galectin-1, a lectin that is 
known to decrease leukocyte trafficking through the endothelium (Croci et al., 2014, 
Norling et al., 2008). 
There is some evidence to suggest that the glycophenotype of leukocytes is also 
modulated during inflammation. Analysis of neutrophils from healthy volunteers by 
mass spectrometry found the majority of N-glycans were complex bi-, tri-, or tetra-
antennary structures with LacNAc extensions and sialylated and fucosylated branches. 
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The O-glycans were predominantly highly sialylated and fucosylated core 2 structures 
(Babu et al., 2009). The glycophenotype was is also modulated by pro-inflammatory 
stimuli as activation with Formyl-Methionyl-Leucyl-Phenylalanine (fMLP) promoted 
rapid and transient neuraminidase release from secondary and tertiary granules, 
leading to removal of sialic acids from glycoproteins, exposing the underlying glycans 
and allowing binding of lectins (Cross and Wright, 1991, Cross et al., 2003). It is not yet 
clear how the glycophenotype is modulated during the process of neutrophil trafficking 
through the endothelium.  
1.4 Galectins 
Galectins are a family of lectins that are defined as having “affinity for β-galactosides 
and significant sequence similarity in their carbohydrate binding sites, the relevant 
amino acids of which have been determined by X-ray crystallography” (Barondes et al., 
1994). Studies have identified 15 mammalian galectins, which are numbered 
sequentially based on date of discovery, however one of these (galectin-11) has since 
been designated ‘galectin-like’ as it does not bind β-galactoside (Cooper et al., 2012, 
Leffler et al., 2004). Galectin-10 is also potentially galectin-like as it preferentially binds 
mannose and not β-galactoside (Swaminathan et al., 1999). Galectins have been 
found in all animal kingdoms as well as plants and fungi and are therefore 
evolutionarily conserved suggesting many important roles for this family of proteins 
(Leffler et al., 2004). 
Of all the galectins, three have been identified to play important roles in innate 
immunity; these are galectin-1, galectin-3 and galectin-9 and thus will be the focus of 
this project (Dias-Baruffi et al., 2010, Cherayil et al., 1989, Kim et al., 2007, Wada and 
Kanwar, 1997, Wada et al., 1997).    
1.4.1 Structure 
Galectin-1 was initially discovered in the electric eel where it was termed electrolectin, 
since then many galectins have been identified in various species, tissues, and cell 
types, all of which were differently named depending on the source and the investigator 
(Teichberg et al., 1975). This led to confusion and an inability to link different reports of 
structure and function; therefore in 1993 the galectins were characterised into three 
subtypes depending on their structural characteristics in an attempt to provide some 
clarity to the various members of the family as shown in Figure 1.8 (Hirabayashi and 
Kasai, 1993).  
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Figure 1.8: Schematic of the structure of the three subtypes of galectins. Prototype galectins have a 
single CRD; chimeric galectins have a single CRD with an extended N-terminus and tandem repeat 
galectins have two distinct CRDs joined by a short linker peptide.  
Prototype galectins have a single carbohydrate recognition domain (CRD) and can 
homodimerise physiologically to exert their effects; these include galectins-1, -2, -5, -7, 
-10, -13 and -14 (it has since been shown that galectin-5, -7 and -10 can exist as 
monomers under physiological conditions) (Hirabayashi and Kasai, 1993). Galectin-3 is 
the only known chimeric galectin, it has a single CRD linked to an extended non-lectin 
region (Hirabayashi and Kasai, 1993). Tandem-repeat galectins have two distinct 
CRDs with different binding properties that are joined by a short-linker peptide; it was 
initially postulated that proteolytic cleavage of the linker peptide enabled each CRD to 
elicit its effects however it is now known that both CRDs as well as the linker peptide 
are essential for the effects of the protein through increasing signalling potency (Earl et 
al., 2011). Tandem-repeat galectins include galectins-4, -8, -9, -12 and -15 
(Hirabayashi and Kasai, 1993).  
The X-ray crystallography structure of the CRD was determined in 1993 by Lobsanov 
and colleagues who determined that each monomer is composed of eleven strands 
arranged in a β-sandwich with five strands in one sheet and six strands in the other 
(Lobsanov et al., 1993). The CRD consists of 135-140 amino acids however only four 
are conserved between the entire galectin family, these are a glycine at position 25, a 
tryptophan at position 80, a glutamic acid at position 83 and an arginine at position 
125. These conserved amino acids reside in a structure known as the ligand binding 
groove (LBG), the part of the CRD where the β-galactoside residue binds (Di Lella et 
al., 2011). Although only these four amino acids residues are conserved there is high 
homology between the other residues in the CRD especially between galectins of the 
same subtype (Guardia et al., 2011).  
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1.4.2 Expression 
Galectins are soluble proteins found throughout all cellular compartments however it is 
also well documented that they are found in the extracellular environment where they 
act on cell surface receptors to elicit their effects however extensive analysis of the 
genes confirms the proteins do not express a secretion signal sequence (Hughes, 
1999), thus they join proteins such as Annexin A1 (AnxA1) in being exported from the 
cell by an as yet unknown mechanism (March et al., 1985, Perretti and D'Acquisto, 
2009). Until 2001 IL-1β was included in this category however it was determined that it 
is secreted via microvesicles that are released from monocytes in response to an 
increase in cytosolic calcium, this mechanism has yet to be assessed for galectin 
secretion (MacKenzie et al., 2001). 
Of the fifteen galectins described in the literature eleven are expressed in humans. 
Galectins-1, -3 and -9, known to elicit immunomodulatory functions, are as would be 
expected, expressed in cells pertinent to the inflammatory response with expression 
levels modulated in response to inflammatory mediators.  
1.4.2.1 Endothelial Cells 
Vascular endothelial cells are known to express low levels of galectins-1, -3 and -9 
under basal conditions but this is modulated in response to activation of the cells 
(Thijssen et al., 2008). Galectin-1 expression is increased upon activation of HUVECs 
with human serum or lipopolysaccharide and in human aortic endothelial cells (HAECs) 
following stimulation with minimally oxidised low-density lipoprotein (Baum et al., 
1995). The increased expression of galectin-1 seen following activation correlates with 
a localisation of the protein to the cell surface (Thijssen et al., 2008). Galectin-3 in 
HUVECs is up-regulated upon activation with IL-1 (50ng/mL) for 4 hours (Rao et al., 
2007). However in vivo studies have shown a decrease in the expression of galectin-3 
in rat endothelial cells following 4-hour carrageenan-induced peritonitis (Gil et al., 
2006b)(Gil et al., 2006b). Galectin-9 is also increased in HUVECs following stimulation 
with interferon- (10ng/mL) or polyinosinic-polycytidylic acid (poly-IC), a double-
stranded RNA (Alam et al., 2011, Ishikawa et al., 2004, Imaizumi et al., 2002). 
1.4.2.2 Monocytes and Macrophages 
Galectin-1 is detected on the surface of isolated human monocytes under basal 
conditions, levels are unaltered upon classical activation of the cells to an M1 
phenotype but surface levels increase upon alternative activation to M2 monocytes 
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(Novak et al., 2012). Galectin-1 is also detected in macrophages from sputum samples 
and expression is significantly decreased in asthmatic patients (Sanchez-Cuellar et al., 
2012). Galectin-3 is highly expressed by human and murine monocytes and 
macrophages and levels increase in correlation with the differentiation of the cell; 
murine alternative macrophages express significantly more galectin-3 than classical 
macrophages (Ho and Springer, 1982, Sato and Hughes, 1994, MacKinnon et al., 
2008, Novak et al., 2012). Upon activation with calcium ionophore (A23187) the 
expression of galectin-3 significantly decreases and this coincides with an increase in 
the extracellular environment confirming the lectin is being released from the cell (Liu 
et al., 1995). Resident peritoneal macrophages express low levels of galectin-3, these 
cells are a distinct population of macrophages that are derived from the yolk sac during 
embryogenesis and these differentiate to repopulate the peritoneal cavity following 
depletion (Yona et al., 2013). Galectin-9 is expressed in human macrophages collected 
from sputum samples in healthy volunteers and, similar to galectin-1, levels are 
significantly decreased in asthmatic patients (Sanchez-Cuellar et al., 2012).  
1.4.2.3 Neutrophils 
Galectin expression in both human and murine neutrophils is negligible, although there 
are reports of modification during inflammation. Galectin-1 expression is significantly 
decreased upon human neutrophil adhesion to an endothelial monolayer in vitro (Gil et 
al., 2006b)(Gil et al., 2006b). The expression of galectin-3 in neutrophils is somewhat 
controversial and appears to be species-dependent as a report by Gil et al showed an 
increase in the expression of the protein following carrageenan-induced peritonitis in 
recruited neutrophils in a rat model while Sato and colleagues showed no expression 
of the protein in murine neutrophils that were recruited to the air pouch in response to 
lipopolysaccharide (LPS) (Gil et al., 2006b, Truong et al., 1993, Farnworth et al., 2008, 
Sato et al., 2002b). This discrepancy may be a result of the differences in detection 
methods; Gil and colleagues used immunofluorescence to assess the expression of 
galectin-3 in situ while Sato et al plated exudate from the air pouch onto plastic and 
collected the non-adherent neutrophils before analysis by western blot, a method which 
may have lacked the sensitivity to detect low levels (Gil et al., 2006b, Sato et al., 
2002b). Human neutrophils express low levels of galectin-3 and this is not modulated 
upon transendothelial migration (Gil et al., 2006b)(Gil et al., 2006b), the lectin could 
also be detected in neutrophils from sputum samples collected from healthy and 
asthmatic patients and no difference was seen between the two groups (Sanchez-
Cuellar et al., 2012). 
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1.4.3 Function 
Although galectins bind specifically to LacNAc residues they do so with relatively low 
affinity, this is increased by up to 100-fold by arrangement of the LacNAc residues into 
repeating chains (Rabinovich and Toscano, 2009, Ahmad et al., 2002). They bind 
residues expressed on cell surface glycoproteins and form galectin-glycoprotein 
lattices as shown in Figure 1.9.  
 
Figure 1.9: Galectin functions on a single cell and between cells. A. Galectins can cross-link 
receptors on a cell surface to induce signal transduction, they can bind receptors to inhibit the 
binding of alternative ligands and they can cluster receptors to allow other ligands access to their 
receptors. B. Galectins can cross-link cells to promote cell-cell adhesion or cells to extracellular 
matrix to promote cell-matrix adhesion. 
Galectins can cross-link receptors on the same cell leading to activation of signalling 
pathways, inhibition of other ligands binding to the receptors or even increase binding 
by clustering inappropriate receptors out of the way allowing ligands to reach their 
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receptors (Rabinovich et al., 2007). The galectins can also cross-link receptors 
between cells or between cells and extracellular matrix proteins to promote adhesion 
(Rabinovich et al., 2007). The functions of galectins-1, -3 and -9 upon binding to their 
ligands will be discussed individually.  
1.4.4 Galectin-1 
Galectin-1 is a 14 kilodalton (kDa) prototype galectin that homodimerises under 
reducing conditions via specific amino acids in its N-terminus; the monomer is also 
bioactive but has a lower affinity for ligands than the dimeric form; this is important as 
both forms can be detected in solution (Cho and Cummings, 1995, Hirabayashi and 
Kasai, 1984, Leppänen et al., 2005, Giudicelli et al., 1997). Galectin-1 can be oxidised 
or reduced reversibly, which is important as reduced galectin-1 has immunoregulatory 
and pro-apoptotic properties while oxidised galectin-1 has no effect on immune cells 
(Guardia et al., 2014). The highly oxidative environment at inflammatory sites facilitates 
the oxidation of galectin-1 allowing leukocytes to be recruited and elicit their effects 
without being impeded by the anti-inflammatory properties of the lectin. As the 
leukocytes migrate away from the inflammatory site into healthy tissue the environment 
normalises and the reduced galectin-1 homodimerises to elicit its effects and protect 
healthy tissue (Stowell et al., 2009a).   
Galectin-1 binds preferentially to LacNAc monomers expressed on core 2 and core 4 
O-glycans or bi-antennary complex N-glycans and the binding is inhibited by the 
presence of an α2,6-linked, but not by α2,3-linked, sialic acid residues as the lectin 
binds to the terminal motif (Stowell et al., 2004, Stowell et al., 2008a, Leppänen et al., 
2005). 
Many of the studies assessing galectin-1 functions have been performed on T cells as 
the lectin plays an important role in chronic inflammatory diseases where it has been 
designated anti-inflammatory. Galectin-1 promotes the apoptosis of human and murine 
Th1 and Th17 cells while having no effect on Th2 cells due to differential glycosylation 
of the cells; Th1 and Th17 cells express high levels of LacNAc on their surfaces which 
are permissive for galectin-1 binding while on Th2 cells these residues are capped with 
2,6-linked sialic acid that blocks galectin-1 binding (Toscano et al., 2007). The 
LacNAc residues on Th1 and Th17 cells are expressed on core 2 O-glycans of CD7, 
CD43 and CD45, upon galectin-1 binding CD43 and CD45 are sequestered on the cell 
surface leaving CD7 isolated and this initiates the apoptotic caspase pathway (Pace et 
al., 1999, Brandt et al., 2008, Galvan et al., 2000).  
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1.4.4.1 Galectin-1 in Animal Models of Inflammation 
Galectin-1 null mice were generated and exhibit no phenotypic abnormalities under 
standard conditions except for a deformity in olfactory nerve development; these mice 
do have deficiencies when challenged as discussed below (Poirier and Robertson, 
1993, Puche et al., 1996). Galectin-1 null mice have been subjected to various 
inflammatory pathologies in order to assess the phenotype when challenged as shown 




Increased susceptibility to disease (Toscano et 
al., 2007) 
Collagen-induced Arthritis 
Increased severity of disease (Iqbal et al., 
2013) 
Graft vs Host Disease 
Earlier rejection of skin grafts (Moreau et al., 
2012) 
Interleukin-1 Intravital Microscopy 
Decreased leukocyte adhesion and emigration 
(Cooper et al., 2008) 
Experimental Acute Myocardial 
Infarction 
Increased inflammation and damage (Seropian 
et al., 2013) 
Carrageenan-induced Paw 
Oedema 
Reduced leukocyte recruitment in the second 
half of an inflammatory response (Iqbal et al., 
2011) 
Table 1-1: Overview of the phenotype of galectin-1 null mice subjected to various inflammatory 
pathologies. 
Galectin-1 null mice have increased susceptibility to experimental autoimmune 
encephalomyelitis and significantly more pathological signs of collagen-induced 
arthritis compared to wild type mice and this correlates with an increase in interleukin-
17 and interferon- levels suggesting an increased number of Th1 and Th17 cells 
compared to control (Toscano et al., 2007, Iqbal et al., 2013). Galectin-1 null mice have 
also been used to study the innate immune response using intravital microscopy to 
visualise the microvasculature following activation with IL-1 where increased 
leukocyte recruitment was observed compared to wild type mice (Cooper et al., 2008). 
Paw oedema was induced in galectin-1 null mice using carrageenan and this led to 
reduced leukocyte recruitment in the second half of the inflammatory response, as 
galectin-1 is an anti-inflammatory protein this was an unexpected finding however it 
was also demonstrated that galectin-9, a second anti-inflammatory member of the 
galectin family, was increased in these mice.   
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Through the induction of T cell apoptosis galectin-1 is able to attenuate many T cell-
driven pathologies as demonstrated by several groups using recombinant galectin-1 in 
various models of inflammation as shown in Table 1-2.  







single dose with 
antigen or at onset of 
clinical symptoms 
Preventative and therapeutic 





(ip) daily for 11 days 
beginning at onset of 
clinical symptoms 
Skewing from Th1 to Th2 
profile and attenuation of the 






30 minutes prior to 
Con-A administration 
Decreased pro-inflammatory 
cytokine production and 
increased T cell apoptosis 
(Santucci et al., 2003) 
Graft vs Host 
Disease 
Mice 
250g/ip three times 
weekly from bone 
marrow transplant 
until death 
Amelioration of weight loss, 
inflammatory destruction of 
target organs and mortality 





400g/iv daily for 7 
days following TNBS 
injection or starting 2 
weeks after onset of 
clinical symptoms 
Protective and therapeutic 





50g/ip every other 
day for 1 week either 
week 1 or week 3 
after disease 
induction 
Suppression of pathology 





100g/ip single dose 
3 minutes prior to 
reperfusion 
Attenuation of pathology 






single dose 30 
minutes prior to 
phospholipase A2 
Decreased leukocyte 





0.3g/ip single dose 1 
hour prior to IL-1β 
administration 
Decreased neutrophil 
recruitment to peritoneal 
cavity (La et al., 2003) 
Table 1-2: Overview of the phenotype of mice following use of recombinant galectin-1 in animal 
models of inflammation. 
The effects of exogenous galectin-1 have been studied by administration of 
recombinant protein to animals at different stages of the inflammatory process in 
different disease models and these studies provide evidence that galectin-1 is able to 
both prevent and treat many inflammatory conditions. The first evidence of an anti-
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inflammatory role for galectin-1 came from its effect in a model of experimental 
autoimmune myasthenia gravis. Rabbits were administered 100µg of galectin-1 both 
prophylactically and therapeutically with both schedules leading to prevention and 
attenuation of clinical symptoms respectively (Levi et al., 1983). The majority of the 
literature has since focused on the effects of galectin-1 in T cell driven models such as 
collagen-induced arthritis, Concanavalin-A-induced hepatitis and Trinitrobenzene 
Sulphonic acid-induced colitis; these have been performed using doses of rGal-1 from 
20g - 400g per mouse and these all promoted amelioration of disease due to 
induction of apoptosis in Th1 and Th17 cells (Rabinovich et al., 1999, Santucci et al., 
2003, Baum et al., 2003, Toscano et al., 2006, Seropian et al., 2013).  
The first study to investigate the role of galectin-1 in a model of innate immunity was 
performed by Rabinovich et al (1992) in a model of phospholipase A2-induced paw 
oedema. Rats were administered 5ng of galectin-1 into the paw 30 minutes before 
phospholipase A2 and decreased leukocyte recruitment was seen (Rabinovich et al., 
2000). In another study mice were given 0.3µg rGal-1 in a model of neutrophil-driven 
inflammation, interleukin-1-induced peritonitis; these mice showed decreased 
neutrophil recruitment to the peritoneal cavity (La et al., 2003). The mechanisms by 
which galectin-1 exerts its anti-inflammatory effects have yet to be fully elucidated, 
however it is known to bind innate immune cells and elicit various responses as 
discussed below.  
1.4.4.2 Monocytes and Macrophages 
Galectin-1 binds to an as yet unknown receptor on human monocytes and promotes 
increased expression of Fc receptor 1 (FCR1) leading to increased phagocytosis and 
a decreased expression of major histocompatibility class II (MHC II) thus decreasing 
the ability of monocytes to act as antigen presenting cells (Barrionuevo et al., 2007). 
The lectin is chemotactic for human monocytes, but not human macrophages, via a 
p44/42 mitogen activated kinase (MAPK) pathway (Malik et al., 2009) and galectin-1 is 
able to convert murine macrophages to a pro-resolving phenotype, characterised by 
expression of 12/15-lipoxygenase and loss of phagocytic capacity, which is important 
for the resolution of the inflammatory response (Rostoker et al., 2013).  
1.4.4.3 Neutrophils 
Almkvist and colleagues demonstrated increased binding of galectin-1 to human 
neutrophils that had exudated compared to those in the peripheral circulation (Almkvist 
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et al., 2002). Once bound to its counter-receptors on neutrophils galectin-1 is able to 
induce a reversible exposure of phosphatidylserine (PS), which is not linked to an 
increase in apoptosis of the cells but acts as an ‘eat-me’ signal inducing preaparesis of 
the neutrophils by monocytes, an act that may serve to limit damage to healthy tissue 
(Stowell et al., 2009b, Dias-Baruffi et al., 2003). Galectin-1 also inhibits platelet-
activating factor (PAF)-induced CD11b upregulation and decreased neutrophil-
endothelial interactions and neutrophil chemotaxis (Cooper et al., 2008, La et al., 
2003).  
 
Figure 1.10: Summary of the effects of galectin-1 on immune cells. The effects of galectin-1 on 
lymphocytes, monocytes, neutrophils and endothelial cells as determined by studies on isolated 
human cells and in vivo using wild type and galectin-1 null mice.  
1.4.5 Galectin-3 
Galectin-3 is a 29kDa chimera type galectin that oligomerises in solution via its 
extended N-terminus to form multimers that can cross-link heterogeneous receptors 
(Ahmad et al., 2004). The non-lectin N-terminus is composed of repeats of the amino 
acid sequence (Tyr-Pro-Gly-Pro-Glu-Ala-Thr-Pro-Ala-Pro-Gly-Ala), which is repeated 
ten times in murine galectin-3 and five times in human galectin-3 (Albrandt et al., 1987, 
Cherayil et al., 1990). The N-terminus is a target for matrix metalloproteinases (MMP)-2 
and -9 and this cleavage inhibits oligomerisation of galectin-3 and its ability to cross-
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link receptors and thus many of the effects of galectin-3 on cells (Hsu et al., 1992, 
Yang et al., 1998, Ochieng et al., 1994, Yamaoka et al., 1995).  
Galectin-3 binds preferentially to poly-LacNAc residues with at least 3 repeats of the 
sequence expressed on N-glycans elongated by N-acetylglucosaminyltransferase V 
(MGAT5). The lectin is able to bind in the presence or absence of sialic acid residues 
as it binds internal residues on a glycan chain and it’s binding is improved in the 
presence of α-fucose (Rabinovich and Toscano, 2009, Henrick et al., 1998, Stowell et 
al., 2008a). 
1.4.5.1 Galectin-3 in Animal Models of Inflammation 
Like their galectin-1 null counterparts, galectin-3 null mice exhibit few phenotypic 
alterations when not challenged with the exception of reduced cellularity in their bone 
marrow when compared to littermate controls under standard conditions (Brand et al., 
2011, Colnot et al., 1998a). It was initially postulated that galectin-1 and galectin-3 
might compensate for each other however galectin-1/galectin-3 double null mutant 
mice have no overt phenotypic abnormalities confirming that these lectins have distinct 
actions (Colnot et al., 1998a). 
Further studies have been performed using the galectin-3 null mice in models of 
inflammatory disease as summarised in Table 1-3.  
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Pathology Outcome 
Hepatic Fibrosis Reduced fibrosis (Henderson et al., 2006) 
Ovalbumin-induced Asthma 
Decreased airway hypersensitivity with decreased 
Th2 responses but increased Th1 responses 
(Zuberi et al., 2004) 
Experimental Autoimmune 
Encephalomyelitis 
Milder disease and reduced leukocyte infiltrate 
(Jiang et al., 2009) 
Antigen-induced Arthritis 
Suppression of joint damage and decreased 
cytokine production (Forsman et al., 2011) 
LPS-induced Septic Shock Increased susceptibility (Li et al., 2009) 
Thioglycollate-induced Peritonitis 
Reduced neutrophil and monocyte recruitment not 
associated with increased apoptosis or 
phagocytosis (Colnot et al., 1998b, Hsu et al., 
2000) 
Wound Healing 
Slower wound healing, could be rescued by 
galectin-7 administration (Cao et al., 2002) 
Pneumococcal Pneumonia with 
Streptococcal pneumoniae 
Increased bacteraemia and lung damage, 
decreased phagocytic capability of macrophages – 
can be rescued by administration of recombinant 
galectin-3 (Farnworth et al., 2008) 
Respiratory Tularaemia 
Decreased leukocyte infiltration and augmentation 
of sepsis development (Mishra et al., 2013) 
Parasitic protozoan cutaneous 
infection with Leishmania major 
Decreased neutrophil recruitment in initial 48 hours 
followed by normalisation to wild type levels, 
significantly increased parasitic burden – can be 
rescued by administration of recombinant galectin-
3 (Bhaumik et al., 2013) 
Table 1-3: Overview of the phenotype of animal models of inflammation in galectin-3 null mice. 
Galectin-3 was initially designated a pro-inflammatory lectin due to its roles in T cell-
driven inflammatory disease including hepatic fibrosis, ovalbumin-induced asthma, 
experimental autoimmune encephalomyelitis, all of which were attenuated in the 
galectin-3 null mice; this is most likely due to the ability of galectin-3 to skew the T cell 
profile from Th2 towards Th1 and Th17-driven pathology (Henderson et al., 2006, 
Zuberi et al., 2004, Jiang et al., 2009). Recent studies have demonstrated a role for 
galectin-3 in innate immunity protecting against specific infectious stimuli potentially by 
acting as a danger-associated molecular pattern (DAMP) (Bhaumik et al., 2013). 
Infection with Streptococcus pneumoniae or Leishmania major is considerably more 
severe in galectin-3 null mice compared with wild type animals but no differences were 
seen in the response to Escherichia coli infection; these protective effects were 
rescued by administration of recombinant galectin-3 (Farnworth et al., 2008, Bhaumik 
et al., 2013, Sato et al., 2002b). This may be linked to the ability of galectin-3 to 
promote the recruitment of leukocytes to inflammatory sites as demonstrated by a 
reduction of neutrophil and monocyte recruitment in galectin-3 null mice in models of 
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thioglycollate-induced peritonitis and wound healing (Colnot et al., 1998b, Hsu et al., 
2000, Cao et al., 2002).  
The ability of galectin-3 to act as a leukocyte chemoattractant was confirmed in the 
murine dorsal air pouch. Injection of galectin-3 into the air pouch resulted in recruitment 
of monocytes (Sano et al., 2000). 
Pathology Species Dose Outcome 
Dorsal Air Pouch Mouse 
1µM/subcutaneous 
(sc) single dose 4 
hours prior to 
exudate collection 
Increased recruitment of 
monocytes than induced by 
monocyte chemoattractant 
protein (MCP)-1 (Sano et al., 
2000) 
Table 1-4: Overview of the phenotype of mice following use of recombinant galectin-3 in animal 
models of inflammation. 
Mechanistic insights into the effect of galectin-3 on innate immunity have been 
provided by in vitro studies.  
1.4.5.2 Endothelial Cells 
High concentrations (1g/mL, equivalent to 32nM) of galectin-3 promote the release of 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-6 from HUVECs and human microvascular 
endothelial cells (HMVECs) in vitro, these cytokines act in an autocrine or paracrine 
manner to up-regulate E-selectin, ICAM-1 and VCAM-1 on endothelial cells (Chen et 
al., 2013) which may explain some of the effects of galectin-3 on leukocyte trafficking. 
As well as actions on the endothelium, galectin-3 also directly affects leukocytes. 
1.4.5.3 Monocytes and Macrophages 
It acts cooperatively with LPS to promote increased expression of IL-1β from human 
monocytes (Jeng et al., 1994); it also cross-links CD13 expressed on human monocyte 
cell surfaces to promote homotypic aggregation (Mina-Osorio et al., 2007).  Studies 
using a Boyden chamber have demonstrated an ability of galectin-3 to act as a 
chemoattractant for both human monocytes and macrophages (Sano et al., 2000). 
Whilst murine galectin-3 null macrophages exhibit defective phagocytic capabilities 
compared to wild type cells confirming the role of the lectin as an opsonin (Sano et al., 
2003, Farnworth et al., 2008, Karlsson et al., 2009). Presence of galectin-3 is able to 
increase both the proportion of macrophages that can phagocytose and the number of 
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cells phagocytosed per macrophage leading to a large increase in net phagocytosis 
(Karlsson et al., 2009); this may be due to the lectin “bridging” phagocytic prey to the 
phagocytes via the Mer receptor tyrosine kinase (MerTK) (Caberoy et al., 2012). 
Galectin-3-deficient macrophages have defective alternative activation; perhaps 
suggesting the resolution of inflammation would be impaired in the galectin-3 null mice 
(MacKinnon et al., 2008). This hypothesis is strengthened by a recent study which 
showed galectin-3 (60g/mL) increases the production of IL-10 from human monocytes 
when co-cultured with a TLR1/TLR2 ligand (19-kD lipopeptide) and this inhibits the 
GM-CSF-induced differentiation into dendritic cells thus reducing inflammation (Chung 
et al., 2013).  
1.4.5.4 Neutrophils 
Resting human neutrophils express low levels of the receptors for galectin-3 (CD66a 
and CD66b) when compared to activated cells as they are released from secondary 
granules; thus providing an explanation for the lack of response to the lectin by 
peripheral blood neutrophils (Almkvist et al., 2001, Feuk-Lagerstedt et al., 1999). Upon 
binding to the activated neutrophil galectin-3 increases the phagocytic capability, 
degranulation and the production of reactive oxygen species (ROS); the lectin can also 
cross-link neutrophil receptors to laminin and promote adhesion of the cells (Fernández 
et al., 2005, Kuwabara and Liu, 1996, Farnworth et al., 2008, Yamaoka et al., 1995). 
Addition of exogenous galectin-3 to neutrophils promotes survival of the cells and this 
may be due to the ability of the lectin to activate the neutrophil (Farnworth et al., 2008, 
Hsu et al., 2000).  
Like galectin-1, galectin-3 is able to induce the exposure of PS on the human 
neutrophil cell surface without a concurrent induction of apoptosis and this promotes 
the preaparesis of neutrophils by monocytes and macrophages (Stowell et al., 2008b). 
This suggests galectin-3 may play a role not just in the initiation of the neutrophil-driven 
inflammatory response as described above but may also be involved in the clearance 
of neutrophils once their function is completed, yet further work is required to assess 
this pathway.  
Limited experimentation has been performed on the role of galectin-3 in murine 
neutrophils due to published reports suggesting murine neutrophils do not express the 
lectin (Sato et al., 2002b, Farnworth et al., 2008). However contrary to this hypothesis it 
is known that galectin-3 plays a role in neutrophil recruitment as galectin-3 null mice 
have decreased numbers of neutrophils recruited in models of thioglycollate-induced 
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peritonitis and pneumococcal pneumonia compared to wild type mice, a phenotype that 
can be rescued by the use of recombinant galectin-3 (Colnot et al., 1998b, Hsu et al., 
2000, Henderson et al., 2006). This may be due to the ability of the lectin to cross-link 
cells to the extracellular matrix thus acting directly as an adhesion molecule, as 
demonstrated in 2-integrin-independent transmigration (Sato et al., 2002b).  
 
Figure 1.11: Summary of the effects of galectin-3 on immune cells. The effects of galectin-3 on 
lymphocytes, monocytes, neutrophils and endothelial cells as determined by studies on isolated 
human cells and in vivo using wild type and galectin-3 null mice.  
1.4.6 Galectin-9 
Galectin-9 is a 36kDa tandem-repeat lectin that has two functionally distinct CRDs; the 
murine C-terminal CRD is 70% homologous to rat galectin-5 while the N-terminal CRD 
is 40% homologous to murine galectin-3, the two CRDs are only 35% identical (Nagae 
et al., 2006). There are five known isoforms of galectin-9 that are produced by splice 
variation and three of these differ in length of the linker region, they are 35, 36 and 
40kDa in size with the most common isoform being the medium (36kDa) isoform, the 
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fourth has a truncated C-terminal CRD while the final isoform has a posttranslational 
modification that results in restricted expression (Chabot et al., 2002, Heusschen et al., 
2014). Studies have suggested the N-terminus of galectin-9 can homodimerise 
however this has not been shown in vivo (Nagae et al., 2006).  
Galectin-9 binds to poly-LacNAc residues with at least 3 repeats of the sequence on 
complex tri- and tetra-antennary N-glycans following removal of the sialic acid capping 
structure (Rabinovich and Toscano, 2009, Sato et al., 2002b, Sato et al., 2002a).  
Originally identified as a T cell-derived eosinophil chemoattractant galectin-9 has since 
been demonstrated to be produced by and to elicit effects on other inflammatory cells 
including T cells, monocytes and neutrophils (Hirashima, 2000).   
Like galectins-1 and -3, galectin-9 also shows activity in T cell-driven pathologies, 
again through its ability to induce apoptosis of Th1 and Th17 cells (Wada et al., 1997); 
this occurs via binding to glycan chains on T-cell immunoglobulin domain and mucin 
domain (Tim)-3, which is highly expressed by both Th1 and Th17 cells and increases 
upon their activation (Zhu et al., 2005, Hastings et al., 2009). T cell apoptosis is 
achieved through a different pathway than galectin-1, thus lending evidence to the 
hypothesis that galectin-1 and galectin-9 can compensate for each other in the 
absence of the lectin or its ligands, a fact further supported by studies using galectin-1 
null mice in which increased levels of galectin-9 were seen (Bi et al., 2008, Iqbal et al., 
2011).  
1.4.6.1 Galectin-9 in Animal Models of Inflammation 
Numerous in vivo models have been used to demonstrate the immunomodulatory 
actions of galectin-9. It appears to have anti-inflammatory properties when 
administered during inflammation as in all of the models reported to date it attenuates 
many of the clinical symptoms of the disease, generally these effects can be assigned 
to the ability of galectin-9 to induce T cell apoptosis including the effects during 
experimental autoimmune encephalomyelitis, collagen-induced arthritis and graft vs 
host disease (Zhu et al., 2005, Seki et al., 2007, Seki et al., 2008, Sakai et al., 2011, 
He et al., 2009) Table 1-5.  
CHAPTER 1: INTRODUCTION 
51 






from day 3 of 
disease induction 
to day 9 
Reduced disease severity and 




10g/iv daily from 
date of booster 
vaccine (day 21) 
Decreases Th1 and Th17 
cytokines and induces 
differentiation of Tregs (Seki et 





minutes prior to 
Con-A injection 
Amelioration of disease (Lv et 
al., 2012) 
Graft vs Host 
Disease 
Mice 
100g/ip daily for 
14 days from 





production (Sakai et al., 2011, 





minutes prior to 
inhalation of Ova 
Suppression of IgE-antigen 
complex formation and 
reduced allergic activity (Niki 




7g/ip with LPS 
injection 
Recruitment of prostaglandin 
E2-secreting neutrophils and 
suppression of the response 
(Tsuboi et al., 2007) 
Table 1-5: Overview of the phenotype of mice following use of recombinant galectin-9 in animal 
models of inflammation. 
Non-obese diabetic (NOD) mice were generated that over-expressed galectin-9  and 
were shown to have protection against development of autoimmune diabetes 
compared to littermate controls; suggesting a role for galectin-9 in protection against 
inflammatory disease (Chou et al., 2009).  
Galectin-9 null mice are more susceptible to LPS-induced vasculitis, using the 
Shwartzman reaction, this appears to be due to the ability of galectin-9 to recruit a 
population of neutrophils that are pro-resolution and release prostaglandin E2 (Tsuboi 
et al., 2007) 
Several in vitro studies have been performed that assess the role of galectin-9 in 
myeloid leukocytes and these have demonstrated roles of the lectin in acute 
inflammation.  
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1.4.6.2 Monocytes and Macrophages 
Galectin-9 induces apoptosis of monocytes in a CRD-dependent manner by promoting 
an influx of calcium into the cell leading to caspase activation, providing further 
evidence that galectin-9 is anti-inflammatory (Kashio et al., 2003).  
1.4.6.3 Neutrophils 
A recent study has shown that Tim-3 is expressed on human neutrophils and increases 
upon activation of these cells; binding of galectin-9 to this receptor induces granule 
release from the neutrophil. Galectin-9 also acts as an opsonin for gram-negative 
bacteria as shown by increased phagocytosis of Pseudomonas aeruginosa by 
neutrophils; this occurs via cross-linking receptors on the bacterial cell surface to Tim-3 
expressed on human neutrophils (Vega-Carrascal et al., 2014). This data suggests that 
galectin-9 plays an important role in the clearance of bacteria; potentially enforcing the 
hypothesis that galectin-9 is a pro-resolution protein.  
 
Figure 1.12: Summary of the effects of galectin-9 on immune cells. The effects of galectin-9 on 
lymphocytes, monocytes, neutrophils and endothelial cells as determined by studies on isolated 
human cells and in vivo using wild type mice.  
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1.5 Scope of the Thesis 
1.5.1 Hypothesis 
Previous reports have demonstrated a clear role for glycosylation in the modulation of 
an inflammatory response; this is mediated by the effects of lectins binding to 
glycoconjugates that are differentially expressed dependent on the leukocytes 
maturation and activation status. This glycosylation determines the recruitment, 
activation and removal of leukocytes from the site of inflammation by regulating the 
lectin binding permissibility of the cell.  
This thesis challenges the hypothesis that the glycophenotype of a myeloid cell is 
modulated over the course of an inflammatory response allowing permissibility for the 
binding, and therefore actions of galectins-1, -3 and -9 in order to promote resolution 
and restore homeostasis.  
1.5.2 Aims 
The hypothesis will be addressed using the following aims:  
1. To characterise the modulation of the glycophenotype of human and murine 
neutrophils following an inflammatory stimulus and/or cell trafficking using a 
lectin binding assay with a validated panel of lectins.  
2. To assess whether galectin binding to human neutrophils is altered by 
transmigration and if this correlates with the changes in the glycophenotype. 
3. To investigate how the expression of galectins alters in human leukocytes 
following an inflammatory stimulus and/or cell trafficking. 
4. To investigate how the expression of galectins-1, -3 and -9 changes over the 
course of a resolving inflammatory response using a murine model of zymosan-
induced peritonitis.  
5. To determine the role of galectin-3 on murine leukocytes during a resolving 
inflammatory response.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell Culture 
Dulbecco’s phosphate buffered saline (DPBS) with calcium and magnesium and DPBS 
without calcium and magnesium, fetal bovine serum (FBS), fungizone, Hanks buffered 
saline solution (HBSS), human serum, Medium 199 with Earle’s Salts with L-glutamine 
(M199), penicillin/streptomycin and Roswell Park Memorial Institute medium 1640 
(RPMI) with L-glutamine were purchased from GE Healthcare, Buckinghamshire, UK. 
CellTrace™ carboxyfluorescein succinimidyl ester, Dynabeads and trypsin/EDTA 
(0.025%/0.01%) were purchased from Invitrogen, Paisley, UK. Type II collagenase was 
purchased from Lorne Laboratories, Reading, UK. Accutase and fibronectin from 
human plasma were purchased from Millipore, Watford, UK. Acetic acid, capsaicin, cell 
dissociation solution, crystal violet, dextran (molecular weight 450,000-650,000), fMLP, 
gelatin type B from bovine skin, Hanks Balanced salt solution 10X, Histopaque 1077, 
phosphate buffered saline (PBS), sodium citrate, human recombinant tumour necrosis 
factor-α (hrTNF-α) and zymosan were purchased from Sigma-Aldrich, Poole, UK. 3µm 
transwell inserts for 6-well plates were purchased from Scientific Laboratory Supplies, 
Yorkshire, UK. An EasySep murine neutrophil negative selection kit was purchased 
from StemCell, Grenoble, France. Nunc LabTek II Chamber Slide Systems were 
purchased from Thermo Scientific, St-Leon Rot, Germany.   
2.1.2 Flow Cytometry 
Annexin V-FITC apoptosis detection kit and BD FACS lysing solution were purchased 
from BD Pharmingen, Oxford, UK. Intracellular fixation and permeabilisation buffers 
were purchased from eBioscience, Hatfield, UK. A secondary streptavidin antibody 
conjugated to phycoerythrin (PE) was purchased from Invitrogen, Paisley, UK. Bovine 
serum albumin (BSA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
sodium salt, paraformaldehyde (PFA) and sodium chloride were purchased from 
Sigma-Aldrich, Poole, UK. Recombinant forms of human Galectins-1, -3 and -9 (stable) 
were kindly provided by GalPharma, Takamatsu, Kagawa, Japan.  
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2.1.3 Molecular Biology Reagents 
Gel red DNA dye was purchased from Biotium, Cambridge, UK. Trizol reagent was 
purchased from Invitrogen, Paisley, UK. A 1-kilobase molecular weight DNA ladder 
was purchased from New England Biolabs, Hitchin, UK. Tris-Acetate EDTA (TAE) 
buffer was purchased from Promega, Southampton, UK. Deoxyribonucleotide 
triphosphate (dNTP), dithiothreitol (DTT), first strand Buffer, oligo(DT)15, primers, 
Qiagen mini-kit, QiaShredder columns, RNAse out and SuperScript were purchased 
from Qiagen, Manchester, UK. 2-Propanolol, -mercaptoethanol, chloroform, Galectin-
3 genotyping primers, molecular biology grade 100% ethanol, and REDExtract-N-Amp 
2 PCR kit were purchased from Sigma-Aldrich, Poole, UK. ReddyMix PCR master-mix 
was purchased from Thermo-Scientific, St-Leon Rot, Germany.  
2.1.4 Other Reagents 
Isoflurane was purchased from Abbott Laboratories, Maidenhead, UK. ProLong gold 
antifade mountant with 4',6-diamidino-2-phenylindole (DAPI) was purchased from Life 
Technologies, Paisley, UK. Mouse Galectin-1 and Galectin-3 duo set ELISA kits were 
purchased from R&D Systems, Abingdon, UK. Haematoxylin was purchased from 
Sigma-Aldrich, Poole, UK. Eosin was purchased from VWR, Leicestershire, UK.  








































Mouse IgG1 κ APC 61D3 eBioscience 250ng/mL 
Human 
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Mouse IgG1 FITC/PE 80H3 AbD Serotec 1g/mL 
Human 
CD35 
Mouse IgG1 PE E11 AbD Serotec 20g/mL 
Human 
CD62E/P 
Mouse IgG1 FITC 1.2B6 AbD Serotec 100ng/mL 
Human 
CD146 













Rat IgG2a PE M3/38 eBioscience 1μg/mL 
Mouse 
Galectin-9 






































Rat IgG2b Alexa-Fluor 647 2B11 eBioscience 200ng/mL 
Mouse 
Ly6C 
Rat IgG2c PerCP-Cy5.5 HK1.4 eBioscience 200ng/mL 
Mouse 
Neutrophil 
Rat IgG2a FITC 7/4 Abcam 250ng/mL 
Mouse 
CCR2 






Goat IgG Chicken Whole Alexa-Fluor 488 Poly Invitrogen 400ng/mL 
Table 2.1: List of antibodies used for Flow Cytometry. 
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Host/Isotype Fluorochrome Clone Supplier 
Mouse IgG1  APC P3.6.2.1 eBioscience 
Mouse IgG1  Pe-Cy5.5 P3.6.2.8.1 eBioscience 
Mouse IgG1 PE P3.6.2.8.1 eBioscience 
Mouse IgG1  PE P3.6.2.8.1 eBioscience 
Mouse IgG1 FITC P3.6.2.8.1 eBioscience 
Rat IgG2a PE eBR2a eBioscience 
Rat IgG2a Alexa Fluor-488 eBR2a eBioscience 
Rat IgG2a APC eBR2a eBioscience 
Rat IgG2a FITC eBR2a eBioscience 
Rat IgG2b APC eB149/10H5 eBioscience 
Rat IgG2b Alexa Fluor-647 eB149/10H5 eBioscience 
Rat IgG2c Pe-Cy5.5 R2C-23A3 eBioscience 
Table 2.2: List of isotype controls used for Flow Cytometry. 
2.1.6 Lectins 
Biotinylated Lycopersicon esculentum Lectin (LEL), Biotinylated Peanut Agglutinin 
(PNA), Biotinylated Phaseolus vulgaris Leucoagglutinin (PHA-L), Biotinylated Ricinus 
communis Agglutinin120 (RCA120), Biotinylated Sambucus nigra Agglutinin (SNA) and 
Biotinylated Ulex europaeus Agglutinin I (UEA I) were purchased from Vector 
Laboratories, Peterborough, UK.  
2.2 In Vitro Methods 
2.2.1 Isolation and Culture of Primary Human Umbilical Vein 
Endothelial Cells (HUVEC) 
Umbilical cords were kindly supplied by the midwifery staff at the Royal London 
Hospital (Ethics approval REC reference number: 06/Q0605/40). Cords were collected 
in HBSS containing penicillin (100U), streptomycin (10μg/mL) and fungizone 
(2.5μg/mL) and stored at 4°C until processing. HUVECs were isolated by collagenase 
digestion of the interior umbilical vein as described by Jaffe et al with some minor 
modifications as described below (Jaffe et al., 1973).  
A butterfly needle was inserted into one end of the umbilical vein and clamped in place. 
Approximately 30mL PBS containing antibiotics (penicillin (100U), streptomycin 
(10g/mL) and fungizone (2.5g/mL)) was perfused through the vein using a 50mL 
sterile syringe to wash away residual blood and identify any perforations in the cord. 
The other end of the cord was clamped and approximately 20-25mL 0.1% type II 
collagenase in serum-free M199 (containing antibiotics) was added; the vein was then 
incubated for 14 minutes in a humidified chamber in 5% carbon dioxide at 37°C.  
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The collagenase solution was transferred to a 50mL falcon tube and the cord flushed 
with 30mL PBS (containing antibiotics), which was also added to the tube; the cord 
was then flushed through with air to remove any remaining cells. Cells were 
centrifuged at 300g for 10 minutes, the supernatant removed and the pellet re-
suspended in 10mL complete medium (M199 containing antibiotics and 20% human 
serum) and transferred to a T75 flask (75cm2), which had been pre-coated with 0.5% 
gelatin for 20 minutes.  
The cells were incubated in a humidified chamber in 5% carbon dioxide at 37°C; the 
medium was changed after 24 hours to remove the erythrocytes and then every 48 
hours until approximately 95% confluent. The yield from this procedure was typically 
0.5-1.5 x 106 per cord.  
Once at 95% confluence the cells were sub-cultured approximately one T75 flask into 
three. Cells were rinsed with PBS prior to addition of 0.025% Trypsin/0.01% EDTA 
solution to remove any serum; once the cells began to detach and round up the flask 
was tapped firmly to loosen all cells and complete medium was added to inactivate the 
trypsin. The cells were then split between the required gelatinised T75 flasks. Cells 
were used up to passage 3 where they still retained a good response to hrTNF- as 
assessed by adhesion molecule up-regulation.  
2.2.2 Isolation of Human PMN from Whole Blood 
The local research committee approved experiments with healthy volunteers and 
informed consent was provided according to the declaration of Helsinki. Human blood 
was obtained from healthy volunteers using a 21-gauge needle and transferred to a 
50mL falcon tube containing a 1/10 volume of 3.2% (w/v) sodium citrate to prevent 
clotting. Blood was initially centrifuged at 137g for 20 minutes to separate the platelet-
rich plasma, which was then removed, before 10mL DPBS (without calcium or 
magnesium) and 8mL dextran (6% w/v) was gently layered on top of the blood. The 
tube was sealed and inverted gently until homogenously distributed and then left for 
erythrocytes to bind dextran and sediment for 30 minutes. The top layer containing 
leukocytes was then gently collected and layered onto 10mL Histopaque 1077 in a 
50mL falcon tube and this was centrifuged at 483g for 30 minutes resulting in layer 
formation as shown in Figure 2.1. 
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Figure 2.1: PMN isolation from human whole blood using dextran sedimentation. Following removal 
of platelet-rich plasma and sedimentation of erythrocytes the blood was layered gently onto 
Histopaque 1077 and centrifuged at 483g for 30 minutes resulting in layers of plasma/PBS, 
peripheral blood mononuclear cells, Histopaque 1077 and PMN/erythrocytes.  
Peripheral blood mononuclear cells (PBMCs) were removed first to prevent 
contamination of the polymorphonuclear cells (PMN), following this most of the 
Histopaque and plasma layers were removed leaving only the PMN and erythrocytes. 
The erythrocytes were lysed using 9mL of ice-cold ultrapure water for approximately 10 
seconds and once lysed the cells were rapidly mixed with 1mL 10X Hanks Balanced 
Salt Solution to return the solution to the correct isotonic balance. This was made up to 
50mL with PBS and centrifuged at 215g for 10 minute to pellet the PMN. 
The PMN pellet was re-suspended in 5-10mL PBS (depending on the size of the pellet) 
and a 10μL aliquot was mixed with 990μL Turks Stain (dH2O containing 3% acetic acid 
and 0.01% crystal violet) and counted using a haemocytometer as seen in Figure 2.2. 
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Figure 2.2: Counting grid on a Neubauer Haemocytometer. Cells are counted in each of the 4 
corners as indicated by the red square. 
The calculation below in Figure 2.3 was used to determine the total number of PMN in 
the solution and then following a further wash step in PBS the cells were re-suspended 
in RPMI (+ 10% FBS) at a concentration of 3 x 106 per mL ready for use.  
 
Figure 2.3: Calculation used to determine total number of cells after counting with a 
haemocytometer. 
2.2.3 Collection of Exudated Human PMN 
Capsaicin is a stimulus that promotes neurogenic inflammation (through activation of 
dorsal root ganglion) by activation of Transient Receptor Potential Cation Channel 
subfamily V member 1 (TRPV1) receptors. Activation results in the release of 
calcitonin-related gene product (CGRP) and substance P, these neuropeptides act on 
the local vasculature to promote inflammation (Helme and McKernan, 1985). Tobasco 
sauce (purchased from the McIlhenny Co, Avery Island, Los Angeles, USA) contains 
high levels of capsaicin (0.33mg capsaicinoids/mL) as determined by high pressure 
liquid chromatography (Gonzalez et al., 1998) and thus induces this effect when 
administered orally.   
The local research committee approved experiments with healthy volunteers and 
informed consent was provided according to the declaration of Helsinki (Ethics 
approval REC reference number: QMREC2010/17). Volunteers were asked to rinse the 
buccal cavity three times with 20mL of a 0.9% saline mouthwash (made with Maldon 
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sea salt as it contains low levels of impurities compared to other table salts and Evian 
water) for 30 seconds and then a 10% Tobasco solution in saline (20mL for 30 
seconds). These were discarded and the volunteer asked not to eat or drink anything 
for the following hour. The volunteers were then asked to rinse again three times with 
saline and these samples were collected and centrifuged at 300g for 10 minutes to 
pellet the cells. The cells were pooled and re-suspended in 5mL PBS (+0.1% BSA) and 
an aliquot (10µL) was taken and diluted 1/5 in Turks solution for counting using a light 
microscope. Approximately 5-10 x 106 cells were collected per donor using this 
protocol and 80-90% of these were PMN with the remainder of cells collected being 
buccal epithelial cells. 
2.2.4 PMN Adhesion to a HUVEC Monolayer in a 6-well Plate 
HUVECs were seeded onto 0.5% gelatin coated wells of a 6-well plate and left to 
become fully confluent in a humidified incubator at 5% carbon dioxide at 37C, all 
subsequent incubation steps were performed in a humidified incubator. Once confluent 
endothelial monolayers were treated with 10ng/mL hrTNF- for 4 hours to promote 
activation and up-regulation of adhesion molecules, particularly E-selectin and ICAM-1.  
Following this incubation HUVECs were washed with PBS and PMN were added (1mL 
complete RPMI containing 3 x 106 PMN per well) for 30 minutes.  
After the incubation period the RPMI was collected and HUVECs were washed gently 
with PBS to remove any non-adherent PMN, these were collected into a falcon tube. 
Cell Dissociation Solution was used to remove PMN that were adherent to the 
underlying HUVEC monolayer and the cells were then washed gently with PBS to 
collect all adherent PMN. The HUVECs were then incubated with Accutase for 10 
minutes and the well was washed with PBS to ensure all remaining cells were 
recovered. The three populations of cells, non-adherent, adherent and transmigrated 
were centrifuged at 300g for 10 minutes to pellet the cells. An aliquot was taken and 
assayed for the expression of neutrophil activation markers as described later and the 
remaining pellet was then re-suspended in PBS (+0.1% BSA) with 1% PFA to fix the 
cells. These were stored overnight at 4C overnight before lectin binding assays were 
performed.  
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2.2.5 PMN Transmigration through a HUVEC Monolayer on a 
Transwell Insert 
A previous study demonstrated that although the 6-well transmigration assay allows 
easy assessment of adherent leukocytes it cannot distinguish between those bound to 
the apical surface and those that have transmigrated (Muller and Luscinskas, 2008); 
therefore a second model of transmigration was utilised using a transwell insert as 
performed by Krankel et al in 2011 and modified for neutrophil, rather than monocyte, 
transmigration (Kränkel et al., 2011). 
A 3m transwell insert was placed inside a well of a 6-well plate and coated with 
10ng/mL fibronectin in 0.5% gelatin; this was left to incubate for a minimum of 2 hours. 
The inserts were then washed with PBS before HUVECs were seeded onto the 
membrane and grown to confluence; this was confirmed using staining with Wheat 
Germ Agglutinin (WGA). Briefly HUVECs on the insert were fixed with 1% PFA 
overnight and then stained with WGA conjugated to Alexa-Fluor 488 in PBS at a 
concentration of 5g/mL for 20 minutes. Cells were visualised using an EVOS Digital 
Inverted Microscope as shown in Figure 2.4.  
 
Figure 2.4: Wheat germ agglutinin staining of a confluent monolayer of HUVECs on a transwell insert. 
HUVECs were plated on a 3m transwell insert that had been pre-coated with 10ng/mL fibronectin 
in 0.5% gelatin; cells were grown to confluence and fixed in 1% PFA overnight. HUVECs were 
incubated with WGA (5g/mL) for 20 minutes and visualised at 40X magnification.  
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For transmigration assays the HUVECs were treated with 10ng/mL hrTNF- for 4 
hours, at which point the medium was removed and the transwell insert gently washed 
with PBS. 1mL complete HUVEC medium was placed at the bottom of the well and 
1mL RPMI (containing 3 x 106 PMN) was placed on top of the transwell insert and 
incubated for 90 minutes.  
Non-adherent cells were collected from the top of the transwell insert by gently 
washing with PBS, the transwell insert was transferred to a new 6-well plate and 
incubated for 10 minutes with Accutase to remove all adherent PMN and the 
transmigrated PMN were collected from the lower well and the underside of the 
transwell insert.  
The three populations of cells, non-adherent, adherent and transmigrated were 
centrifuged at 300g for 10 minutes to pellet the cells. The pellet was then either re-
suspended in PBS (+0.1% BSA) and 1% PFA to fix the cells for lectin binding, or used 
immediately in galectin expression, galectin binding assays or to assess the expression 
of neutrophil activation markers as described below. Fixed cells were stored at 4C 
overnight before lectin binding was performed.  
2.2.6 Secreted Factor Diffusion Assay 
HUVECs were grown to confluence on a 3m transwell insert as in the transwell 
transmigration assay however isolated PMN (3 x 106 per mL in RPMI + 10% FCS) were 
placed in the bottom of the well with 1mL RPMI (+10% FCS) on top of the transwell. 
The plate was incubated at 37C in 5% carbon dioxide for 90 minutes and the PMN 
collected from under the transwell.  
2.2.7 Flow Cytometric Analysis 
Flow Cytometry is a technique used to determine the properties of individual cells in a 
solution using their size and density characteristics and can also be used to quantify 
the expression levels of specific antigens on the cell surface using fluorescently 
labelled antibodies. The sample is passed through a central channel on the Flow 
Cytometer, which is surrounded by an outer sheath through which sheath fluid (PBS) 
passes at a speed greater than that of the sample. This creates a phenomenon known 
as hydrodynamic focusing in which a drag force is exerted on the central chamber and 
the sample is narrowed to form a single stream of cells as shown in Figure 2.5. 
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Figure 2.5: Schematic of the flow cell of a Flow Cytometer. The faster stream of sheath fluid creates 
a single stream of cells that can be analysed individually. 
Cells are individually analysed for size, shape and fluorescence using specific lasers. 
As they pass through the laser each cell scatters the light in different directions, light 
scattered in a straight line is detected by the forward scatter lens (FSC) and this is a 
measure of the cell size. Light scattered approximately 90 to the side is detected by 
the side scatter lens (SSC) and is a measure of the density of the cell and therefore its 
granularity. This allows cells with different properties to be distinguished from each 
other, for example human whole blood can be differentiated into lymphocytes, 
monocytes and neutrophils as seen in Figure 2.6. 
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Figure 2.6: Forward/Side scatter plot for human whole blood following red blood cell lysis. Different 
properties allow cells to be differentiated in a heterogeneous population. Human blood was collected 
from healthy volunteers and the red cells lysed using BD FACS Lysing solution, leukocytes were then 
labelled with antibodies for CD16 (neutrophils), CD14 (monocytes), and CD3 (lymphocytes) and 
analysed by Flow Cytometry.  
Cells can be labelled with antibodies directed to specific antigens on the cell surface or 
intracellularly, these antibodies can be directly conjugated to a fluorochrome, or a 
secondary antibody conjugated to a fluorochrome can be used. Fluorochromes absorb 
light of specific wavelengths released by lasers in the system and emit light of a longer 
wavelength; the light emitted is passed through a series of filters set to specific 
wavelengths, light of the specific wavelength is refracted to the lens for detection while 
light of a different wavelength passes straight through to the next laser as shown 
diagrammatically in Figure 2.7. 
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Figure 2.7: Schematic of the fluorescence system inside a Flow Cytometer. Fluorochromes are 
excited by light emitted from the lasers and release light of a different wavelength; this is passed 
through a series of filters and refracted to the correct lens for detection. 
The amount of fluorescent signal detected is proportional to the number of 
fluorochromes and therefore the number of antigens on the cell and can hence be used 
to quantify the expression of antigens. A range of different fluorochromes that emit at 
different wavelengths can be used on the same sample to identify multiple antigens on 
the cells as long as care is taken to ensure they do not require the same lens for 
detection. Lenses that detect similar wavelengths (for example FL1 and FL2) can 
experience fluorescence spill over and thus compensation is required to prevent 
artefacts appearing in samples containing more than one fluorochrome. This can be 
performed before or after running the samples as long as single stain controls are 
used. 
2.2.8 AMNIS ImageStreamX Mark II 
The ImageStream is a highly sensitive imaging cytometer that is able to capture 
multifluorescent images of cells as they pass through the flow cell allowing visual 
assessment of the internalisation of particles within cells. Samples are prepared using 
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the same method as previously described for the Flow Cytometer and once again 
compensation it important to prevent fluorescence spill over.  
2.2.9 Lectin Binding Assay  
To determine the glycophenotype on the neutrophil cell surface at different stages of 
transmigration a validated panel of lectins was used that are known to have 
specificities for a range of terminal residues on N- and O-glycans as described in Table 
2.3 and shown diagrammatically in Figure 2.8. All lectins were initially titrated to obtain 
the optimal working concentrations; these are given in Table 2.3. 





Terminal -galactose residues 
(Baenziger and Fiete, 1979) 
0.156g/mL 
Peanut Agglutinin (PNA) 
Terminal galactose residues bound to N-
acetylglucosamine in an -linkage 
(LacNAc) (Lotan et al., 1975) 
50g/mL 
Lycopersicon 
esculentum Lectin (LEL) 
Poly-LacNAc residues with a minimum of 
3 repeats, can be at the end of a glycan 
chain or capped with a sialic acid 




Terminal sialic acid in an -2,6 linkage to 




Agglutinin I (UEA I) 
Terminal -linked fucose residues bound 





Complex tri- and tetra-antennary N-
glycans (Cummings and Kornfeld, 1982) 
20g/mL 
Table 2.3: Plant lectins used to determine the glycophenotype. Glycan binding preferences and 
working concentrations are reported. 
Lectin binding enables the investigator to study changes in the glycophenotype; this 
involves the addition of plant-derived lectins to the cell of interest and quantification of 
their binding. Plant-derived lectins are used because they are easy to isolate and purify 
and have well-defined binding specificities therefore various laboratories assessing 
galectin binding have employed this technique as a surrogate to assess galectin 
binding preferences (Muglia et al., 2011, Toscano et al., 2007).  
Plant lectins that are commonly used for the assessment of the glycophenotype in 
respect to galectin binding include Ricinus communis agglutinin120 (RCA120), Peanut 
agglutinin (PNA), Lycopersicon esculentum lectin (LEL), Sambucus nigra agglutinin 
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(SNA), Ulex europaeus agglutinin I (UEA I) and Phaseolus vulgaris leucoagglutinin 
(PHA-L) and their binding preferences are shown in Figure 2.8. 
 
Figure 2.8: Schematic for lectin binding specificities. A. Galactose-specific lectin RCA120 binds -
linked galactose, B. LacNAc-specific lectins PNA and LEL bind mono- and poly-LacNAc respectively, C. 
Sialic acid-specific lectin SNA binds 2,6-linked sialic acid and D. Other common glycan-binding 
lectins UEA I and PHA-L bind -linked fucose and complex tri- and tetra-antennary N-glycans 
respectively. Red text describes galectin binding permissibility indicated by expression of the glycan 
residues.   
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RCA120 is a lectin that binds to -linked galactose residues; galectins are defined by 
their binding to -galactoside therefore this can be employed to assess the overall 
galectin binding potential of the cell of interest (Goldstein et al., 1981, Baenziger and 
Fiete, 1979).  
PNA binds specifically to mono-LacNAc residues following the removal of their 2,6-
linked sialic acid cap, this is indicative of permissibility to galectin-1 binding (Stowell et 
al., 2004, Leppänen et al., 2005, Ahmad et al., 2002). LEL binds specifically to poly-
LacNAc residues with greater than three repeats of the disaccharide structure in the 
absence or presence of sialic acid, which is identical to the binding preferences of 
galectin-3 and similar to that of galectin-9 (Rabinovich and Toscano, 2009, Lotan et al., 
1975, Merkle and Cummings, 1987). 
Expression of a sialic acid capping structure is important as it can inhibit the binding of 
galectins-1 and -9 but has no effect on the binding of galectin-3, as this binds internal 
residues (Leppänen et al., 2005). SNA binds 2,6-linked sialic acid (Rogerieux et al., 
1993).  
Other common glycan modifications of the cell that affect galectin binding include the 
expression of 1,3-linked fucose residues; fucose is a component of the sialyl Lewis x 
motif and therefore has a role in selectin-dependent rolling however they are also large 
monosaccharides that protrude from the cell surface and are therefore able to block the 
binding of galectins-1 and -9 via steric hindrance (Stowell et al., 2004, Erbe et al., 
1993). Galectin-3 binding is increased in the presence of α-linked fucose (Stowell, 
2008). UEA I binding indicates the presence of 1,3-linked fucose residues (Hormia et 
al., 1983).  
The final common modification involved in galectin binding is the expression of 
complex tri- and tetra-antennary N-glycans as galectin-9 preferentially binds N-
acetyllactosamine residues expressed on these structures; a lectin specific for these is 
PHA-L (Rabinovich and Toscano, 2009, Cummings and Kornfeld, 1982).  
Fixed PMN from the 6-well or transwell transmigration assays were re-suspended at a 
density of 2 x 105 cells per well in PBS (+0.1% BSA) and then plated on a 96-well U-
bottomed plate. The lectins were added in lectin buffer (10.9mM HEPES sodium salt 
and 158.4mM sodium chloride in deionised water) at 50L per well leaving an 
unlabelled and a secondary only well without lectin. This was left to incubate on ice in 
the dark for 45 minutes. Following this incubation the cells were washed twice in PBS 
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(+0.1% BSA) and the secondary antibody (Streptavidin-PE) was added for all 
necessary wells at a concentration of 120ng/mL in 30L PBS (+0.1% BSA) and 
incubated for 30 minutes on ice in the dark. The cells were then washed twice in PBS 
(+0.1% BSA) and stored at 4C until ready for analysis by Flow Cytometry. This assay 
was also performed on buccal neutrophils that had been fixed overnight and on murine 
peripheral blood and peritoneal exudate leukocytes in conjunction with anti-Ly6G 
(clone – 1A8) to identify neutrophils following 4 hour peritonitis with 1mg zymosan per 
mouse as described (section 2.3.4.1). 
Adherent PMN from the transwell transmigration assay that had been treated with 
Accutase showed a markedly modulated binding of PNA, UEA I and PHA-L when 
compared to the non-adherent and transmigrated populations. Freshly isolated 
neutrophils were therefore treated with Accutase and assessed for their binding of 
these lectins before and after. As shown in Figure 2.9 there was a large difference in 
the binding of lectins to neutrophils following treatment with Accutase suggesting it is 
modulating glycan expression on the surface of the PMN. This led to the transmigrated 
PMN in the 6-well assay and the adherent PMN from the transwell assay being 
excluded from the data as these had been treated with Accutase.  
 
Figure 2.9: Accutase treatment of freshly isolated neutrophils. Freshly isolated neutrophils were 
treated for 10 minutes with Accutase or PBS at 37˚C and then analysed for the binding of PNA, UEA I 
and PHA-L. 
To eliminate the human serum in the complete HUVEC medium as a modulator of the 
glycophenotype PMN were isolated and either fixed immediately or treated with 
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complete HUVEC medium for 90 minutes and then fixed. The following day the 
glycophenotype of the PMN was assessed as described. No differences could be seen 
for any of the lectins bound to the cell following treatment with complete HUVEC 
medium (Figure 2.10).  
 
Figure 2.10: Lectin binding to freshly isolated PMN and those that had been treated with complete 
HUVEC medium for 90 minutes. PMN were isolated from healthy volunteers and either fixed 
immediately or incubated with complete HUVEC medium for 90 minutes and then fixed. The PMN 
were then assessed for their binding of a validated panel of lectins. Grey – secondary antibody only, 
blue – untreated PMN and red – complete HUVEC medium. Data are expressed as histograms of 
median fluorescence intensity.  
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In some experiments PMN were isolated from healthy donors and treated with vehicle 
(PBS), 10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C to mimic the period for 
which the PMN were transmigrated in the transwell transmigration assay. PMN were 
also isolated from the Tobasco mouthwash protocol outlined in section 2.2.3. PMN 
from the secreted factor diffusion assay were also assayed for lectin binding. All PMN 
were fixed overnight in 1% PFA before lectin binding was analysed.  
2.2.10 Neutrophil Activation Marker Expression Assay 
Unfixed PMN collected from the transwell and 6-well assays were re-suspended in 
PBS (+0.1% BSA) and plated onto a 96-well U-bottomed plate at a density of 2 x 105 
cells per well. CD11b (clone ICRF44) and CD62L (clone DREG-56) antibodies were 
added in PBS (+0.1% BSA), as were isotype controls and left to incubate for 30 
minutes on ice in the dark before washing the cells twice. The cells were then stored in 
1% PFA at 4C until ready to analyse by Flow Cytometry.  
2.2.11 Granule Release Assay 
Unfixed PMN collected from the transwell assay were re-suspended in PBS (+0.1% 
BSA) and then plated at a density of 2 x 105 cells per well to allow detection of antigens 
released from granules – CD35 (clone E11) for secretory vesicles and CD66b (clone 
80H3) for secondary granules. The antibodies including isotype controls were added at 
50L per well in PBS (+0.1% BSA) and left to incubate on ice in the dark for 30 
minutes. Following incubation the cells were washed twice in PBS (+0.1% BSA) and 
stored in 1% PFA at 4C until ready for analysis by Flow Cytometry.  
2.2.12 Galectin Expression Assay 
2.2.12.1 Isolated PMN – Cell Surface 
Unfixed PMN from the transwell assay were re-suspended in PBS (+0.1% BSA) and 
plated in 96-well U-bottomed plates at a density of 2 x 105 per well. The purified 
galectin-1, -3 and -9 antibodies (polyclonal) were added at 50L per well in PBS 
(+0.1% BSA) and left to incubate on ice in the dark for 30 minutes. Following this 
incubation the cells were washed twice in PBS (+0.1% BSA) and the secondary 
antibody (chicken anti-goat IgG – alexa-Fluor 488) was added at a concentration of 
120ng/mL in 30L per well (including a secondary antibody only well) and left to 
incubate on ice in the dark for 30 minutes. Following this incubation the cells were 
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washed twice in PBS (+0.1% BSA) and stored in 1% PFA at 4C until ready for 
analysis by Flow Cytometry.  
2.2.12.2 Isolated PMN - Intracellular 
PMN from the buccal cavity and those isolated from the peripheral circulation were 
taken from healthy volunteers and paired for each donor, these were washed twice in 
PBS (+0.1% BSA) and then plated in 96-well U-bottomed plates at a density of 2 x 105 
per well. Anti-CD66b (clone 80H3) antibodies were added to all wells except the 
unlabelled and secondary antibody only to differentiate PMN from buccal epithelial 
cells and these were incubated on ice in the dark for 30 minutes. Cells were washed 
twice and then incubated in fixation buffer for 20 minutes at room temperature in the 
dark. Once fixed permeabilisation buffer was added to the cells and they were washed 
three times. Galectin-1, -3, and -9 antibodies (polyclonal) were diluted in 
permeabilisation buffer then added to the cells at 50L per well and then incubated on 
ice in the dark for 45 minutes. The cells were then washed twice and incubated with 
the appropriate secondary antibody (chicken anti-goat IgG alexa-Fluor 488) for 30 
minutes on ice. Following this the cells were washed and re-suspended in PBS (+0.1% 
BSA) and stored at 4C until ready for analysis by Flow Cytometry.  
2.2.13 Galectin Binding Assay 
PMN from the transwell assay and freshly isolated PMN were washed twice in PBS 
(+0.1% BSA) and re-suspended in DPBS (with calcium and magnesium) and 0.1% 
BSA; the PMN were treated with either recombinant human galectin-1, -3 or -9 at 10nM 
and left to incubate in a water bath at 37C for 10 minutes. Following this the cells were 
plated onto a 96-well U-bottomed plate at a density of 2 x 105 per well and stained as in 
the galectin expression assay above.  
Galectin binding median fluorescence intensities (MFI) were obtained by subtracting 
the MFI of the galectin binding assay from the MFI of the galectin expression assay for 
the same protocol using the same donor. This gave a value for the bound galectin 
whilst subtracting that endogenously expressed by the cell as shown in Figure 2.11. 
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Figure 2.11: Calculation used to assess the binding of recombinant galectins. Isolated PMN were 
allowed to transmigrate across a confluent monolayer of HUVECs on a 3m transwell insert and the 
pre- and post-transmigration populations were collected. The population was divided and half were 
treated with recombinant galectins-1, -3 or -9 for 15 minutes at 37C. All PMN were then labelled 
with galectin antibodies and their levels assessed by Flow Cytometry. Once MFI values had been 
obtained the bound galectin could be ascertained by subtracting the expression of galectin of the 
PMN from the total expression seen following treatment with the recombinant protein. 
2.2.14 Galectin-3 Internalisation Assay 
Freshly isolated PMN were obtained from healthy volunteers and re-suspended in 
DPBS with calcium and magnesium (+0.1% BSA) at 1 x 106 per mL, the cells were 
treated with either recombinant galectin-3 (10nM or 1µM) or vehicle (PBS). One treated 
and one untreated group was incubated at 37C and another at 4C for 2 hours. The 
cells were then incubated with 30mM lactose for 15 minutes at 37C to remove cell 
surface bound galectins. The cells were then plated onto a 96-well U-bottomed plate at 
a density of 2 x 105 cells per well and the intracellular expression of galectin-3 
assessed following section 2.2.12.1.  
2.3 In Vivo Methods 
2.3.1 Mice 
Male C57BL/6 mice were obtained from Charles River, Margate, UK. Breeding pairs of 
galectin-3 null mice (B6.Cg-Lgals3tm1Po1/J) were provided by the Consortium for 
Functional Glycomics (http://functionalglycomics.org) and a colony was established at 
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Charles River, Margate, UK. These mice were on a C57BL/6 background and age- and 
sex-matched controls were used for all experimental work. All animals were fed 
standard laboratory chow and water ad libitum and were maintained on a 12 hour light-
dark cycle under specific pathogen-free conditions. All experiments were performed 
with mice 6-7 weeks old, strictly following U.K. Home Office regulations (Guidance on 
the Operation of Animals, Scientific Procedures Act 1986).  
2.3.2 Genotyping 
Tail clips from the galectin-3 null colony were sent from Charles River and the DNA 
was extracted using the REDExtract-N-Amp tissue PCR kit (Sigma). Tail clippings 
smaller than 1cm long were incubated with 50L extraction solution and 12.5L tissue 
preparation solution at room temperature for 10 minutes. The solutions were then 
heated to 95C for 5 minutes and then 50L of neutralisation solution was added; the 
tail clippings were removed and the DNA was amplified using PCR.  
The DNA (approximately 0.1g per reaction) was added to a 0.2mL PCR tube along 
with 10L REDExtract-N-Amp PCR Reaction Mix and galectin-3 primers at 1M as 
seen in Table 2.4 and the solution was made up to 20L with RNAse free water. 
Genotype Primer Sequence 
Wild Type GAGGAGGGTCAAAGGGAAAG 
Heterozygous GACTGGAATTGCCCATGAAC 
Homozygous TCGCCTTCTTGACGAGTTCT 
Table 2.4: Primers used for genotyping galectin-3 null mice. 
Samples were put in the PCR machine and the following cycle was used; 94C for 2 
minutes and then followed a cycle of (94C for 30 seconds, 65C for 30 seconds and 
72C for 30 seconds) x 35; this was followed by incubation at 72C for 3 minutes. Once 
complete the amplified DNA was run on a gel immediately.  
2.3.3 Gel Electrophoresis 
A 1.5% agarose gel was made in TAE buffer with 2L of gel red added to allow 
visualisation of the DNA. Once set the gel was placed in an Electrophoresis machine 
filled with TAE buffer and 10L of the amplified DNA was loaded into the wells, along 
with a 1 kilobase DNA ladder. The gel was run at 80 constant volts until the dye front 
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reached the end of the gel. This was then read on the Protein Simple FluorChem E 
machine using ultraviolet illumination for 100ms.  
2.3.4 Inflammatory Mouse Models 
2.3.4.1 Resolving Zymosan-Induced Peritonitis Mouse Model 
Zymosan is a cell wall sugar derived from yeast (Saccharomyces cereviseae) 
composed of a 1,3-glucan core linked to chitin and 1,6-glucans that has been used 
for many years to study inflammation and phagocytosis. It exerts its effects on the cells 
by activating the TLR2 pathway, which is expressed on monocytes, macrophages, 
neutrophils, and endothelial cells (Underhill, 2003). Zymosan binding results in an 
increased production of pro-inflammatory cytokines and this induces an inflammatory 
response. It has been previously shown in our lab and by others that 1mg zymosan per 
mouse induces an inflammatory response characterised by high recruitment of 
neutrophils and monocytes that resolves within 72-96 hours and therefore this protocol 
was utilised for the purposes of this study (Ajuebor et al., 1999, Navarro-Xavier et al., 
2010).  
Male C57BL/6 mice were injected intraperitoneally on the left hand side with 1mg 
zymosan in 1mL sterile, filtered PBS as previously described by Doherty et al in 1985, 
0-hour mice received no treatment (Doherty et al., 1985). At 4, 24, 48, 72 and 96 hours 
post injection the mice were anaesthetised, along with the 0-hour controls, with 
isoflurane and a cardiac puncture was performed with a 25-gauge needle and a 1mL 
syringe containing 0.1mL sodium citrate and the blood was stored in a falcon tube on 
ice. The mice were then sacrificed by cervical dislocation.  
Peritoneal lavages were performed with a 23-gauge needle and syringe containing 
4mL PBS (+3mM EDTA); a small incision was made in the skin taking care not to 
penetrate the lining of the peritoneal cavity, the solution was injected and washed 
around the cavity to collect exudated cells, the exudate was then collected and stored 
in a falcon tube on ice. Following the lavage the right leg was removed and the femurs 
isolated and cleaned with sterile gauze; the ends of the femur were then removed and 
the bone flushed with 1mL PBS (+3mM EDTA) using a 23-gauge needle and a 2mL 
syringe. The bone marrow cells were collected into a falcon tube and stored on ice.  
A lobe of lung was collected from 0 hour control mice for RNA extraction by cutting into 
the ribs to open the chest cavity, the heart and lungs were then lifted gently using 
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forceps to prevent damage occurring and a lobe of one of the lungs was removed, this 
was then placed into 1mL Qiagen RNAlater and frozen at -80C until ready for use.  
In some experiments zymosan-induced peritonitis was performed on male and female 
galectin-3 null mice at age 6 weeks with age and sex matched wild type controls. 
Peritoneal lavage fluid was collected from these mice at 48, 72 and 96 hours post 
zymosan administration in order to assess differences at the resolution phase of the 
inflammatory response. Differential leukocyte counts and apoptosis assays were 
performed on these samples as described later.  
2.3.4.2 Murine Dorsal Air Pouch Model 
Male C57BL/6 mice were injected subcutaneously with 2.5mL of sterile filtered air into 
the dorsal skin using a 23-gauge needle and a 45m filter; 3 days later mice were 
given a second injection of 2.5mL air into the pre-existing pouch. At day 6 mice were 
injected with 1mg zymosan in 500L sterile filtered PBS into the pouch or with PBS 
alone and left for 4 or 24 hours. Mice were sacrificed using increasing concentrations 
of carbon dioxide. The air pouch was lavaged using 2mL PBS (+3mM EDTA) using a 
23-gauge needle and a 2mL syringe without opening the skin and the cells were 
collected and stored on ice. Death was then confirmed using cervical dislocation.  
2.3.4.3 Adoptive Transfer 
Male C57BL/6 mice (10 weeks old) were anaesthetised with isoflurane and a cardiac 
puncture was performed with a 25-gauge needle and a 1mL syringe containing 0.1mL 
sodium citrate and the blood was stored in a falcon tube on ice. Neutrophils were 
isolated from the blood using negative selection as described in section 2.3.8; isolated 
neutrophils were re-suspended at 100 x 106 per mL in sterile PBS and labelled with 
CellTrace™ Carboxyfluorescein succinimidyl ester (CFSE).  
Male galectin-3 null mice were placed in a warming box set to 30°C for approximately 
10 minutes and then immediately transferred into a restrainer and 100µL of neutrophil 
suspension was injected intravenously per mouse. 15 minutes after this the mice were 
injected intraperitoneally with zymosan as previously described; 4 hours later the mice 
were sacrificed and the peritoneal cavities lavaged to collect recruited leukocytes. 
CFSE-positive leukocytes were assessed for their intracellular galectin-3 expression.  
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2.3.5 Flow Cytometry 
2.3.5.1 Peripheral Blood  
An aliquot (10L) of the peripheral blood was removed for counting; this was diluted in 
Turks solution and counted using a haemocytometer to obtain total cell counts per 
mouse. BD FACS lysing solution was used to lyse erythrocytes in the remaining blood 
and the leukocytes were pelleted by centrifugation at 300g for 10 minutes. Following 
re-suspension in PBS (+0.1% BSA) cells were plated onto a 96-well U-bottomed plate 
at a density of 2 x 105 cells per well for staining.  
2.3.5.2 Exudate  
Aliquots (10L) of the peritoneal and air pouch exudates were removed for counting (in 
Turks). The remainder of the exudate was centrifuged at 300g for 10 minutes to pellet 
the cells, the supernatant was collected and frozen for ELISA analysis and the cells 
were then re-suspended in PBS (+0.1% BSA) and plated onto a 96-well U-bottomed 
plate at a density of 2 x 105 cells per well for staining.  
2.3.5.3 Bone Marrow  
Flushed bone marrow was put through a 70m cell strainer to remove any bone 
fragments or non-cellular debris and the collected solution was centrifuged at 300g for 
10 minutes to pellet the cells. The cells were re-suspended in PBS (+0.1% BSA) and 
an aliquot (10L) was removed for counting (in Turks). The remaining cells were plated 
onto a 96-well U-bottomed plate at a density of 2 x 105 cells per well for staining.  
2.3.5.4 Intracellular Cell Staining  
The cells were washed twice in PBS (+0.1% BSA) and incubated with an antibody to 
CD16/CD32 (clone 83) at 0.25g/mL to prevent non-specific binding for 10 minutes on 
ice in the dark. The peripheral blood and peritoneal exudate were then incubated with 
Ly6G (clone 1A8) to label neutrophils, F4/80 (clone BM8) to label 
monocytes/macrophages and Gr-1 (clone RB6-8C5) to differentiate between classical 
and non-classical monocytes/macrophages. The bone marrow cells were incubated 
with Ly6G and CXCR4 (clone 2B11) to label bone marrow neutrophils and Ly6C (clone 
HK1.4) to label bone marrow monocytes. The cells were incubated on ice in the dark 
for 30 minutes.  
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The cells were then washed twice in PBS  (+0.1% BSA) and fixed in 100L BD fixation 
buffer per well for 10 minutes at room temperature. Once fixed the cells were re-
suspended and washed three times in BD permeabilisation buffer to allow intracellular 
staining. The cells were then incubated with antibodies for galectin-1 (polyclonal), 
galectin-3-PE (clone M3/38) and galectin-9 (polyclonal) on ice in the dark for 45 
minutes, the cells were washed twice and a secondary antibody for galectins-1 and -9 
(chicken anti-goat IgG alexa-Fluor 488) was added for 30 minutes on ice in the dark. 
Following this cells were washed twice and re-suspended in PBS at 4C until ready for 
analysis by Flow Cytometry.  
Leukocytes could be differentiated into neutrophils and classical/non-classical 
monocytes/macrophages using specific antibodies by Flow Cytometric assessment. 
Once the cells had been defined as neutrophils or monocytes/macrophages using the 
specific antibodies the expression of the galectins could be assessed using double 
staining as in Figure 2.12. 
 
Figure 2.12: Galectin-3 expression in Ly6G positive murine neutrophils. Mice were injected with 1mg 
zymosan i.p. and leukocytes were collected from the peritoneal cavity 4-hours post injection. 
Leukocytes were double stained for Ly6G (clone 1A8) and galectin-3 (clone M3/38) and assessed by 
Flow Cytometry. Initially the cells were gated for Ly6Ghigh expression and this population was then 
analysed for galectin-3 expression.  
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Following the analysis of galectin expression on monocytes it was seen that there were 
large variations in expression levels between cells. It was therefore important to 
differentiate between classical and non-classical monocytes/macrophages as these 
different subsets may express different levels of the galectins. An antibody targeted to 
Gr-1 (clone RB6-8C5), which binds both Ly6G and Ly6C residues, was used as a 
double stain along with F4/80 (clone BM8) as Ly6C is highly expressed on classical 
monocytes/macrophages and is expressed in lower levels on non-classical 
monocytes/macrophages as shown in Figure 2.13. 
 
Figure 2.13: Identification of classical and non-classical populations of monocytes and 
macrophages. Murine leukocytes collected from peritoneal lavage 72-hours post 1mg zymosan-
induced peritonitis were assessed for their expression of F4/80 and Gr-1. Classical 
monocytes/macrophages are F4/80high and Gr-1high while non-classical monocytes/macrophages are 
F4/80high and Gr-1low. Neutrophils can also be identified using these antibodies as they are 
F4/80negative and Gr-1high. 
2.3.5.5 Cell Surface Staining  
Peritoneal exudate cells were washed twice in PBS (+0.1% BSA) and then re-
suspended in a CD16/CD32 antibody (clone 83) at 0.25g/mL to prevent non-specific 
binding; this was incubated for 10 minutes on ice in the dark. Following this the cells 
were incubated with a combination of Ly6G (clone 1A8) to label neutrophils and 
Galectin-3-PE (clone M3/38) for 30 minutes on ice in the dark. The cells were then 
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washed twice in PBS (+0.1% BSA) and stored in 1% PFA until ready for analysis by 
Flow Cytometry.  
2.3.6 Apoptosis Assay  
Peritoneal exudate leukocytes from galectin-3 null mice and wild type controls were 
plated onto a 96-well U-bottomed plate at a density of 1 x 106 cells per well and 
washed twice in PBS (+0.1% BSA) and then re-suspended in a CD16/CD32 antibody 
(clone 83) at 0.25g/mL for 10 minutes on ice in the dark. Following this the neutrophils 
were labelled with Ly6G (clone 1A8) for 30 minutes on ice in the dark. The cells were 
washed twice in ice cold PBS (+0.1% BSA) and re-suspended in 100L 1x Annexin V 
binding buffer and transferred to FACS tubes; leukocytes were incubated with 5L 
Annexin V and 5L PI (along with single stain controls) at room temperature in the dark 
for 15 minutes. Following this 400L of 1x Annexin V binding buffer was added to each 
tube and analysed immediately by Flow Cytometry.  
2.3.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
A high-binding 96-well plate was coated with 100L per well capture antibody (Rat, 
anti-mouse galectin-3, 2g/mL in PBS), covered with parafilm and left at 4C overnight. 
The following morning the coating buffer was aspirated off and the plate washed three 
times by filling each well with PBS (+0.05% Tween-20) for 30 seconds and discarding; 
the final wash was aspirated off to ensure wells were empty. The wells were then 
blocked with 200L PBS (+1% BSA) and incubated at room temperature for 1 hour. 
The PBS was aspirated and the plate washed three times as previously described. The 
recombinant mouse galectin-3 standard was diluted to 1000pg/mL in PBS (+1% BSA) 
and six serial dilutions were performed to create a standard curve to 15.625pg/mL. 
100L of each standard dilution was added in duplicate leaving a pair of wells without 
galectin-3 to act as a blank for the analysis.  
The supernatants from the peritoneal exudates were then added in duplicate to the rest 
of the wells after a 1:5 dilution in PBS (+1% BSA) and the plate was incubated at room 
temperature for 2 hours. The samples were aspirated and the plate washed three times 
as previously described. The detection antibody (Goat, anti-mouse galectin-3, 
200ng/mL in PBS +1% BSA) was added to each well (100L) and incubated at room 
temperature for 2 hours. The detection antibody was aspirated and the plate washed 
three times as previously described. 100L Streptavidin-HRP was then added to the 
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wells and this was incubated at room temperature for 20 minutes. The Streptavidin-
HRP was aspirated and the plate washed three times as previously described.  
100L Tetramethylbenzidine (TMB) solution was added to each well and incubated for 
approximately 20 minutes, 50L 1M phosphoric acid was then added to each well to 
stop the reaction and the plate was immediately read using a Labsystems MultiScan 
Bichromatic Plate Reader using the wavelength subtraction mode which allows the 
plate to be read at 450nm but with readings at 570nm subtracted to reduce background 
absorbance values. 
The galectin-3 concentrations of the cell-free supernatants from the peritoneal exudate 
were interpolated from the standard curve shown in Figure 2.14. 
 
 
Figure 2.14: Standard curve produced for galectin-3 ELISA. 
2.3.8 Neutrophil Isolation by Negative Selection 
Peritoneal exudate cells and bone marrow cells were collected from mice following a 4 
hour zymosan-induced peritonitis protocol as described in section 2.3.5.2 an aliquot 
(10L) of each population was taken for counting in Turks solution to obtain the total 
cell number and another aliquot (200L) was taken to stain for Ly6G to assess starting 
neutrophil purity.  
The cells were centrifuged at 300g for 10 minutes to obtain a pellet and this was re-
suspended in PBS (+2% BSA) at a concentration of 1 x 108 cells per mL, normal rat 
serum was then added to each sample at 50L/mL of cell suspension. The volumes of 
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each sample were made up to 500L in PBS (+2% BSA). 25L of the mouse neutrophil 
enrichment cocktail was added to each sample and this was incubated on ice for 15 
minutes, the tube was then filled with PBS (+2% BSA) and this was centrifuged at 300g 
for 10 minutes. The pellet was re-suspended in 500L PBS (+2% BSA) and 25L biotin 
selection cocktail was added to the sample, this was incubated on ice for 15 minutes.  
The magnetic particles were vortexed for 30 seconds to ensure there were no 
aggregates and 75L of this was added to each sample, and incubated on ice for 10 
minutes. The entire sample was then transferred to a 5mL polystyrene round bottomed 
tube and made up to 5mL with PBS (+2% BSA), this was all placed in an Invitrogen 
DynaMag-15 magnet for 5 minutes to allow all cells that are not neutrophils to be 
bound to the magnet leaving the neutrophils in suspension. The neutrophils were 
collected into a falcon and the negative fraction was re-suspended in PBS (+2% BSA). 
This process was repeated twice more to collect as many neutrophils from the 
supernatant as possible.  
Following this the neutrophil fraction was also placed in the magnet in an attempt to 
remove any contaminating cells that would affect the purity. From this fraction an 
aliquot (10L) of each population was taken for counting in Turks solution to obtain the 
yield and another aliquot (200L) was taken to stain for Ly6G to assess final neutrophil 
purity. 
Both the neutrophil fraction and the negative fraction were re-suspended in 350L 
Qiagen RLT Buffer containing 10L -mercaptoethanol/mL to lyse the cells ready for 
RNA extraction. This was then frozen at -80C until ready to extract the RNA. 
2.3.9 Neutrophil Isolation by Positive Selection 
Negative selection resulted in a low yield and purity for both the bone marrow and the 
peritoneal exudate cells and therefore a positive selection method was attempted in 
order to increase both these parameters.  
Bone marrow and peritoneal exudate were collected as previously described, an 
aliquot (10L) was taken for counting in Turks solution on a haemocytometer and the 
cells were centrifuged at 300g for 10 minutes to pellet the cells. The pellet was re-
suspended in PBS (+0.1% BSA) to a final concentration of 1 x 107 cells per mL and to 
this 10g/mL purified rat anti-mouse Ly6G antibody was added and incubated on ice in 
the dark for 20 minutes.  
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During this incubation period 100L sheep anti-rat Dynabeads per mL of sample 
were washed in 1mL PBS (+0.1% BSA) by placing in the magnet, leaving for 2 minutes 
and pouring off the supernatant, once washed the beads were re-suspended in PBS 
(+0.1% BSA) at their original volume.  
Once the incubation was completed 2mL PBS (+0.1% BSA) was added to each sample 
and they were centrifuged at 300g for 10 minutes. The pellet was then re-suspended to 
1 x 107 cells per mL in PBS (+0.1% BSA) and 100L Dynabeads added per mL of 
sample. The sample was rotated gently for 20 minutes and then the total volume was 
increased by 1mL to limit the trapping of unbound cells, this was placed in the magnet 
for 2 minutes and the supernatant kept to analyse as the negative fraction. The 
remaining neutrophils were washed three times by re-suspending in 1mL PBS (+0.1% 
BSA) and placing in the magnet for 1 minute then pouring off the supernatant.  
An aliquot of the sample (100L) was then put on a slide and allowed to air dry and this 
was stained with Haematoxylin and Eosin to confirm no eosinophil contamination, the 
rest of the sample was transferred to an eppendorf, centrifuged at 8000g for 1 minute 
and the pellet was re-suspended in 750L Trizol reagent and frozen at -80C until 
ready to isolate RNA.  
2.3.10 RNA Extraction using the RNeasy Mini-Kit 
The lung tissue positive control, isolated neutrophils and negative fractions were 
defrosted on ice and the lung was weighed to ensure the tissue was less than 30mg. 
This was then placed in a homogenisation tube with 600L Qiagen RLT buffer 
containing 10L -mercaptoethanol/mL and homogenised using a Precellys 24 
homogeniser at 6800rpm for 1 minute.  
The neutrophil and negative fractions were syringed with a 1mL 27-gauge tuberculin 
syringe at least 5 times per sample to ensure all cells were lysed and then 350L 70% 
molecular biology grade ethanol was added to each sample (including the lung tissue) 
and this was mixed until clear. The entire volume was then transferred to a Qiagen 
column and centrifuged at 8000g for 15 seconds and the flow through discarded, 
700L of RW1 buffer was added to the column and this was centrifuged at 8000g for 
15 seconds and again the flow through was discarded.  
500L RPE buffer containing 1 volume of ethanol was added to the column and again 
centrifuged at 8000g for 15 seconds and the flow through was discarded. This stage 
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was repeated with another 500L RPE buffer and centrifuged at 8000g for 2 minutes 
and this time the collection tube was discarded and replaced with a new one. This was 
spun at 8000g for 1 minute and the column was then placed into a 1.5mL RNAse-free 
eppendorf, 30L RNAse-free water was added directly to the membrane and allowed 
to sit for 1 minute before centrifuging at 8000g for 1 minute. The column was then 
discarded and 1L of RNA was assessed on an ND-1000 Nanodrop Spectrometer; a 
beam of near-monochromatic light is passed through the droplet of RNA and the light 
transmitted through the sample is measured. The ratio of sample absorbance at 260 
and 280nm is given and this is used to assess the purity of the RNA with 2 being 
considered pure, deviations from this number can suggest contamination with protein 
or phenol. A second ratio of sample absorbance at 260 and 230nm is given and this is 
a secondary measure of purity. The Nanodrop also provides a concentration for the 
RNA present in the sample in ng/L. The RNA was then frozen at -80C until ready for 
cDNA synthesis.  
2.3.10.1 QiaShredder Column 
Assessment of the 260/280 and 260/230 values obtained from the Nanodrop readings 
described in section 2.3.10 showed high levels of contamination and low levels of RNA 
from the neutrophils, this may be due to the difficulty in fully lysing neutrophils that has 
been reported in the literature. The protocol was therefore repeated using a 
QiaShredder column, which is designed to help lyse cells more efficiently than 
syringing.  
700L of the neutrophil fraction in Qiagen RLT Buffer containing 10L -
mercaptoethanol/mL was added to the top of the QiaShredder column and this was 
centrifuged at 8000g for 2 minutes, the column was discarded and the eluted material 
loaded onto the top of a Qiagen column and the RNeasy Mini-Kit protocol followed as 
above.  
2.3.11 RNA Extraction using Trizol 
Nanodrop readings following use of the QiaShredder column were still low for RNA 
levels and still exhibited high levels of salt contamination therefore a Trizol procedure 
was attempted in order to obtain higher levels of RNA from the neutrophils.  
Once the neutrophils had been isolated the cell pellet was re-suspended in 750L 
Trizol reagent and this was frozen at -80C until ready to extract the RNA.  
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The samples were defrosted on ice and then 200L of chloroform was added and the 
sample shaken vigorously by hand for 15 seconds. This was incubated at room 
temperature for 10 minutes and then centrifuged at 8000g for 15 minutes at 4C. The 
aqueous phase was transferred to a clean eppendorf and 500L 2-propanolol was 
added and mixed, this was incubated at room temperature for 10 minutes and then 
centrifuged at 8000g for 10 minutes at 4C. The supernatant was discarded and the 
cells washed in 1mL 75% ethanol, this was centrifuged at 8000g for 5 minutes at 4C, 
the majority of the ethanol was aspirated and the rest left to air-dry. The pellet was re-
suspended in 40L RNAse-free water and the RNA concentration determined on the 
Nanodrop. The RNA was then frozen at -80C. 
This provided the best yield of RNA from the neutrophils (although the salt 
contamination levels were still high) and therefore was chosen as the method from 
which cDNA synthesis was performed.  
2.3.12 Complementary DNA (cDNA) synthesis  
The RNA was defrosted on ice and then 11L was mixed with 1L oligo(DT)15 and 1L 
dNTP mix, and incubated in a MWG Biotech Primus-96 plus PCR machine at 65C for 
5 minutes. Following a 5 minute incubation on ice each sample then received 4L first 
strand buffer, 1L DTT, 1L RNAse out and 1L Superscript (controls were included 
which received everything but Superscript). This was all incubated in the PCR machine 
at 50C for 1 hour and then 70C for 15 minutes. Once the cDNA had been produced 
this was frozen at -20C until ready for PCR.  
2.3.13 Polymerase Chain Reaction (PCR) 
The cDNA was defrosted on ice and then 1L of each sample was mixed with 10L 
ReddyMix PCR MasterMix and 1L of each gene specific primer required (Qiagen 
Quantitec Primer Assay), the primers used were for Lgals3, Lgals9, Ly6g, Cd68 and 
Rpl32. This was incubated in the PCR machine at 94C for 5 minutes and then 
followed a cycle of (94C for 30 seconds, 55C for 30 seconds and 72C for 30 
seconds) x 35; this was followed by incubation at 72C for 10 minutes. Once complete 
the amplified DNA was stored at -20C or run on a 2% agarose gel immediately as 
described in section 2.3.3.  
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2.4 Statistical Analysis 
Statistical significance was assessed using SPSS computer software. Data is 
expressed as mean  standard error of the mean (SEM) of n experiments. All data 
were tested for normal distribution and power calculations were performed using 
G*Power software (Faul et al., 2009). A Grubbs test was used to identify statistical 
outliers and these were removed before tests were performed. Statistical differences 
were analysed by two-tailed T-test for 2 groups, one-way analysis of variance 
(ANOVA) followed by a Bonferroni or Dunnetts post hoc test (depending on if 
comparing all values or each value to a control respectively) or two-way ANOVA 
followed by Bonferroni post hoc test. In assays where repeated measures were 
performed a repeated measures test was utilised. In all cases a P value ≤ 0.05 was 
considered significant to reject the null hypothesis and differences were considered 
significant.   
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3 Modulation of the Neutrophil 
Glycophenotype and Galectin 
Binding Profile 
3.1 Introduction 
The glycosylation of adaptive immune cells is known to be of particular importance to their 
recruitment, activation and clearance from an inflammatory site (Wright and Cooper, 2014); 
the glycophenotype is modulated dependent on the extracellular environment, which allows 
binding of lectins to take place and affect cell functions. 
Galectins-1, -3 and -9 are known to be immunomodulatory as they bind to, and elicit actions 
from immune cells. Galectins-1 and -9 are predominantly anti-inflammatory as they decrease 
leukocyte recruitment and skew towards a Th2 phenotype during disease (Rabinovich et al., 
2000, La et al., 2003, He et al., 2009), while galectin-3 is considered pro-inflammatory as it 
increases leukocyte recruitment and skews towards a Th1/Th17 phenotype (Colnot et al., 
1998b, Hsu et al., 2000).  
The actions of galectins are determined not only by the cellular expression of the proteins 
but also by the target cell permissibility to galectin binding, the glycophenotype of the cell. 
Work has been performed on the glycophenotype of adaptive immune cells and how this 
pertains to galectin binding but the innate immune system has not been characterised in this 
way.  
This study therefore set out to delineate the effects of inflammation on the neutrophil 
glycophenotype, as well as elucidate the temporal and spatial modulation of galectins during 
resolving inflammation.  
The aims of this section were therefore to characterise the modulation of the glycophenotype 
of human and murine neutrophils following an inflammatory stimulus and/or cell trafficking 
using a lectin binding assay with a validated panel of lectins.  
Following this the binding of galectins-1, -3 and -9 will be assessed following the same 
inflammatory stimuli and/or cell trafficking to determine whether this correlates with the 
glycophenotypic changes seen.  
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Initially freshly isolated human PMN were assessed at varying stages of trafficking across an 
endothelial monolayer that had been pre-treated for 4 hours with 10ng/mL hrTNF-α to induce 
activation and up-regulate E-selectin on the HUVEC surface. To distinguish changes caused 
by PMN activation and those due to transendothelial migration the glycophenotype of human 
PMN was characterised following activation with soluble mediators such as hrTNF- 
(10ng/mL) and fMLP (1M); stimulants that release secretory vesicles and secondary 
granules respectively. Human PMN were also treated with conditioned medium from 
activated endothelial cells to determine the role of endothelial cell-derived soluble factors on 
PMN glycophenotype. A novel human model of PMN extravasation was also utilised in which 
neurogenic inflammation was used to recruit PMN to the buccal cavity within 1 hour. 
Assessment of the glycophenotype is able to provide an approximation of the permissibility 
for galectin binding to neutrophils. In order to determine the accuracy of lectin binding, the 
binding of recombinant galectins to PMN under the same conditions was assayed.  
To characterise the modulation in a pathophysiological setting an in vivo murine zymosan-
induced peritonitis model was used, which results in robust neutrophil recruitment to the 
peritoneal cavity within 4 hours of administration. The glycophenotype of murine neutrophils 
collected from the peripheral circulation was compared to those collected from the peritoneal 
cavity following 4 hour zymosan-induced peritonitis.  
3.1.1 Glycophenotype of Freshly Isolated Human Neutrophils 
Human PMN were isolated from whole blood of healthy volunteers as described in section 
2.2.2, fixed in 1% PFA overnight and a validated panel of lectins was used to label specific 
terminal glycosylation motifs as shown in Table 2.3, lectin binding was assessed by Flow 
Cytometry as shown in Figure 3.1. 
Basally, human PMN express a glycophenotype characterised by low binding levels of PNA 
(55.87 ± 14.53) and UEA I (13.14 ± 3.123) indicative of low expression of terminal mono-
LacNAc and 1,3-linked fucose residues. Whereas high binding levels of RCA120 (711.4 ± 
145.4), LEL (726.5 ± 216.2), PHA-L (930.4 ± 150.3) and SNA (310.6 ± 116.6) were 
observed, which are indicative of high expression of -linked galactose, poly-LacNAc chains 
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Figure 3.1: Representative histograms showing basal lectin binding on freshly isolated human PMN. Blood 
was taken from healthy volunteers and PMN were isolated by dextran sedimentation and fixed overnight. 
PMN were then incubated with plant lectins for specific glycans and binding was analysed by Flow 
Cytometry. Shaded peak = secondary antibody only. N = 5 per group, MFI = mean  SEM. 
3.1.2 Modulation of the Neutrophil Glycophenotype during 
Adhesion to Endothelial Cells 
An assay was performed to assess the glycophenotype of PMN during the process of 
adhesion to an endothelial monolayer in a 6-well plate. Isolated PMN from healthy 
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volunteers were added to a well in which a confluent monolayer of HUVECs had been pre-
treated for 4 hours with 10ng/mL hrTNF-. The cells were incubated together for 30 minutes 
before non-adherent and adherent PMN were collected from the plate and analysed for their 
expression of neutrophil activation markers (CD11b and CD62L), freshly isolated PMN were 
also used as a control as shown in Figure 3.2.  
The expression of CD62L was high on freshly isolated PMN (536.5 ± 77.94) and this 
decreased by more than 97% in non-adherent and adherent cells (13.06 ± 2.541, P = 0.0026 
and 8.457 ± 1.729, P = 0.0025 respectively); while the expression of CD11b was high in 
freshly isolated PMN (984.2 ± 45.37) and remained unchanged during co-culture with, and 
adhesion to HUVECs (1034 ± 52.12 and 901.3 ± 36.07). Taken together this suggests that 
the non-adherent and adherent PMN were primed yet not fully activated.  
 
Figure 3.2: Neutrophil activation marker expression in human PMN collected from activated endothelial 
cells. Blood was taken from healthy volunteers, PMN were isolated and added to a 6-well plate in which a 
confluent monolayer of HUVECs had been pre-treated for 4 hours with 10ng/mL hrTNF-. The cells were 
incubated together for 30 minutes, adherent and non-adherent PMN were collected and the expression of 
CD62L and CD11b assessed by Flow Cytometry in comparison with freshly isolated PMN. A. Representative 
histogram and graph of CD62L expression and B. Representative histogram and graph of CD11b 
expression. Shaded peak = isotype control. Data are expressed as mean  SEM, N = 3 per group, *** P < 
0.001 vs freshly isolated PMN as analysed by one-way ANOVA with Bonferroni post hoc test.  
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The glycophenotype of these PMN was then assessed by lectin binding. A 69% reduction in 
RCA120 binding could be seen between non-adherent and adherent PMN indicating a 
significant loss of -linked galactose residues as PMN adhere to an endothelial monolayer 
(1832  477.98 vs 573.7  530.1, P = 0.003) Figure 3.3. 
 
Figure 3.3: Binding of a -linked galactose-specific lectin to non-adherent and adherent human PMN 
following incubation with HUVECs. Freshly isolated PMN were incubated for 30 minutes with HUVECs that 
had been pre-treated with 10ng/mL hrTNF-. Non-adherent (NA) and adherent (A) PMN were collected 
from the well and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to 
assess the expression of bound lectin. Figure shows representative histogram and graph of RCA120 binding. 
Grey = secondary antibody binding, blue = non-adherent PMN and red = adherent PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 4 per group. ** P < 0.01 as 
analysed by two-tailed paired T test. 
An overall trend was seen with lectin binding that was indicative of galectin binding 
permissibility with a reduction in lectin binding following PMN adhesion to the endothelial cell 
monolayer. A 50% reduction in PNA binding (14.18  7.59 vs 7.79  5.60, P = 0.026); a 30% 
decrease in LEL binding (463.9  263.2 vs 327.8  185.2, P = 0.03) and a 28% reduction in 
PHA-L binding (462.0  169.3 vs 334.7  108.5, P = 0.025; Figure 3.4) was observed. This 
indicated of a loss of mono- and poly-LacNAc residues as well as complex tri- and tetra-
antennary N-glycans as neutrophils adhere to the endothelial monolayer.   
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Figure 3.4: Binding of lectins indicative of galectin binding permissibility to non-adherent and adherent 
human PMN following incubation with HUVECs. Freshly isolated PMN were incubated for 30 minutes with 
HUVECs that had been pre-treated with 10ng/mL hrTNF-. Non-adherent (NA) and adherent (A) PMN were 
collected from the well and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was 
used to assess the expression of bound lectin. A. Representative histogram and graph of PNA binding, B. 
Representative histogram and graph of LEL binding and C. Representative histogram and graph of PHA-L 
binding. Grey = secondary antibody binding, blue = non-adherent PMN and red = adherent PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 5-7 donors per group. * P < 
0.05 as analysed by two-tailed paired T test.  
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There was an overall decrease in 2,6-linked sialic acid expression following PMN adhesion 
as indicated by a 42% reduction in SNA binding when compared to non-adherent PMN 
(149.3  82.72 vs 87.03  43.28, P = 0.014) Figure 3.5.  
 
Figure 3.5: Binding of an 2,6-linked sialic acid-specific lectin to non-adherent and adherent human PMN 
following incubation with HUVECs. Freshly isolated PMN were incubated for 30 minutes with HUVECs that 
had been pre-treated with 10ng/mL hrTNF-. Non-adherent (NA) and adherent (A) PMN were collected 
from the well and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to 
assess the expression of bound lectin. Figure shows representative histogram and graph of SNA binding. 
Grey = secondary antibody binding, blue = non-adherent PMN and red = adherent PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 5 per group. * P < 0.05 as 
analysed by two-tailed paired T test.  
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The expression of -linked fucose residues was significantly reduced following PMN binding 
to endothelial cells as indicated by a 53% decrease in UEA I binding (3.44  1.69 vs 1.63  
1.16, P = 0.035) Figure 3.6. 
 
Figure 3.6: Binding of -linked fucose-specific lectin to non-adherent and adherent human PMN following 
incubation with HUVECs. Freshly isolated PMN were incubated for 30 minutes with HUVECs that had been 
pre-treated with 10ng/mL hrTNF-. Non-adherent (NA) and adherent (A) PMN were collected from the well 
and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to assess the 
expression of bound lectin. Figure shows representative histogram and graph of UEA I binding. Grey = 
secondary antibody binding, blue = non-adherent PMN and red = adherent PMN. Data are expressed as 
median fluorescence intensity per donor for paired samples, n = 6 per group. * P < 0.05 as analysed by 
two-tailed paired T test.  
3.1.3 Galectin Binding to Isolated Neutrophils during Adhesion 
to Endothelial Cells 
The binding of recombinant galectins-1, -3 and -9 (10nM) to PMN that were non-adherent 
and adherent collected from the 6-well adhesion assay was assessed. PMN were collected 
as previously described and incubated with recombinant galectins at 37°C for 15 minutes to 
allow binding; following this the PMN were washed and assessed for the expression of 
galectin on the cell surface compared to those that were not treated with recombinant 
protein. The total binding was calculated by subtracting the endogenous galectin expression 
from that seen in treated cells from the same donor.  
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Galectin-1 binding to freshly isolated PMN was low (5.194 ± 1.497) however this increased 
by approximately 4-fold in PMN that were in contact with, but not adherent to, the 
endothelium (18.43 ± 2.791) and this decreased back to basal levels upon adhesion to the 
endothelial monolayer (7.537 ± 2.515) as shown in Figure 3.7.  
 
Figure 3.7: Recombinant galectin-1 binding to PMN during adhesion to an endothelial monolayer. Freshly 
isolated PMN were left to adhere for 30 minutes to a HUVEC monolayer that had been pre-treated with 
10ng/mL hrTNF-. Non-adherent and adherent PMN were treated with recombinant galectin-1 (10nM) or 
vehicle for 15 minutes at 37C and assessed for their level of galectin-1 on the cell surface using Flow 
Cytometry compared to freshly isolated PMN. Endogenous expression of galectin-1 was subtracted from 
the total level to obtain the bound galectin-1 per group. Figure shows graph of recombinant galectin-1 
binding. Data are expressed as mean  SEM, n = 3 per group, ** P < 0.01 vs freshly isolated as analysed 
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The binding of galectin-3 to freshly isolated PMN was higher than that of galectin-1 (110 ± 
16.75) and although significance was not reached this appears to decrease as cells come 
into contact with, and adhere to the endothelium (49.63 ± 14.37 and 49.00 ± 20.09 
respectively) as shown in Figure 3.8.  
 
Figure 3.8: Recombinant galectin-3 binding to PMN during adhesion to an endothelial monolayer. Freshly 
isolated PMN were left to adhere for 30 minutes to a HUVEC monolayer that had been pre-treated with 
10ng/mL hrTNF-. Non-adherent and adherent PMN were treated with recombinant galectin-3 (10nM) or 
vehicle for 15 minutes at 37C and assessed for their level of galectin-3 on the cell surface using Flow 
Cytometry compared to freshly isolated PMN. Endogenous expression of galectin-3 was subtracted from 
the total level to obtain the bound galectin-3 per group. Figure shows graph of recombinant galectin-3 
binding. Data are expressed as mean  SEM, n = 3 per group and are analysed by one-way ANOVA with 
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Galectin-9 binding was high in freshly isolated PMN (294.5 ± 64.5) and this was not 
significantly modulated upon contact with, or adhesion to a HUVEC monolayer (357. 8 ± 
57.68 and 271.1 ± 59.97 respectively) as shown in Figure 3.9. 
 
Figure 3.9: Stable, recombinant galectin-9 binding to PMN during adhesion to an endothelial monolayer. 
Freshly isolated PMN were left to adhere for 30 minutes to a HUVEC monolayer that had been pre-treated 
with 10ng/mL hrTNF-. Non-adherent and adherent PMN were treated with stable, recombinant galectin-9 
(10nM) or vehicle for 15 minutes at 37C and assessed for their level of galectin-9 on the cell surface 
using Flow Cytometry compared to freshly isolated PMN. Endogenous expression of galectin-3 was 
subtracted from the total level to obtain the bound galectin-9 per group. Figure shows graph of stable, 
recombinant galectin-9 binding. Data are expressed as mean  SEM, n = 3 per group and are analysed by 
one-way ANOVA with Bonferroni post hoc test. 
3.1.4 Modulation of the Neutrophil Glycophenotype during 
Transendothelial Migration 
Freshly isolated PMN were assessed for the modulation of their glycophenotype during 
transendothelial migration using a transwell system. HUVECs were seeded onto a transwell 
insert with 3m pores and left to become fully confluent (typically overnight), the cells were 
then stimulated for 4 hours with 10ng/mL hrTNF- to up-regulate cell adhesion molecules 
required for PMN adhesion and transmigration. Isolated PMN were added to the top of the 
transwell and allowed to transmigrate for 90 minutes. PMN were then collected from the top 
of the transwell (non-transmigrated) and from under the transwell (transmigrated). The 
collected populations of PMN were then assessed for their expression of activation markers 
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Similar to that seen in the 6-well assay freshly isolated PMN expressed high levels of CD62L 
(601.8 ± 84.91) and this was decreased by approximately 98% in non-transmigrated and 
transmigrated PMN (12.0 ± 1.167, P = 0.0025 and 6.967 ± 0.718, P = 0.0025 respectively). 
CD11b was also highly expressed by freshly isolated PMN (250.2 ± 25.29) but this was not 
modulated upon transmigration through an endothelial monolayer (343.8 ± 19.96 and 282.3 
± 3.65).  
 
Figure 3.10: Neutrophil activation marker expression in human PMN collected from the transwell assay. 
Blood was taken from healthy volunteers, PMN were isolated and added to a transwell on which a 
confluent monolayer of HUVECs had been pre-treated for 4 hours with 10ng/mL hrTNF-. The cells were 
allowed to transmigrate for 90 minutes and the expression of CD62L and CD11b was assessed by Flow 
Cytometry and compared to PMN that had not transmigrated (top well of transwell) as well as control PMN 
(that had not come into contact with HUVECs). A. Representative histogram and graph of CD62L expression 
and B. Representative histogram and graph of CD11b expression. Data are expressed as mean  SEM, N = 
3 per group, ** P < 0.01 vs freshly isolated PMN as analysed by one-way ANOVA with Bonferroni post hoc 
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Non-transmigrated and transmigrated PMN were then assessed by lectin binding. The 
expression of -linked galactose residues was significantly reduced as PMN transmigrated 
through an endothelial monolayer as shown by a 52% decrease in RCA120 binding (2109.67 
 937.16 vs 1020.22  450.53, P = 0.009) Figure 3.11.  
 
Figure 3.11: Binding of a -linked galactose-specific lectin to non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had 
been pre-treated with 10ng/mL hrTNF-. Non-transmigrated (NT) and transmigrated (T) PMN were 
collected and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to 
assess the expression of bound lectin. Figure shows representative histogram and graph of RCA120 binding. 
Grey = secondary antibody binding, blue = non-transmigrated PMN and red = transmigrated PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 10 per group. ** P < 0.01 
as analysed by two-tailed paired T test.  
As with the adherent cells a trend towards decreased lectin binding was seen between non-
transmigrated and transmigrated PMN. A 46% reduction in PNA binding was seen which 
was indicative of a decrease in the expression of mono-LacNAc residues as PMN traverse 
the endothelial monolayer (25.91  13.64 vs 14.06  7.78, P = 0.015) Figure 3.12a. No 
significant modulation could be seen when comparing LEL binding between non-
transmigrated and transmigrated PMN suggesting no statistically significant difference in the 
expression of poly-LacNAc residues, however a trend towards decreased expression on 
transmigrated PMN was observed with 2 out of 6 donors (269.2  123.0 vs 137.6  53.68, P 
= 0.127) Figure 3.12b. A decrease in the expression of complex tri- and tetra-antennary N-
glycans was seen as indicated by a 49% decrease in the binding of PHA-L when comparing 
non-transmigrated and transmigrated PMN (838  163.8 vs 420.7  44.84, P = 0.039) 
Figure 3.12c. 
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Figure 3.12: Binding of lectins indicative of galectin binding permissibility to non-transmigrated and 
transmigrated human PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a 
HUVEC monolayer that had been pre-treated with 10ng/mL hrTNF-. Non-transmigrated (NT) and 
transmigrated (T) PMN were collected and fixed overnight in 1% PFA before lectin binding took place. Flow 
Cytometry was used to assess the expression of bound lectin.  A. Representative histogram and graph of 
PNA binding, B. Representative histogram and graph of LEL binding and C. Representative histogram and 
graph of PHA-L binding. Grey = secondary antibody binding, blue = non-transmigrated PMN and red = 
transmigrated PMN. Data are expressed as median fluorescence intensity per donor for paired samples, n 
= 10 per group for PNA, 9 per group for LEL and 10 per group for PHA-L. * P < 0.05 as analysed by two-
tailed paired T test.  
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SNA binding decreased by 59% when comparing non-transmigrated and transmigrated PMN 
indicative of a decrease in the expression of 2,6-linked sialic acid residues upon 
transendothelial migration (469.30  348.58 vs 194.80  55.57, P = 0.048) Figure 3.13. 
 
Figure 3.13: Binding of an 2,6-linked sialic acid-specific lectin to non-transmigrated and transmigrated 
human PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF-. Non-transmigrated (NT) and transmigrated (T) PMN were 
collected and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to 
assess the expression of bound lectin.  Figure shows representative histogram and graph of SNA binding. 
Grey = secondary antibody binding, blue = non-transmigrated PMN and red = transmigrated PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 9 per group. * P < 0.05 as 
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The expression of fucose was significantly reduced in PMN that have transmigrated through 
an endothelial monolayer compared to those that didn’t as indicated by a 71% decrease in 
UEA I binding (21.99  14.08 vs 6.27  4.26, P = 0.006) Figure 3.14.  
 
Figure 3.14: Binding of an -linked fucose-specific lectin to non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had 
been pre-treated with 10ng/mL hrTNF-. Non-transmigrated (NT) and transmigrated (T) PMN were 
collected and fixed overnight in 1% PFA before lectin binding took place. Flow Cytometry was used to 
assess the expression of bound lectin.  Figure shows representative histogram and graph of UEA I binding. 
Grey = secondary antibody binding, blue = non-transmigrated PMN and red = transmigrated PMN. Data are 
expressed as median fluorescence intensity per donor for paired samples, n = 10 per group. ** P < 0.01 
as analysed by two-tailed paired T test.  
3.1.5 Galectin Binding to Isolated Neutrophils Pre- and Post-
Transendothelial Migration  
To assess the binding of galectins-1, -3 and -9 to human neutrophils following 
transendothelial migration the model of transwell transmigration was utilised once more as 
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Galectin-1 binding was low in freshly isolated PMN (5.658  2.399); this increased by 
approximately 4-fold in non-transmigrated PMN and this increased again by 1.5-fold as PMN 
transmigrated (21.52  6.70 and 32.30  8.17 respectively) suggesting an increase in 
binding sites for galectin-1 becoming available as PMN transmigrate though an endothelial 
monolayer as shown in Figure 3.15. 
 
 
Figure 3.15: Binding of recombinant galectin-1 to non-transmigrated and transmigrated human PMN. 
Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had been 
pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were treated with 
recombinant galectin-1 (10nM) or vehicle for 15 minutes at 37C and assessed for their level of galectin-1 
on the cell surface using Flow Cytometry compared to freshly isolated PMN. Endogenous expression of 
galectin-1 was subtracted from the total level to obtain the total bound galectin-1 per group. Figure shows 
graph of recombinant galectin-1 binding. Data are expressed as mean  SEM, n = 6 per group, * P < 0.05 
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Galectin-3 bound to freshly isolated PMN at high levels compared to galectin-1 (108.7  
29.8) and this was not modulated significantly by contact with, or transmigration through 
endothelial cells (143.02  105.94 and 112.05  42.99 respectively) suggesting the number 
of counter-receptors for galectin-3 were unchanged upon PMN transendothelial migration as 
shown in Figure 3.16. 
 
Figure 3.16: Binding of recombinant galectin-3 to non-transmigrated and transmigrated human PMN. 
Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had been 
pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were collected, treated 
with recombinant galectin-3 (10nM) or vehicle for 15 minutes at 37C and assessed for their level of 
galectin-3 on the cell surface using Flow Cytometry compared to freshly isolated PMN. Endogenous 
expression of galectin-3 was subtracted from the total level to obtain the total bound galectin-3 per group. 
Figure shows graph of recombinant galectin-3 binding. Data are expressed as mean  SEM, n = 6 per 
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Very high galectin-9 binding could be seen in freshly isolated PMN (851.4  342.9) however 
this was not modulated as PMN come into contact with, and traffic through an endothelial 
monolayer (816.58  438.01 and 521.8  151.09, P = 0.075) suggesting that, similar to 
galectin-3, the number of counter-receptors for galectin-9 were unchanged as shown in 
Figure 3.17.  
 
Figure 3.17: Binding of stable, recombinant galectin-9 to non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had 
been pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were collected, 
treated with stable, recombinant galectin-9 (10nM) or vehicle for 15 minutes at 37C and assessed for 
their level of galectin-9 on the cell surface using Flow Cytometry compared to freshly isolated PMN. 
Endogenous expression of galectin-9 was subtracted from the total level to obtain the total bound galectin-
9 per group. Figure shows graph for stable, recombinant galectin-9 binding. Data are expressed as mean  
SEM, n = 6 per group and analysed by one-way ANOVA with Bonferroni post hoc test.  
3.1.6 Identification of Granule Release during Neutrophil 
Transendothelial Migration 
As the glycophenotype was modulated by transendothelial migration (section 3.1.4) it was 
important to ascertain whether the changes were arising via PMN granule release or via 
interaction with the endothelial cells. Thus PMN were treated with stimulants that induce 
granule release similar to that seen in the transwell transmigration assay and the 
glycophenotype compared.  
Non-transmigrated and transmigrated PMN were collected following the transwell 
transmigration assay and without fixation were analysed for their expression of granule 
release markers, CD35 (a marker for secretory vesicles) and CD66b (a marker for 
secondary granules). hrTNF- (10ng/mL) and fMLP (1M) were used as positive controls to 
stimulate freshly isolated PMN as these induce the release of secretory vesicles and 
secondary granules respectively (Norling et al., 2012).  
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Freshly isolated PMN express low levels of CD35 (68.93 ± 12.86) and there was a significant 
increase in expression in non-transmigrated (198.7 ± 35.06, P = 0.0156) and transmigrated 
PMN (164.0 ± 24.89, P = 0.0189) as shown in Figure 3.18. 
 
Figure 3.18: Secretory vesicles are released following activation of human PMN. PMN were isolated from 
healthy volunteers and either allowed to transmigrate for 90 minutes through a confluent monolayer of 
HUVEC cells that had been pre-treated with hrTNF- (10ng/mL) for 4 hours or directly stimulated with 
10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C. PMN were collected from each treatment and 
assessed for their expression of CD35 using Flow Cytometry compared to freshly isolated PMN. Shaded 
peak = isotype control. Data are expressed as mean  SEM, n = 3-5 per group. * P < 0.05 vs control as 













CHAPTER 3: RESULTS (1) 
110 
CD66b was expressed by freshly isolated PMN at low levels (32.09 ± 4.599), this was not 
significantly modulated in PMN that have not transmigrated through the monolayer (56.57 ± 
12.55), however a significant increase in the expression of CD66b was seen in PMN that 
had transmigrated through the endothelial monolayer by approximately 3 fold (92.77 ± 9.742, 
P = 0.026). The positive control fMLP also induced CD66b up-regulation as expected 
(Figure 3.19). These results indicate that transendothelial migration promotes the release of 
secondary granules from PMN.  
 
Figure 3.19: Neutrophil secondary granules are released following transmigration. PMN were isolated from 
healthy volunteers and either allowed to transmigrate for 90 minutes through a confluent monolayer of 
HUVEC cells that had been pre-treated with hrTNF- (10ng/mL) for 4 hours or directly stimulated with 
10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C. PMN were collected from each treatment and 
assessed for their expression of CD66b using Flow Cytometry compared to freshly isolated PMN. Shaded 
peak = isotype control. Data are expressed as mean  SEM, n = 3-5 per group.  * P < 0.05 and *** P < 
0.001 vs control as analysed by One-Way ANOVA with Dunnetts post-hoc test. 
Non-transmigrated PMN release their secretory vesicles while those that have transmigrated 
through begin to release their secondary granules. Thus freshly isolated PMN were treated 
with 10ng/mL hrTNF- (which induces the release of secretory vesicles only) or 1µM fMLP 
(which induces the release of secretory vesicles, tertiary granules and secondary granules) 
for 90 minutes at 37C. The PMN were fixed overnight in 1% PFA and then incubated with 
the lectins shown in Table 2.3 to assess whether granule release induced the changes seen 
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RCA120 binding was high in freshly isolated PMN (711.4  145.4) and this did not change in 
control PMN, which were incubated at 37C for 90 minutes (695.8  140.6). Mobilisation of 
PMN granules using 10ng/mL hrTNF- and 1M fMLP was unable to induce changes in the 
expression of -linked galactose residues on the PMN following 90-minute incubation as 
demonstrated by no modulation of binding of RCA120 (731.7  165.4 and 713.5  139.8 
respectively) (Figure 3.20). 
 
Figure 3.20: Binding of RCA120 to human PMN following 90-minute stimulation with hrTNF- or fMLP. PMN 
were isolated from healthy volunteers and either fixed immediately (freshly isolated) or incubated with 
vehicle (PBS), 10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C. Following this the cells were 
washed twice in PBS and fixed overnight in 1% PFA. The fixed PMN were incubated with lectins and the 
binding assessed using Flow Cytometry. Figure shows representative histogram and graph for RCA120 
binding. Shaded peak = isotype control. Data are expressed as mean  SEM, N = 7 per group and are 
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PNA binding was low on freshly isolated PMN (55.87  14.53) and this was unaltered in 
control, hrTNF-α or fMLP treated cells (52.72  17.49, 70.64  20.44 and 61.94  18.92 
respectively). LEL binding was high on freshly isolated PMN (726.5  216.2) and, similar to 
PNA was not modulated in control, hrTNF-α or fMLP treated cells (686.3  205.4, 609.1  
169 and 594.1  172.2 respectively). PHA-L binding was also high on freshly isolated PMN 
(930.4  150.3) and this was also unaltered in control, hrTNF-α or fMLP treatment (868.2  
152.5, 1100  195 and 1030  173.6 respectively). Taken together this suggests granule 
release does not cause the changes in mono- or poly-LacNAc residues or complex tri- and 
tetra-antennary N-glycans seen during transmigration (Figure 3.21).   
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Figure 3.21: Binding of lectins indicative of galectin binding permissibility to human PMN following 90-
minute stimulation with hrTNF- or fMLP. PMN were isolated from healthy volunteers and either fixed 
immediately (freshly isolated) or incubated with vehicle (PBS), 10ng/mL hrTNF- or 1M fMLP for 90 
minutes at 37C. Following this the cells were washed twice in PBS and fixed overnight in 1% PFA. The 
fixed PMN were incubated with lectins and the binding assessed using Flow Cytometry. A. Representative 
histogram and graph for PNA binding, B. Representative histogram and graph for LEL binding and C. 
Representative histogram and graph for PHA-L binding. Shaded peak = isotype control. Data are expressed 
as mean  SEM, n = 7 per group and are analysed by repeated measures one-way ANOVA with Bonferroni 
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Sialic acid was expressed at high levels by freshly isolated PMN (310.6  176.6) and 
although large deviations were detected within data sets it appears that the expression of 
2,6-linked sialic acid was not modulated by incubation at 37˚C or stimulation of human 
PMN with 10ng/mL hrTNF- or 1M fMLP as shown by no change in the binding of SNA 
(511.3  325.6, 605.6  393.2 and 497  288.2 respectively) (Figure 3.22). 
 
Figure 3.22: Binding of SNA to human PMN following 90-minute stimulation with hrTNF- or fMLP. PMN 
were isolated from healthy volunteers and either fixed immediately (freshly isolated) or incubated with 
vehicle (PBS), 10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C. Following this the cells were 
washed twice in PBS and fixed overnight in 1% PFA. The fixed PMN were incubated with lectins and the 
binding assessed using Flow Cytometry. Figure shows representative histogram and graph for SNA binding. 
Shaded peak = isotype control. Data are expressed as mean  SEM, n = 7 per group and are analysed by 
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UEA I binding was low on freshly isolated PMN (13.14  3.123) and there was no modulation 
of the binding of UEA I and thus expression of fucose residues on human PMN following 
stimulation with vehicle, 10ng/mL hrTNF- or 1M fMLP (11.08  2.701, 15.82  3.365 and 
13.1  3 respectively) (Figure 3.23). 
 
Figure 3.23: Binding of UEA I to human PMN following 90-minute stimulation with hrTNF- or fMLP. PMN 
were isolated from healthy volunteers and either fixed immediately (freshly isolated) or incubated with 
vehicle (PBS), 10ng/mL hrTNF- or 1M fMLP for 90 minutes at 37C. Following this the cells were 
washed twice in PBS and fixed overnight in 1% PFA. The fixed PMN were incubated with UEA I and the 
binding assessed using Flow Cytometry. Figure shows representative histogram and graph for UEA I 
binding. Shaded peak = isotype control. Data are expressed as mean  SEM, n = 7 per group and are 
analysed by repeated measures one-way ANOVA with Bonferroni post hoc test.  
3.1.7 Galectin Binding to Isolated Neutrophils following Granule 
Release 
The binding of recombinant galectins-1, -3 and -9 was then assessed following 90-minute 
stimulation with 10ng/mL hrTNF- or 1M fMLP to determine the effect of secretory vesicle 
and secondary granule release respectively on the binding of the galectins and compared to 
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The binding of galectin-1 to freshly isolated PMN was low (1.828  0.705) and this was 
unchanged in PMN that were treated with 10ng/mL hrTNF- (2.738  1.085) or 1M fMLP 
(1.2  0.7517, P = 0.031) for 90 minutes suggesting no change in galectin-1 counter-
receptors occurred following release of secretory vesicles or secondary granules (Figure 
3.24).  
 
Figure 3.24: Binding of recombinant galectin-1 to isolated PMN following 90-minute stimulation with 
hrTNF- or fMLP. Freshly isolated PMN were incubated with 10ng/mL hrTNF- or 1M fMLP for 90 minutes 
at 37C; PMN were collected, treated with recombinant galectin-1 (10nM) or vehicle for 15 minutes at 
37C and assessed for their level of galectin-1 on the cell surface using Flow Cytometry compared to 
freshly isolated PMN. Endogenous expression of galectin-1 was subtracted from the total level to obtain 
the total bound galectin-1. Figure shows graph of recombinant galectin-1 binding. Data are expressed as 
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Binding of galectin-3 to freshly isolated PMN was higher than that seen for galectin-1 (47.38 
 10.2); this was not modulated following 90-minute treatment with either 10ng/mL hrTNF- 
or 1M fMLP (37.06  21.43 and 53.16  21.49 respectively) suggesting no change in the 
binding sites for galectin-3 following granule release (Figure 3.25).  
 
Figure 3.25: Binding of recombinant galectin-3 to isolated PMN following 90-minute stimulation with 
hrTNF- or fMLP. Freshly isolated PMN were incubated with 10ng/mL hrTNF- or 1M fMLP for 90 minutes 
at 37C; PMN were collected, treated with recombinant galectin-3 (10nM) or vehicle for 15 minutes at 
37C and assessed for their level of galectin-3 on the cell surface using Flow Cytometry compared to 
freshly isolated PMN. Endogenous expression of galectin-3 was subtracted from the total level to obtain 
the total bound galectin-3. Figure shows graph of recombinant galectin-3 binding. Data are expressed as 
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Galectin-9 binds highly to freshly isolated PMN (388.1  62.67) and this level does not 
change following 90-minute stimulation with 10ng/mL hrTNF- (397.7  12.22) however the 
binding significantly increases upon treatment with 1M fMLP (576.4  112.1, P = 0.015). 
This suggests under basal conditions receptor(s) for galectin-9 are present on the PMN and 
these either increase or additional receptors are translocated to the cell surface upon 
release of secondary granules (Figure 3.26). 
 
Figure 3.26: Binding of stable, recombinant galectin-9 to isolated PMN following 90-minute stimulation 
with hrTNF- or fMLP. Freshly isolated PMN were incubated with 10ng/mL hrTNF- or 1M fMLP for 90 
minutes at 37C; PMN were collected, treated with stable, recombinant galectin-9 (10nM) or vehicle for 15 
minutes at 37C and assessed for their level of galectin-9 on the cell surface using Flow Cytometry 
compared to freshly isolated PMN. Endogenous expression of galectin-9 was subtracted from the total level 
to obtain the total bound galectin-9. Figure shows stable, recombinant galectin-9 binding. Data are 
expressed as mean  SEM, n = 4 per group, * P < 0.05 vs freshly isolated unless otherwise indicated as 
analysed by one-way ANOVA with Bonferroni post hoc test. 
3.1.8 Effect of Endothelial Cell-Derived Factors on the 
Glycophenotype of Neutrophils 
As the changes in human PMN glycophenotype was not a consequence of granule release 
(section 3.1.6) the role of the endothelium and endothelial-derived factors were therefore 
assessed. 
Freshly isolated PMN were placed in the bottom well of 6-well plate and a confluent 
monolayer of HUVECs on a transwell insert that had been pre-treated with 10ng/mL hrTNF-
 for 4 hours was added above the PMN. The cells were incubated together at 37C for 90 
minutes to mimic the conditions seen in the transwell transmigration assay, following this the 
PMN were collected, fixed overnight and assessed for their glycophenotype as previously 
performed. 
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As described before, the binding of RCA120 was high in freshly isolated PMN and this did not 
change following 90 minute incubation at 37C. However, a significant increase occurred as 
a consequence of endothelial-derived factors (922.1  178.1 vs 2068  511.5, P = 0.019), 
which matches the increase seen in cells that come into contact with the HUVEC but neither 
adhere nor transmigrate confirming that these changes were due to a secreted factor from 
the activated endothelium (Figure 3.27).  
 
Figure 3.27: RCA120 binding to PMN that were separated from direct cell-cell contract with HUVECs by a 
transwell. PMN were isolated from healthy volunteers and placed in the lower well of a 6-well plate with a 
pre-activated confluent monolayer of HUVEC cells on a transwell on top. This was incubated at 37C for 90 
minutes and the binding of RCA120 was assessed in comparison to freshly isolated PMN and those that had 
been incubated in the absence of HUVECs. Figure shows representative histogram and graph of RCA120 
binding. Shaded peak = isotype control. Data are expressed as mean ± SEM, n = 5 per group, * P < 0.05 
as analysed by one-way ANOVA with Bonferroni post hoc test.  
The expression of mono-LacNAc residues was low in freshly isolated cells compared to the 
expression of poly-LacNAc residues and complex tri- and tetra-antennary N-glycans as 
determined by binding of PNA, LEL and PHA-L respectively (52.22  9.871, 874.4  197.9 
and 958.4  12.7). No significant modulation of expression of these residues was observed 
following stimulation with endothelial cell-derived secreted factors; this was particularly 
evident for PNA binding (54.28  10.43). However, a trend towards increased expression 
was seen with LEL (1288  263.5) and PHA-L (1388  21.2) but this did not reach statistical 
significance as shown in Figure 3.28. This opposes the findings from non-adherent and non-
transmigrated PMN as these demonstrate decreased binding of PNA, LEL and PHA-L 
compared to freshly isolated cells and thus this cannot be attributed to a secreted endothelial 
factor.  
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Figure 3.28: Galectin-permissive lectin binding to PMN that were separated from direct cell-cell contact 
with HUVECs by a transwell. PMN were isolated from healthy volunteers and placed in the lower well of a 6-
well plate with a pre-activated confluent monolayer of HUVEC cells on a transwell on top. This was 
incubated at 37C for 90 minutes and the binding of lectins was assessed in comparison to freshly 
isolated PMN and those that had been incubated in the absence of HUVECs. A. Representative histogram 
and graph showing binding of PNA, B. Representative histogram and graph showing binding of LEL and C. 
Representative histogram and graph showing binding of PHA-L. Shaded peak = isotype control. Data are 
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The expression of 2,6-linked sialic acid was high on freshly isolated PMN as demonstrated 
by SNA binding (393.2  136.1) and, similar to that seen with LEL and PHA-L, the binding of 
SNA appeared to follow a trend towards an increase upon incubation with factors secreted 
from activated HUVECs (859.7  181) as shown in Figure 3.29. This correlated with the 
finding from PMN in the transwell assay that have not transmigrated as these also 
demonstrated an increase in the expression of 2,6-linked sialic acid; PMN that were non-
adherent to the endothelium exhibit decreased SNA binding however these were in contact 
with the HUVECs for a shorter period of time. 
 
Figure 3.29: SNA binding to PMN that were separated from direct cell-cell contact with HUVECs by a 
transwell. PMN were isolated from healthy volunteers and placed in the lower well of a 6-well plate with a 
pre-activated confluent monolayer of HUVEC cells on a transwell on top. This was incubated at 37C for 90 
minutes and the binding of SNA was assessed in comparison to freshly isolated PMN and those that had 
been incubated in the absence of HUVECs. Figure shows representative histogram and graph of SNA 
binding. Shaded peak = isotype control. Data are expressed as mean ± SEM, n = 5 per group and are 
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The binding of UEA I was low in freshly isolated PMN suggesting low expression of -linked 
fucose residues however upon contact with mediators that were released from activated 
HUVECs this increased approximately 3-fold (27.61  9.02 vs 101.6  19.97, P = 0.017) as 
seen in Figure 3.30. As with SNA binding this closely mimicked the response seen in PMN 
that did not transmigrate through the HUVECs in the transwell assay but not those that were 
non-adherent in the 6-well assay suggesting endothelial cell-derived factors were causing 
these effects but may take a longer time frame than 30 minutes to do so.  
 
Figure 3.30: UEA I binding to PMN that were separated from direct cell-cell contact with HUVECs by a 
transwell. PMN were isolated from healthy volunteers and placed in the lower well of a 6-well plate with a 
pre-activated confluent monolayer of HUVEC cells on a transwell on top. This was incubated at 37C for 90 
minutes and the binding of UEA I was assessed in comparison to freshly isolated PMN and those that had 
been incubated in the absence of HUVECs. Figure shows representative histogram and graph of UEA I 
binding. Shaded peak = isotype control. Data are expressed as mean ± SEM, n = 5 per group, * P < 0.05 
vs freshly isolated PMN as analysed by one-way ANOVA with Bonferroni post hoc test.  
3.1.9 Modulation of the Glycophenotype of Neutrophils during 
Exudation to the Buccal Cavity 
Although the transwell transmigration assay is able to provide information on the effect of 
PMN transendothelial migration it is unable to accurately portray the recruitment of PMN that 
occurs pathologically. During inflammation PMN respond to chemokines and cytokines by 
transmigrating through an endothelial monolayer to leave the circulation and then traffic to 
an inflammatory site through the extracellular matrix coming into contact with many other cell 
types; once at the site of inflammation the primary granules are released and the PMN are 
phenotypically very different to those in the circulation (Chilvers et al., 2000). In order to 
provide a more pathophysiological model of human PMN recruitment healthy volunteers 
were utilised to collect PMN that had recruited to the Buccal cavity in response to mild 
inflammation.   
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Healthy volunteers performed the Tobasco mouth rinse as described in section 2.2.3 and 
the exudated PMN were collected (approximately 5-10 x 106 per donor), fixed overnight in 
1% PFA and assessed for their lectin binding compared to paired peripheral blood samples.  
No difference was seen in the binding of RCA120 when comparing peripheral blood 
neutrophils to those recruited in response to neurogenic inflammation suggesting no 
modulation of the expression of -linked galactose residues (760.2  138.7 vs 782.8  145.1) 
Figure 3.31.  
 
Figure 3.31: Lectin binding profile for -linked galactose residues on human peripheral blood and 
exudated PMN. Healthy volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour 
exudated PMN were collected by saline wash, peripheral blood PMN were also isolated by dextran 
sedimentation. Both groups of PMN were washed twice and fixed overnight in 1% PFA. The fixed PMN were 
incubated with lectins and the binding was assessed using Flow Cytometry. Figure shows representative 
histogram and graph for RCA120 binding. Grey = secondary antibody only, burgundy = peripheral blood PMN 
and purple = exudated PMN. Data are expressed as mean  SEM, n = 7 per group, and are analysed by 
two-tailed T test.  
The expression of mono-LacNAc residues on recruited PMN was significantly higher than 
peripheral blood PMN as shown by a 9-fold increase in binding of PNA (27.83  3.498 vs 
264.3  89.78, P = 0.0411) Figure 3.32a. The binding of LEL and PHA-L was not 
significantly modulated between the two groups suggesting no significant differences could 
be seen in the expression of poly-LacNAc residues (1095  199.1 vs 858.2  239.0) or of 
complex tri- and tetra-antennary N-glycans (850  175.9 vs 936.4  82.02) Figure 3.32.  
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Figure 3.32: Lectin binding profile for galectin binding-permissive residues on human peripheral blood and 
exudated PMN. Healthy volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour 
exudated PMN were collected by saline wash, peripheral blood PMN were also isolated by dextran 
sedimentation. Both groups of PMN were washed twice and fixed overnight in 1% PFA. The fixed PMN were 
incubated with lectins and the binding was assessed using Flow Cytometry. A. Representative histogram 
and graph for PNA binding, B. Representative histogram and graph for LEL binding and C. Representative 
histogram and graph for PHA-L binding. Grey = secondary antibody only, burgundy = peripheral blood PMN 
and purple = exudated PMN. Data are expressed as mean  SEM, n = 7 per group, * P < 0.05 vs peripheral 
blood as analysed by two-tailed T test.  
 
 
CHAPTER 3: RESULTS (1) 
125 
The expression of 2,6-linked sialic acid was significantly increased in PMN that have 
trafficked to the buccal cavity compared to those in the peripheral blood with a 2 fold 
increase in SNA binding (333.2  16.76 vs 747.1  56.6, P = 0.0146) Figure 3.33.  
 
Figure 3.33: Lectin binding profile for 2,6-linked sialic acid-specific residues on human peripheral blood 
and exudated PMN. Healthy volunteers rinsed their mouths with a 10% Tobasco solution and following 1 
hour exudated PMN were collected by saline wash, peripheral blood PMN were also isolated by dextran 
sedimentation. Both groups of PMN were washed twice and fixed overnight in 1% PFA. The fixed PMN were 
incubated with lectins and the binding was assessed using Flow Cytometry. Figure shows representative 
histogram and graph for SNA binding. Grey = secondary antibody only, burgundy = peripheral blood PMN 
and purple = exudated PMN. Data are expressed as mean  SEM, n = 7 per group, * P < 0.05 vs peripheral 
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Fucose residues were not significantly modulated when comparing recruited PMN to those in 
the peripheral circulation as demonstrated by the lack of difference in UEA I binding (26.62  
6.606 vs 16.24  5.860) Figure 3.34.  
 
Figure 3.34: Lectin binding profile for -linked fucose residues on human peripheral blood and recruited 
PMN. Healthy volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour exudated 
PMN were collected by saline wash, peripheral blood PMN were also isolated by dextran sedimentation. 
Both groups of PMN were washed twice and fixed overnight in 1% PFA. The fixed PMN were incubated with 
UEA I and the binding was assessed using Flow Cytometry. Figure shows representative histogram and 
graph for UEA I binding. Grey = secondary antibody only, burgundy = peripheral blood PMN and purple = 
exudated PMN. Data are expressed as mean  SEM, n = 7 per group, Data are analysed by two-tailed T 
test.  
3.1.10 Galectin Binding to Neutrophils during Exudation to the 
Buccal Cavity 
Galectin binding was compared between PMN isolated from the peripheral circulation of 
healthy volunteers and those that had trafficked to the buccal cavity in response to pro-
inflammatory stimulation (Tobasco mouth rinse). PMN were collected from paired donors 
and incubated with recombinant galectins-1, -3 or -9 for 15 minutes at 37˚C; following this 
the cells were washed and analysed for the level of bound galectin by subtracting the 
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The binding of galectin-1 to peripheral blood PMN was low as previously determined 
however PMN that extravasated to the buccal cavity had significantly diminished galectin-1 
binding (3.860  1.191 vs 0.1167  0.04, P = 0.0348) as shown in Figure 3.35. 
 
Figure 3.35: Binding of recombinant galectin-1 to peripheral blood and exudated human PMN. Healthy 
volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN were 
collected by saline wash, peripheral blood PMN were also isolated by dextran sedimentation. Both groups 
of PMN were treated with recombinant galectin-1 (10nM) or vehicle for 15 minutes at 37C and assessed 
for their level of galectin-1 on the cell surface using Flow Cytometry compared to freshly isolated PMN. 
Endogenous expression of galectin-1 was subtracted from the total level to obtain the total bound galectin-
1. Figure shows graph of recombinant galectin-1 binding. Data are expressed as mean  SEM, n = 4 per 
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Galectin-3 bound to peripheral blood PMN at a higher level than galectin-1 and this 
significantly increased by almost 65% upon exudation of the PMN to an inflammatory site 
(128.6  5.953 vs 209.6  25.4, P = 0.0361) as shown in Figure 3.36. 
 
Figure 3.36: Binding of recombinant galectin-3 to peripheral blood and exudated human PMN. Healthy 
volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN were 
collected by saline wash, peripheral blood PMN were also isolated by dextran sedimentation. Both groups 
of PMN were treated with recombinant galectin-3 (10nM) or vehicle for 15 minutes at 37C and assessed 
for their level of galectin-3 on the cell surface using Flow Cytometry compared to freshly isolated PMN. 
Endogenous expression of galectin-3 was subtracted from the total level to obtain the total bound galectin-
1. Figure shows graph of recombinant galectin-3 binding. Data are expressed as mean  SEM, n = 4 per 
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Galectin-9 binding was high on peripheral blood PMN however, similar to galectin-3, this 
significantly increased by approximately 95% upon exudation to the buccal cavity in 
response to Tobasco stimulation (223.6  19.46 vs 432.4  39.47, P = 0.009) as shown in 
Figure 3.37. 
 
Figure 3.37: Binding of stable, recombinant galectin-9 to peripheral blood and exudated human PMN. 
Healthy volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN 
were collected by saline wash, peripheral blood PMN were also isolated by dextran sedimentation. Both 
groups of PMN were treated with stable, recombinant galectin-9 (10nM) or vehicle for 15 minutes at 37C 
and assessed for their level of galectin-9 on the cell surface using Flow Cytometry compared to freshly 
isolated PMN. Endogenous expression of galectin-9 was subtracted from the total level to obtain the total 
bound galectin-9. Figure shows graph of stable, recombinant galectin-9 binding. Data are expressed as 
mean  SEM, n = 4 per group, ** P < 0.01 as analysed by one-way ANOVA with two-tailed T-test. 
In summary, galectin-1 binding was not modulated upon human PMN adhesion to an 
endothelial monolayer but increases following transendothelial migration; this contradicts the 
fMLP stimulation assay as those PMN had decreased galectin-1 binding, as do the cells that 
have trafficked to an inflammatory site.  
Galectin-3 binding to human PMN was not significantly modulated by adhesion to or 
transmigration through an endothelial monolayer or by stimulation of the cells with hrTNF-α 
or fMLP; however the binding was significantly increased to PMN that were recruited to the 
buccal cavity in response to pro-inflammatory stimulation (Tobasco mouth wash).  
The binding of stable, recombinant galectin-9 to human PMN was high on freshly isolated 
cells and this was not significantly modulated by adhesion or transmigration through a 
HUVEC monolayer. Upon activation of the PMN with fMLP or trafficking to an inflammatory 
site binding increases, potentially suggesting additional counter-receptor(s) for galectin-9 are 
released under these conditions. 
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3.1.11 Modulation of the Glycophenotype of Murine Neutrophils 
from the Peripheral Blood to the Peritoneal Cavity  
A murine model of acute inflammation was utilised to study the differences in lectin binding 
on murine neutrophils; comparing peripheral blood neutrophils to recruited cells within the 
peritoneal cavity. Zymosan (1mg/mouse) was administered intraperitoneally into male 6-
week old C57BL/6 mice and after 4 hours the mice were anaesthetised and cardiac 
punctures and peritoneal lavages were performed to obtain peripheral blood and exudated 
neutrophils respectively. Neutrophils were identified with a specific Ly6G antibody and a 
validated panel of lectins were used to assess the neutrophil glycophenotype.  
RCA120 binding was low in murine peripheral blood neutrophils compared to human cells and 
binding decreased by approximately 60% when comparing those in the peripheral circulation 
to those that exudated suggesting a loss of -linked galactose upon trafficking (20.84  3.10 
vs 8.18  3.20, P = 0.009) Figure 3.38. 
 
Figure 3.38: Lectin binding profile for -linked galactose residues on murine peripheral blood and 
peritoneal exudate recruited neutrophils. Peritonitis was induced following administration of 1mg zymosan 
ip. and peripheral blood (burgundy) and peritoneal exudate (purple) was collected 4 hours later. 
Neutrophils were labelled with Ly6G and double stained for RCA120 and the binding of lectins to neutrophils 
was analysed by Flow Cytometry. Figure shows representative histogram and graph for RCA120 binding. 
Data are expressed as mean  SEM, N = 3 per group, ** P < 0.01 vs Blood as analysed by two-tailed T 
test. 
Human peripheral blood PMN bind low levels of PNA and high levels of LEL and PHA-L; this 
is altered in murine peripheral blood neutrophils that bind high levels of PNA and PHA-L and 
low levels of LEL. An overall trend towards decreased lectin binding was seen in exudated 
neutrophils compared to those in the peripheral blood with a 81% decrease in the binding of 
PNA (201.53  4.73 vs 38.01  18.51, P = 0.007), a 44% decrease in LEL binding (19.01  
2.07 vs 10.71  1.89, P = 0.001) and an 86% decrease in PHA-L binding (3900.21  193.94 
vs 551.78  125.01, P = 0.0001) Figure 3.39. This was indicative of a significant loss of 
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mono- and poly-LacNAc residues and complex tri- and tetra antennary N-glycans as 
neutrophils trafficked to an inflammatory site.  
 
Figure 3.39: Lectin binding for residues permissive for galectin binding on murine peripheral blood and 
peritoneal exudate recruited neutrophils. Peritonitis was induced following administration of 1mg zymosan 
ip. and peripheral blood (burgundy) and peritoneal exudate (purple) was collected 4 hours later. 
Neutrophils were labelled with Ly6G and double stained for lectins and the binding of lectins to neutrophils 
was analysed by Flow Cytometry. A. Representative histogram and graph for PNA binding, B. 
Representative histogram and graph for LEL binding and C. Representative histogram and graph for PHA-L 
binding. Data are expressed as mean  SEM, N = 3 per group, ** P < 0.01 vs blood as analysed by two-
tailed T test.  
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Murine peripheral blood neutrophils express lower levels of α-linked sialic acid than human 
PMN as demonstrated by lower SNA binding. A significant loss of 2,6-linked sialic acid was 
observed on exudated neutrophils compared to those in the peripheral circulation as 
demonstrated by a 93% loss of SNA binding (49.51  5.32 vs 3.55  1.85, P = 0.006) Figure 
3.40.  
 
Figure 3.40: Lectin binding for 2,6-linked sialic acid residues on murine peripheral blood and peritoneal 
exudate recruited neutrophils. Peritonitis was induced following administration of 1mg zymosan i.p. and 
peripheral blood (burgundy) and peritoneal exudate (purple) was collected 4-hours later. Neutrophils were 
labelled with Ly6G and double-stained for SNA binding and the binding of SNA to neutrophils was analysed 
by Flow Cytometry. Figure shows representative histogram and graph for SNA binding. Data are expressed 
as median fluorescence intensity per sample for paired donors, N = 3 per group, ** P < 0.01 vs blood as 
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Collectively, the data gathered from human and murine studies should be compared to 
assess whether any species differences are observed in neutrophil glycophenotype. Murine 
neutrophils in the peripheral circulation expressed higher levels of α-linked fucose compared 
to human cells. The expression of fucose residues was significantly diminished upon 
neutrophil trafficking to a site of inflammation as demonstrated by a 75% loss of UEA I 
binding to neutrophils in the peritoneal cavity compared to those in the peripheral circulation 
(94.68  5.81 vs 22.98  3.98, P = 0.005) Figure 3.41.   
 
Figure 3.41: Lectin binding for -linked fucose residues on murine peripheral blood and peritoneal exudate 
recruited neutrophils. Peritonitis was induced following administration of 1mg zymosan ip. and peripheral 
blood (burgundy) and peritoneal exudate (purple) was collected 4-hours later, Neutrophils were labelled 
with Ly6G and double-stained for UEA I binding and the binding of UEA I to neutrophils was analysed by 
Flow Cytometry. Figure shows representative histogram and graph for UEA I binding. Data are expressed as 
median fluorescence intensity per sample for paired donors, N = 3 per group, ** P < 0.01 vs blood as 
analysed by two-tailed paired T test. 
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3.2 Discussion 
The glycophenotype of human PMN was modulated by co-culture with, adhesion to and 
transmigration through an endothelial monolayer; this was not a direct consequence of 
granule release, or of endothelial cell-derived mediators as demonstrated by an inability of 
granule release or conditioned medium to mimic the phenotype changes. Thus the 
modulation seen was most likely a combination of the two factors and also a direct 
consequence of transendothelial migration.  
Murine and human models of pathophysiological inflammation were used to collect 
neutrophils that had migrated to an inflammatory site and although it was hypothesised that 
the lectin binding profile of exudated murine neutrophils would be similar to that of human 
exudated neutrophils this was not the case and large variation was seen with many of the 
lectins.  
This study suggests that analysis of the glycophenotype of neutrophils is not a suitable 
marker for galectin binding permissibility, this may be due to the loss of heavily glycosylated 
proteins from the cell surface upon activation skewing the results rather than the action of 
specific glycosylation enzymes as is seen with adaptive immune cells.  
It was initially postulated that the differential responses seen to galectin binding were 
dependent either on the modulation of the glycophenotype of the neutrophil affecting 
galectin binding permissibility or the differential expression of galectins during an 
inflammatory response thus the next chapter addresses the second part of this hypothesis 
by assessing the galectin expression profile in both isolated human neutrophils that have 
been transmigrated through an endothelial monolayer and murine leukocytes in vivo using a 
resolving model of acute inflammation.  
  




RESULTS (2): MODULATION OF THE GALECTIN 
EXPRESSION PROFILE OF LEUKOCYTES 
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4 Modulation of the Galectin 
Expression Profile of Leukocytes 
4.1 Introduction 
Galectins-1, -3 and -9 are all known to be expressed by leukocytes of the innate 
immune system (Gil et al., 2006a, Truong et al., 1993, Sanchez-Cuellar et al., 2012, 
Sato and Hughes, 1994), however these lectins have opposing actions. Galectins-1 
and -9 act on cells of the innate immune system to promote a reduction in recruitment 
(Cooper et al., 2008, Rabinovich et al., 2000, La et al., 2003, He et al., 2009) while 
galectin-3 increases the recruitment of leukocytes to an inflammatory site (Colnot et al., 
1998b, Hsu et al., 2000). It can therefore be hypothesised that the expression of each 
galectin is tightly controlled to ensure leukocytes are not activated during homeostasis.  
Published studies have also demonstrated that the localisation of the galectin affects 
the function with intracellular galectin-3 binding to Bcl-2 proteins in Jurkat T cells and 
preventing apoptosis (Akahani et al., 1997) while the same lectin bound to the surface 
of CD4+ T cells promotes their apoptosis (Fukumori et al., 2003). Therefore it can be 
hypothesised that the cellular expression is also tightly controlled to ensure the correct 
cellular processes are occurring.  
The aims of this study were therefore to investigate how the expression of galectins 
alters in human neutrophils following an inflammatory stimulus and/or cell trafficking.  
Secondly this study aimed to investigate how the expression of galectins-1, -3 and -9 
are modulated over the course of a resolving inflammatory response using a murine 
model of zymosan-induced peritonitis, a model which has been well-characterised to 
resolve over a 96-hour time period.  
The expression of galectins-1, -3 and -9 were assessed in PMN that had transmigrated 
through an endothelial monolayer, both at the cell surface and intracellularly. The 
modulation of expression of galectins-1, -3 and -9 was also characterised in a human 
model of neutrophil recruitment using a Tobasco mouth wash and compared to paired 
peripheral blood PMN. Finally galectin expression was assessed in an in vivo murine 
model of inflammation to characterise how the expression of the galectins is altered on 
myeloid cells during a resolving inflammatory process.   
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4.1.1 Cell Surface Galectin Expression of Isolated 
Neutrophils Pre- and Post-Transendothelial Migration 
Isolated PMN were assessed for their cell surface expression of galectins-1, -3 and -9 
following transendothelial migration using a model of transwell transmigration as 
described previously in section 2.2.5.  
Non-transmigrated human PMN express low levels of galectin-1 and this was further 
decreased upon transmigration through an endothelial monolayer as demonstrated by 
a 55% decrease in the binding of anti-galectin-1 antibodies (7.77  3.68 vs 3.52  1.45, 
P = 0.012) as seen in Figure 4.1. 
 
Figure 4.1: Cell surface expression of galectin-1 on non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF- for 4 hours. Non-transmigrated (NT) and 
transmigrated (T) PMN were collected from the upper and lower chamber respectively and washed 
before staining with an anti-galectin-1 antibody took place and Flow Cytometry was used to assess 
the expression. Figure shows representative histogram and graph for galectin-1 expression. Data are 
expressed as median fluorescence intensity per sample for paired donors, n = 6 per group, * P < 
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The basal expression of galectin-3 on non-transmigrated human PMN was higher than 
galectin-1 however this expression was not significantly altered by transmigration 
through an endothelial monolayer (15.82  6.03 vs 14.75  2.31) Figure 4.2.  
 
Figure 4.2: Cell surface expression of galectin-3 on non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF- for 4 hours. Non-transmigrated (NT) and 
transmigrated (T) PMN were collected from the upper and lower chamber respectively and washed 
before staining with an anti-galectin-3 antibody took place and Flow Cytometry was used to assess 
the expression. Figure shows representative histogram and graph for galectin-3 expression. Data are 
expressed as median fluorescence intensity per sample for paired donors, n = 6 per group and are 
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Similar to galectin-1, the cell surface expression of galectin-9 was very low on non-
transmigrated PMN and this also decreased by 59% following transendothelial 
migration (3.3  2.23 vs 1.34  1.08, P = 0.014) as demonstrated by decreased binding 
of an anti-galectin-9 antibody (Figure 4.3).  
 
Figure 4.3: Cell surface expression of galectin-9 on non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF-. Non-transmigrated (NT) and transmigrated (T) 
PMN were collected from the upper and lower chamber respectively and washed before staining with 
an anti-galectin-9 antibody took place and Flow Cytometry was used to assess the expression. Figure 
shows representative histogram and graph for galectin-9 expression. Data are expressed as median 
fluorescence intensity per sample for paired donors, n = 6 per group, * P < 0.05 as analysed by two-
tailed paired T-test. 
4.1.2 Intracellular Galectin Expression of Isolated 
Neutrophils Pre- and Post-Transendothelial Migration 
PMN from the transwell transmigration assay were also assessed for their intracellular 
expression of galectins-1, -3 and -9 using Flow Cytometry by permeabilising cells 
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Low levels of galectin-1 were expressed by freshly isolated PMN (2.373  0.765) and 
this was not modulated in non-transmigrated (1.083  1.044) or transmigrated PMN 
(1.030  0.156), although a trend towards decreased expression could be seen this did 
not reach statistical significance (Figure 4.4).  
 
Figure 4.4: Intracellular expression of galectin-1 on non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were 
collected from the upper and lower chamber respectively along with freshly isolated PMN. PMN were 
fixed and permeabilised before staining with an anti-galectin-1 antibody took place and Flow 
Cytometry was used to assess the expression. Figure shows representative histogram and graph for 
galectin-1 expression Data are expressed as mean  SEM, n = 3 per group and are analysed by one-
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Galectin-3 was expressed at higher levels than galectin-1 by freshly isolated PMN 
(13.01  3.96), however this was not significantly modulated in non-transmigrated 
(8.777  1.044) and transmigrated PMN (7.333  1.713) Figure 4.5. Intracellular levels 
of galectin-3 were comparable to those seen at the cell surface suggesting all galectin-
3 expressed by human PMN is localised at the cell surface.  
 
Figure 4.5: Intracellular expression of galectin-3 on non-transmigrated and transmigrated human 
PMN. Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer 
that had been pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were 
collected from the upper and lower chamber respectively along with freshly isolated PMN. PMN were 
fixed and permeabilised before staining with an anti-galectin-3 antibody took place and Flow 
Cytometry was used to assess the expression. Figure shows representative histogram and graph for 
galectin-3 expression. Data are expressed as mean  SEM, n = 3 per group and are analysed by one-
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Galectin-9 expression in freshly isolated PMN is negligible (1.413  0.206) and 
although significant decreases are noted in non-transmigrated PMN (0.580  0.150, P 
= 0.012) and transmigrated PMN (0.700  0.134, P = 0.027), due to the extremely low 
levels of expression (MFI values of less than one) these minimal differences can be 
discounted as shown in Figure 4.6. 
 
Figure 4.6: Intracellular expression of galectin-9 on non-transmigrated and transmigrated PMN. 
Freshly isolated PMN were left to transmigrate for 90 minutes through a HUVEC monolayer that had 
been pre-treated with 10ng/mL hrTNF-. Non-transmigrated and transmigrated PMN were collected 
from the upper and lower chamber respectively along with freshly isolated PMN. PMN were fixed and 
permeabilised before staining with an anti-galectin-9 antibody took place and Flow Cytometry was 
used to assess the expression. Figure shows representative histogram and graph for galectin-9 
expression. Data are expressed as mean  SEM, n = 3 per group, * P < 0.05 vs freshly isolated PMN 
as analysed by one-way ANOVA with Bonferroni post hoc test. 
4.1.3 Modulation of the Intracellular Galectin Expression of 
Neutrophils during Exudation to the Buccal Cavity 
Healthy volunteers performed the Tobasco wash as described in section 2.2.3 and the 
exudated PMN collected were paired with isolated peripheral blood PMN from the 
same donor. The PMN were fixed overnight in 1% PFA and then permeabilised before 
anti-galectin-1, -3 and -9 antibodies were used to assess intracellular galectin 
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As previously demonstrated galectin-1 was expressed at low levels by PMN in the 
peripheral circulation and this was not significantly modulated by transmigration to the 
buccal cavity (2.172  0.3474 vs 1.846  0.4532) Figure 4.7.  
 
Figure 4.7: Expression of galectin-1 in human peripheral blood and exudated PMN. Healthy 
volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN 
were collected by saline wash (purple), peripheral blood PMN were also isolated by dextran 
sedimentation (burgundy). Both groups of PMN were washed twice and fixed overnight in 1% PFA, 
the following day the PMN were permeabilised and labelled with galectin-1 antibodies and the 
expression was assessed using Flow Cytometry. Figure shows representative histogram and graph 
for galectin-1 expression. Data are expressed as mean  SEM, n = 5 and are analysed by two-tailed T 
test.  
Galectin-3 was expressed at higher levels by PMN in the peripheral circulation than 
galectin-1 however this was also not significantly modulated by exudation to an 
inflammatory site (13.07  1.852 vs 15.78  2.074) Figure 4.8. 
  
Figure 4.8: Expression of galectin-3 in human peripheral blood and exudated PMN. Healthy 
volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN 
were collected by saline wash (purple), peripheral blood PMN were also isolated by dextran 
sedimentation (burgundy). Both groups of PMN were washed twice and fixed overnight in 1% PFA, 
the following day the PMN were permeabilised and labelled with galectin-3 antibodies and the 
expression was assessed using Flow Cytometry. Figure shows representative histogram and graph 
for galectin-3 expression. Data are expressed as mean  SEM, n = 5 and are analysed by two-tailed T 
test.  
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As previously demonstrated galectin-9 was expressed in human peripheral blood PMN 
at low levels, this was reduced further by transmigration to the buccal cavity (1.378  
0.2122 vs 0.760  0.1425, P = 0.0420), again due to the extremely low expression 
levels this must be taken into account (Figure 4.9). 
 
Figure 4.9: Expression of galectin-9 in human peripheral blood and exudated PMN. Healthy 
volunteers rinsed their mouths with a 10% Tobasco solution and following 1 hour recruited PMN 
were collected by saline wash (purple), peripheral blood PMN were also isolated by dextran 
sedimentation (burgundy). Both groups of PMN were washed twice and fixed overnight in 1% PFA, 
the following day the PMN were permeabilised and labelled with galectin-9 antibodies and the 
expression was assessed using Flow Cytometry. Figure shows representative histogram and graph 
for galectin-9 expression. Data are expressed as mean  SEM, n = 5, * P < 0.05 vs blood as 
analysed by two-tailed T test.  
4.1.4 Modulation of Galectin Expression in Myeloid Cells 
during Acute, Resolving Inflammation 
Zymosan-induced peritonitis (1mg/mouse) is a model used to study the inflammatory 
process from induction to resolution, as it is a well-defined, reproducible model of 
inflammation. The inflammation is characterised by a neutrophil and monocyte-driven 
response that resolves completely over a 96-hour period.  
Male C57BL/6 mice were injected with 1mg zymosan ip and during a 96h time-course 
samples were collected (at 0, 4, 24, 48, 72 and 96 hours post injection); cardiac 
punctures were performed to obtain peripheral leukocytes and peritoneal lavages were 
collected for exudated leukocytes. Femurs were also collected, flushed with PBS and 
this was filtered through a 70m cell strainer to collect bone marrow leukocytes. Total 
leukocyte counts were performed in Turk’s solution for all time points and antibodies 
specific for neutrophils (Ly6G, clone 1A8) and monocyte/macrophages (F4/80, clone 
BM8) were used to differentiate between the two populations using Flow Cytometry 
(bone marrow neutrophils were identified using Ly6G and CXCR4 while bone marrow 
monocytes were labelled with Ly6C).  
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There was a rapid increase in the number of total leukocytes in the peritoneal cavity 
within 4-24 hours of zymosan administration and this remained elevated over the 
course of the response with the increased leukocytes still observed at 96 hours 
compared to 0 hours (Figure 4.10a). The neutrophil number in the peritoneal cavity 
increased sharply over 4-24 hours and then returned back to basal levels within the 96 
hour time course. In contrast the monocyte/macrophage numbers declined within the 
first 4 hours of zymosan treatment and then re-populated the peritoneal cavity over the 
time course ending with a significantly higher number of monocyte/macrophages than 
were present at 0 hour (Figure 4.10b). This correlates with previous studies of 
zymosan-induced peritonitis (Ajuebor et al., 1999). 
 
Figure 4.10: Total and differential leukocyte counts from peritoneal exudate over a 96-hour time 
course following 1mg zymosan-induced peritonitis. Mice were given 1mg zymosan ip and over a 96-
hour time course leukocytes were collected from the peritoneal exudate using peritoneal lavage. A. 
Total leukocytes were stained with Turk’s solution and counted using a light microscope and B. 
Differential leukocyte counts were performed using anti-Ly6G (specific for neutrophils) and anti-
F4/80 (specific for monocyte/macrophages). Data are expressed as mean ± SEM, N = 12 per group. 
* P < 0.05 and ** P < 0.01 vs 0hr time point for total leukocytes, ++ P < 0.01 vs neutrophils at 0hr 
time point and # P < 0.05 vs monocytes at 0hr time point as analysed using One-Way ANOVA with 
Dunnetts post hoc test. 
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The number of total leukocytes within peripheral blood decreased rapidly following 
induction of peritonitis, yet returned to basal levels over the course of the response 
(Figure 4.11a). Monocytes account for the decrease in total cells seen at 4 hours, 
which return to basal levels over the time course. Whilst there were no significant 
modulations in the numbers of neutrophils in the peripheral blood, a trend can be seen 
that mirrors the changes in the peritoneal cavity with a decrease as cells migrate from 
the peripheral blood to the peritoneal cavity and then an increase as the peripheral 
blood re-populates (Figure 4.11b).  
 
Figure 4.11: Total and differential leukocyte counts from peripheral blood over a 96-hour time 
course following 1mg zymosan-induced peritonitis. Mice were given 1mg zymosan ip and over a 96-
hour time course peripheral blood was collected via cardiac puncture, the red cells were lysed and 
the leukocytes assessed. A. Total leukocytes were stained with Turk’s solution and counted using a 
light microscope and B. Differential leukocyte counts were performed using anti-Ly6G (specific for 
neutrophils) and anti-F4/80 (specific for monocytes). Data are expressed as mean ± SEM, N = 8 per 
group. * P < 0.05 and ** P < 0.01 vs 0-hour time point for total leukocytes. # P < 0.05 vs 0-hour 
monocytes as analysed by One-Way ANOVA with Dunnetts post-hoc test. 
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Although no significant modulation of the leukocyte number was observed within the 
bone marrow, a similar yet delayed trend followed the peripheral blood neutrophils with 
a decrease in the number of cells in the bone marrow approximately 24-hours later 
than that seen in the peripheral blood. This is likely to account for leukocyte 
mobilisation to repopulate the peripheral circulation (Figure 4.12). 
 
Figure 4.12: Total and differential leukocyte counts from bone marrow over a 96-hour time course 
following 1mg zymosan-induced peritonitis.  Mice were given 1mg zymosan ip and over a 96-hour 
time course bone marrow was collected via removal of the femur and flushing through with PBS, the 
leukocyte were collected by passing the bone marrow through a 70m cell strainer. A. Total 
leukocytes were stained with Turk’s solution and counted using a light microscope and B. Differential 
leukocyte counts were performed using anti-Ly6G and anti-CXCR4 (specific for bone marrow 
neutrophils) and anti-Ly6C (specific for bone marrow monocytes). Data are expressed as mean ± 
SEM, N = 4 per group. Analysed by One-Way ANOVA with Dunnetts post-hoc test. 
It is known that galectins have differing actions on leukocyte recruitment, for instance 
galectin-1 inhibits neutrophil trafficking while galectin-3 activates neutrophils and 
increases neutrophil-endothelial cell interactions (Cooper et al., 2008, Karlsson et al., 
1998, Sato et al., 2002b). Given that galectins function both endogenously and 
exogenously their expression during a resolving inflammatory response must be both 
spatially and temporally modulated.  
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Supernatants from peritoneal exudates were taken at each time point and assessed for 
galectin-1 and -3 concentrations by ELISA analysis. Galectin-1 expression was high in 
untreated mice (1.701  0.324 ng/mL) and this rapidly decreased by approximately 
50% following the onset of inflammation (0.809  0.103 ng/mL) by 24 hours post 
zymosan. A second peak was seen at 48 hours where levels were similar to that seen 
in control animals (1.804  0.266 ng/mL) and this once again decreased and remained 
low at 96h (Figure 4.13).  
 
Figure 4.13: Galectin-1 concentration in peritoneal exudate fluid over a 96-hour time course 
following 1mg zymosan-induced peritonitis. Mice were given zymosan ip (1mg/mouse) and 
peritoneal lavages were performed at 0, 4, 24, 48, 72 and 96 hours post injection. Peritoneal 
exudate was centrifuged at 300g for 10 minutes and the cell-free supernatant was collected and 
assayed for the concentration of galectin-1 by ELISA. Data are expressed as mean  SEM, n = 4-7 
per group, * P < 0.05 vs 0 hour and # P < 0.05 vs 48 hour as analysed by one-way ANOVA with 
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Galectin-3 was also detected in the peritoneal wash of mice that did not receive any 
zymosan (2.155  0.450 ng/mL) and levels increased over the time course with a peak 
approximately 4-fold higher than time zero at 72 hours. At 96 hours the galectin-3 
concentration was not significantly different from control levels suggesting a return to 
homeostasis had begun (Figure 4.14). 
 
Figure 4.14: Galectin-3 concentration in peritoneal exudate fluid following zymosan-induced 
peritonitis. Mice were given zymosan ip (1mg/mouse) and peritoneal lavages were performed at 0, 
4, 24, 48, 72 and 96 hours post injection. Peritoneal exudate was centrifuged at 300g for 10 
minutes and the cell-free supernatant was collected and assayed for the concentration of galectin-3 
by ELISA. Data are expressed as mean  SEM, n = 4-7 per group, * P < 0.05 and *** P < 0.001 vs 0 
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4.1.4.1 Modulation of Galectin Expression in Murine 
Neutrophils 
To assess the modulation of galectin expression in neutrophils they were specifically 
labelled with Ly6G (clone 1A8), fixed and then permeabilised and galectin expression 
was assessed using specific antibodies. Murine neutrophils showed no expression of 
galectins-1 or -9 in peritoneal exudate, peripheral blood or bone marrow when 
assessed over a 96-hour time course following zymosan-induced peritonitis (Figure 
4.15).  
 
Figure 4.15: Galectin-1 and galectin-9 expression in PMN from peritoneal exudate, peripheral blood 
and bone marrow over a 96-hour time course following 1mg zymosan-induced peritonitis. Mice were 
given 1mg zymosan ip and over a 96-hour time course leukocytes were collected from the peritoneal 
cavity, peripheral blood and bone marrow. The cells were double stained for Ly6G to identify 
neutrophils and galectin-1 or -9 and the expression was assessed using Flow Cytometry. A. Galectin-
1 expression and B. Galectin-9 expression. Data are expressed as Mean ± SEM, n = 12 per group for 
peritoneal exudate, 8 per group for peripheral blood and 4 per group for bone marrow. Analysed by 
Two Way ANOVA with Bonferroni post hoc test. 
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In contrast to galectins-1 and -9, galectin-3 expression within neutrophils was found to 
be modulated in cells recruited to the peritoneal cavity. Low levels of galectin-3 were 
detected in neutrophils from the peripheral blood and bone marrow, however this was 
significantly increased in exudated neutrophils over 72 hours; levels then declined at 
96 hours at which point homeostasis was restored as seen in Figure 4.16. 
 
Figure 4.16: Galectin-3 expression in PMN from peritoneal exudate, peripheral blood and bone 
marrow over a 96-hour time course following 1mg zymosan-induced peritonitis. Mice were injected 
with 1mg zymosan ip and over a 96-hour time course leukocytes were collected from the peritoneal 
cavity, peripheral blood and bone marrow. A. Representative histogram showing neutrophils double-
stained for Ly6g and galectin-3 expression at 4 hours post zymosan. B. Graph showing galectin-3 
expression in neutrophils from the peritoneal exudate, peripheral blood and bone marrow over 96 
hours. Data are expressed as mean ± SEM, n = 12 per group for peritoneal exudate, 8 per group for 
peripheral blood and 4 per group for bone marrow. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs 
peripheral blood at same time point, # P < 0.05 and ### P < 0.001 vs bone marrow at same time 
point as analysed by Two Way ANOVA with Bonferroni post hoc test. 
4.1.4.2 Modulation of Galectin Expression in Murine 
Monocytes/Macrophages 
Initially cells from the peritoneal exudate and peripheral blood were labelled with an 
anti-F4/80 antibody to differentiate monocyte/macrophages from other leukocytes. The 
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cells were double stained with galectin-1, -3 or -9 antibodies and the expression 
assessed by Flow Cytometry.  
Low levels of galectin-1 were detected in peripheral blood and bone marrow 
monocytes, however this was significantly increased in monocyte/macrophages 
recruited to the peritoneal cavity from 24 to 72 hours of zymosan treatment that peaked 
at 72 hours (Figure 4.17). 
  
Figure 4.17: Galectin-1 expression in murine monocytes/macrophages over a 96-hour time course 
following 1mg zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip. and peritoneal 
exudates, peripheral blood and bone marrow leukocytes were collected from 0-96 hours. 
Permeabilised monocytes/macrophages were labelled with anti-F4/80 or anti-Ly6C for bone marrow 
monocytes (clone – HK1.4) and galectin-1 antibodies. Figure shows graph for galectin-1 expression. 
Data are expressed as mean  SEM, n = 8 per group for peritoneal exudate and peripheral blood 
and 4 per group for bone marrow, *** P < 0.001 vs peripheral blood, # P < 0.05, ## P < 0.01 and 
### P < 0.001 vs bone marrow at same time point as analysed by Two-Way ANOVA with Bonferroni 
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Similar to neutrophils, the levels of galectin-3 in peripheral blood and bone marrow 
monocytes was relatively low compared to monocyte/macrophages that exudated to 
the peritoneal cavity. The levels of galectin-3 were raised at 24-72 hours, similar to 
galectin-1, again with a peak in the expression at 72 hours as seen in Figure 4.18. 
 
Figure 4.18: Galectin-3 expression in murine monocytes/macrophages over a 96-hour time course 
following 1mg zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip. and peritoneal 
exudates, peripheral blood and bone marrow leukocytes were collected from 0-96 hours. 
Permeabilised monocytes/macrophages were labelled with anti-F4/80 or anti-Ly6C and galectin-3 
antibodies. Figure shows graph for galectin-3 expression. Data are expressed as mean  SEM, n = 8 
per group for peritoneal exudate and peripheral blood and 4 per group for bone marrow, *** P < 
0.001 vs peripheral blood, ## P < 0.01 and ### P < 0.01 vs bone marrow at same time point as 
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The levels of galectin-9 in bone marrow monocytes was low and this was not 
significantly modulated over the course of zymosan peritonitis; unlike all other galectins 
the expression of galectin-9 increased in peripheral blood monocytes at 4 hours before 
returning to basal levels, although this did not reach significance. Galectin-9 expression 
in peritoneal exudate monocyte/macrophages gradually increased from 4 hours until 72 
hours at which point it was significantly different from the levels in the peripheral blood 
and bone marrow monocytes; levels then declined to basal at 96 hours (Figure 4.19).     
 
Figure 4.19: Galectin-9 expression in murine monocytes/macrophages over a 96-hour time course 
following 1mg zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip. and peritoneal 
exudates, peripheral blood and bone marrow leukocytes were collected from 0-96 hours. 
Permeabilised monocytes/macrophages were labelled with anti-F4/80 or anti-Ly6C for bone marrow 
and galectin-9 antibodies. Figure shows graph for galectin-9 expression. Data are expressed as 
mean  SEM, n = 8 per group for peritoneal exudate and peripheral blood and 4 per group for bone 
marrow, *** P < 0.001 vs peripheral blood and ### P < 0.001 vs bone marrow at same time point 
as analysed by Two-Way ANOVA with Bonferroni post hoc test.  
Within the monocyte/macrophage populations of peripheral blood and peritoneal 
exudate there was variation in the galectin expression suggesting that more than one 
population of cells may be present and thus the monocyte/macrophages were 
phenotypically sorted into classical and non-classical subtypes based on Ly6C 
expression. Classical monocytes express high levels of Ly6C while non-classical 
monocytes express low levels of Ly6C (Gordon and Taylor, 2005). 
Cells from the peritoneal exudate and peripheral blood were collected and labelled with 
F4/80 and Gr-1 (an antibody specific to both Ly6G and Ly6C antigens). Leukocytes 
that were F4/80 positive and Gr-1 high were considered classical 
monocyte/macrophages and those that were F4/80 positive and Gr-1 low were 
considered non-classical monocyte/macrophages.  
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In the peritoneal exudate non-classical monocyte/macrophages were detected at time 
0 in significantly higher numbers than classical monocyte/macrophages. These 
resident cells rapidly depleted within 4-24 hours, followed by an increase that peaked 
at 72 hours at which point the number of monocyte/macrophages returned to 
approximately basal levels by 96 hours. Classical monocyte/macrophages were not 
present at 0 hours however they increased until a peak was reached at 24 hours; the 
cells then declined again by 96 hours (Figure 4.20a). 
Both subtypes of monocytes were present at 0 hours in peripheral blood but a 
significantly larger number of non-classical monocytes were seen. The number of 
classical monocytes in the peripheral circulation remained almost constant while the 
number of non-classical monocytes decreased until 24 hours and then increased to 
numbers above that seen at 0 hours (Figure 4.20b).  
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Figure 4.20: Differential counts for classical and non-classical monocytes from the peritoneal 
exudate and peripheral blood taken over a 96-hour time course following 1mg zymosan-induced 
peritonitis. Mice were injected with 1mg zymosan ip. and peritoneal exudates and peripheral blood 
were collected from 0-96 hours. Leukocytes were double stained with anti-F4/80 and anti-Gr-1 and 
the total numbers of classical and non-classical monocytes calculated. A. Peritoneal exudate 
monocyte/macrophages counts and B. Peripheral blood monocyte counts. Data are expressed as 
mean  SEM, n = 4 per group, ** P < 0.01 and *** P < 0.001 vs classical monocyte/macrophages 
at same time point as analysed by two-way ANOVA with Bonferroni post hoc test.  
At 48 and 72 hours both subtypes of monocyte/macrophages were present and thus 
peritoneal exudate and peripheral blood cells were collected at these time points and 
analysed for their intracellular expression of galectins-1, -3 and -9 using specific 
antibodies.  
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Low levels of galectin-1 were detected in both non-classical and classical monocytes in 
peripheral blood; this was not significantly modulated between 48 and 72 hours 
although a trend towards increased levels of galectin-1 was observed in both subtypes 
(Figure 4.21a).  
Very low levels of galectin-1 were detected in all monocyte/macrophages in the 
peritoneal exudate at 48 hours however levels significantly increased over the time 
course (classical 0.513  0.594 vs 17.25  4.239, P = 0.019; non-classical 1.223  
1.133 vs 30.35  8.707, P = 0.000001). The non-classical monocytes/macrophages in 
the peritoneal exudate also have significantly higher levels of galectin-1 than classical 
monocytes/macrophages at 72 hours post zymosan injection (30.35  4.35 vs 17.25  
2.12, P = 0.004) Figure 4.21b.  
 
Figure 4.21: Galectin-1 expression in classical and non-classical monocytes/macrophages collected 
from the peritoneal cavity and peripheral blood at 48 and 72 hours post zymosan ip. Mice were 
injected with 1mg zymosan ip. and peritoneal exudates and peripheral blood were collected at 48 
and 72 hours. Leukocytes were triple stained with anti-F4/80, anti-Gr-1 and anti-galectin-1. The 
expression of galectin-1 was assessed using Flow Cytometry. A. Peripheral blood monocytes and B. 
Peritoneal exudate monocyte/macrophages. Data are expressed as mean  SEM, n = 4 per group, * 
P < 0.05 and *** P < 0.001 vs 48 hour, ## P < 0.01 as analysed by two-way ANOVA with Bonferroni 
post hoc test.  
Peripheral blood monocytes expressed relatively low levels of galectin-3 compared to 
exudated cells at 48 and 72 hours (Figure 4.18). When analysing galectin-3 expression 
based on monocyte/macrophage phenotype, non-classical cells were found to express 
significantly higher levels of galectin-3 at both 48 and 72 hour time points (48-hour 
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25.05  11.14 vs 81.18  34.75, P = 0.007; 72-hour 26.03  12.59 vs 82.00  29.88, P 
= 0.007) with no modulation in levels over time (Figure 4.22a).  
In the peritoneal exudate levels of galectin-3 in monocyte/macrophages were much 
higher than those in the peripheral blood however at 48 hours the levels were 
comparable between non-classical and classical monocyte/macrophages. Non-
classical monocyte/macrophages do not display significant modulation of galectin-3 at 
72 hours but non-classical monocyte/macrophages have an increase of approximately 
2.25-fold (562.7  143.6 vs 1716  246.1, P = 0.00001) and thus expressed 
significantly higher levels of galectin-3 compared to non-classical 
monocyte/macrophages at 72 hours post zymosan administration (762.3  132.0 vs 
1716  246.1, P = 0.00001) Figure 4.22b.  
 
Figure 4.22: Galectin-3 expression in classical and non-classical monocytes/macrophages collected 
from the peritoneal cavity and peripheral blood at 48 and 72 hours post zymosan ip. Mice were 
injected with 1mg zymosan ip. and peritoneal exudates and peripheral blood were collected at 48 
and 72 hours. Leukocytes were triple stained with anti-F4/80, anti-Gr-1 and anti-galectin-3. The 
expression of galectin-3 was assessed using Flow Cytometry. A. Peripheral blood monocytes and B. 
Peritoneal exudate monocyte/macrophages. Data are expressed as mean  SEM, n = 4 per group. 
*** P < 0.001 vs 48 hour, ### P < 0.001 as analysed by two-way ANOVA with Bonferroni post hoc 
test.  
In the peripheral blood both non-classical and classical monocytes expressed low 
levels of galectin-9 at similar levels that were not modulated over the time course 
(Figure 4.23a).  
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Neither phenotype of monocytes/macrophages expressed galectin-9 at 48 hours, 
however levels significantly increased by 72 hours for both peripheral blood and 
peritoneal cavity cells. The levels of galectin-9 increased more in non-classical 
monocyte/macrophages compared to classical monocyte/macrophages and therefore a 
significant difference in the galectin-9 levels was detected between the two subtypes at 
72 hours (6.993  0.8472 vs 21.9  5.758, P = 0.00001) Figure 4.23b.   
 
Figure 4.23: Galectin-9 expression in classical and non-classical monocytes/macrophages collected 
from the peritoneal cavity and peripheral blood at 48 and 72 hours post zymosan ip. Mice were 
injected with 1mg zymosan ip. and peritoneal exudates and peripheral blood were collected at 48 
and 72 hours. Leukocytes were triple stained with anti-F4/80, anti-Gr-1 and anti-galectin-9. The 
expression of galectin-9 was assessed using Flow Cytometry. A. Peripheral blood monocytes and B. 
Peritoneal exudate monocyte/macrophages. Data are expressed as mean  SEM, n = 4 per group. * 
P < 0.05 and *** P < 0.001 vs 48 hour, ### P < 0.001 as analysed by two-way ANOVA with 
Bonferroni post hoc test.  
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4.2 Discussion 
Levels of galectins-1, -3 and -9 were significantly higher in peritoneal cavity recruited 
leukocytes compared to peripheral blood or bone marrow. This spatial modulation 
suggests a local role for the galectins on leukocytes or that leukocyte-derived galectins 
are required at the inflammatory site and leukocytes deliver these. The expression was 
also temporally modulated with a high level of galectin-3 seen in recruited neutrophils 
at the peak of inflammation (4-24 hours) although this did not decrease back to basal 
levels during the resolution period as may be expected.  
Monocyte/macrophages also demonstrated a temporal modulation of galectins with all 
three increased at 72 hours post zymosan in non-classical monocyte/macrophages. As 
classical monocyte/macrophages are known to secrete high levels of the galectins 
(Novak et al., 2012) this provides an explanation for the difference in levels between 
subsets.  
This study demonstrates that the expression of galectins-1, -3 and -9 are modulated 
over the course of an inflammatory response, potentially to ensure that the leukocytes 
are only ever in contact with the galectin which will promote the correct response for 
the stage of inflammation. This study also demonstrated an up-regulation of galectin-3 
later in the inflammatory process, a time in which it would be expected that the pro-
inflammatory lectin would have been cleared to prevent unwanted actions. Thus it can 
be hypothesised that galectin-3 plays a role not only in the induction of an inflammatory 
response but also in the clearance; this was tested in the next section.  
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5 Roles of Galectin-3 in the 
Resolution of Inflammation 
5.1 Introduction 
Many studies using galectin-3 null mice have indicated a pro-inflammatory role of this 
protein. This genotype exhibits defective leukocyte recruitment in models of 
thioglycollate-induced peritonitis, pneumococcal pneumonia, respiratory tularaemia and 
parasitic protozoan cutaneous inflammation (Colnot et al., 1998b, Hsu et al., 2000, 
Farnworth et al., 2008, Mishra et al., 2013, Bhaumik et al., 2013).  
Contrary to the pro-inflammatory role of galectin-3, the deficient mice also exhibit 
defective alternative activation of macrophages, which display reduced phagocytic 
capabilities compared to wild type cells (MacKinnon et al., 2008, Sano et al., 2003). 
Recombinant galectin-3 (20M) induces the exposure of phosphatidylserine on the 
surface of neutrophils, which does not coincide with increased apoptosis but promotes 
the efferocytosis of neutrophils by monocytes (Stowell et al., 2008a). These findings 
suggest a role for galectin-3 in resolution of the innate inflammatory response and this 
was further investigated firstly to confirm this hypothesis and secondly to elucidate a 
mechanism for this.  
The aim of this section was to determine the role of galectin-3 on murine leukocytes 
during a resolving inflammatory response.  
Initially galectin-3 null mice were used to assess the resolution phase of zymosan-
induced peritonitis and determine if a deficiency was present. Following this, wild type 
mice were used to determine the localisation of galectin-3 in murine neutrophils during 
an inflammatory response and attempts were then made to establish whether murine 
neutrophils could in fact produce galectin-3 as this is controversial in the literature 
(Farnworth et al., 2008, Sato et al., 2002b).  
5.1.1 Effects of Galectin-3-Deficiency during Resolution 
The model of zymosan-induced peritonitis used (1mg/mouse) is well characterised by 
Navarro-Xavier and colleagues who determined peak leukocyte recruitment to be at 24 
hours and the resolution interval (time taken for total leukocytes to reduce by 50%) to 
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be 24 hours and therefore the resolution phase in this model begins at 48 hours post 
zymosan (Navarro-Xavier et al., 2010).  
Initially galectin-3 null mice and age- and sex-matched C57BL/6 controls were given 
zymosan i.p. (1mg/mouse) and following 48, 72 and 96 hours peritoneal lavages were 
performed. Total leukocyte counts were then performed. At 48 hours post zymosan, 
total leukocyte counts were comparable for wild type and galectin-3 null mice however 
at 72 hours there was a trend towards more leukocytes in the peritoneal cavities of 
galectin-3 null mice although this did not reach statistical significance. At 96 hours no 
difference was seen in the total leukocyte count comparing the two strains of mice 
(Figure 5.1). 
 
Figure 5.1: Total leukocyte count for galectin-3 null mice with age- and sex-matched wild type 
controls during the resolution phase of zymosan-induced peritonitis. Mice were injected with 1mg 
zymosan ip and following 48, 72 and 96 hours peritoneal lavages were performed to collect 
exudates. An aliquot of leukocytes was taken prior to staining and counted in Turk’s solution using a 
light microscope. Data are expressed as mean  SEM, n = 3-4 per group. Data are analysed using 
two-way ANOVA with Bonferroni post hoc test.  
The leukocytes were double-stained for F4-80 (clone BM8) and Gr-1 (clone RB6-8C5) 
to allow the percentages of neutrophils (Gr-1 high, F4/80 negative), classical 
monocyte/macrophages (Gr-1 high, F4/80 positive) and non-classical 
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In wild type mice neutrophils accounted for approximately 10% of total leukocytes 
during the resolution phase of zymosan-induced peritonitis (48-96 hours). In contrast 
the proportion of neutrophils in the exudates of galectin-3 null mice significantly 
increased from 48 to 96 hours with approximately 40% of leukocytes recovered being 
neutrophils (Figure 5.2). 
 
Figure 5.2: Neutrophil percentage collected from peritoneal exudate during the resolution phase of 
zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip and following 48, 72 and 96 
hours peritoneal lavages were performed to collect exudates. Leukocytes were labelled with 
antibodies for F4/80 and Gr-1 and those cells that were Gr-1 high and F4/80 negative were 
identified as neutrophils. Data are expressed as mean  SEM, n = 3-4 per group, * P < 0.05 vs wild 
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At 48 hours 20% of the cells recovered from the peritoneum were classical 
monocytes/macrophages in both genotypes and this was not significantly altered at 72 
hours although a trend towards a reduced number was seen in the wild type mice with 
approximately 15% of total leukocytes being classical monocyte/macrophages. By 96 
hours no classical monocyte/macrophages could be detected in either strain of mice 
(Figure 5.3).  
 
Figure 5.3: Classical monocyte/macrophage percentage collected from peritoneal exudate during 
the resolution phase of zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip and 
following 48, 72 and 96 hours peritoneal lavages were performed to collect exudates. Leukocytes 
were labelled with antibodies for F4/80 and Gr-1 and those cells that were Gr-1 high and F4/80 
positive were identified as classical monocyte/macrophages. Data are expressed as mean  SEM, n 
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At 48 hours approximately 40% of cells recovered were non-classical 
monocytes/macrophages in both genotypes and this 40% remained stable in galectin-3 
null mice. In contrast the number of non-classical monocytes/macrophages significantly 
increased in wild type mice at 96 hours (Figure 5.4). 
 
Figure 5.4: Non-classical monocyte/macrophage percentage collected from peritoneal exudate 
during the resolution phase of zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip 
and following 48, 72 and 96 hours peritoneal lavages were performed to collect exudates. 
Leukocytes were labelled with antibodies for F4/80 and Gr-1 and those cells that were Gr-1 low and 
F4/80 positive were identified as non-classical monocyte/macrophages. Data are expressed as 
mean  SEM, n = 3-4 per group, * P < 0.05 vs galectin-3 null mice at same time point as analysed 
by two-way ANOVA with Bonferroni post hoc test.  
Galectin-3 null mice have more neutrophils and less non-classical 
monocyte/macrophages at the later stages of zymosan-induced peritonitis suggesting 
that resolution is impeded in these mice. A previous report demonstrated that 
alternative activation of monocyte/macrophages is defective in galectin-3 null mice 
(MacKinnon et al., 2008) which may explain the reduced numbers of non-classical 
monocytes/macrophages found in this model. The mechanism behind the increased 
PMN counts observed during late stages of peritonitis in galectin-3 null mice is not 
known and therefore is further investigated here.  
Galectin-3 is linked to neutrophil clearance through its ability to induce 
phosphatidylserine exposure, in the absence of apoptosis, on the neutrophil 
surface(Stowell et al., 2008b). A defect in this mechanism might therefore result in 
retention, or lack of clearance of PMN at the inflammatory site.   
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Leukocytes from the peritoneal exudate were labelled with Ly6G (clone 1A8) to identify 
neutrophils and then with Annexin V (AnxV) and propidium iodide (PI) to identify cells 
that were Annexin V positive and PI negative as these are not yet apoptotic, yet have 
exposed phosphatidylserine. 
At 48 and 72 hours after zymosan injection approximately 20% of murine neutrophils in 
the peritoneal cavity were early apoptotic (Annexin V positive, PI negative) and this was 
comparable between wild type and galectin-3 null mice. Of the remaining neutrophils 
approximately 70% were positive for both Annexin V and PI and were thus apoptotic, 
while 10% were viable cells (Annexin V negative, PI negative). At 96 hours 
approximately 5% of neutrophils were early apoptotic and again this was comparable 
between the two strains of mice while the remaining 95% of neutrophils were viable 
cells (Figure 5.5).  
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Figure 5.5: Exposure of phosphatidylserine of murine neutrophils in galectin-3 null and wild type 
mice following zymosan-induced peritonitis. Mice were injected with 1mg zymosan ip and following 
48, 72 and 96 hours peritoneal lavages were performed to collect leukocytes. Neutrophils were 
specifically labelled with Ly6G antibodies and then with Annexin V and propidium iodide and the 
percentage of neutrophils that were Annexin V positive and PI negative was calculated. 
Representative dot plots showing Annexin V and PI double staining for wild type mice at 72 hours 
and KO mice at 96 hours. Data are expressed as mean  SEM, n = 3-4 per group and analysed by 
two-way ANOVA with Bonferroni post hoc test.  
A decrease in the number of neutrophils with exposed phosphatidylserine between 72 
and 96 hours without an increase in apoptotic cells may indicate that an increase in 
efferocytosis occurs between these time points. To test this hypothesis leukocytes 
were collected from the peritoneal cavity at 96 hours post zymosan administration and 
labelled with an F4/80 antibody to specifically identify monocyte/macrophages; 
following this the cells were fixed and permeabilised using permeabilisation buffer 
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before labelling with a Ly6G antibody. These leukocytes were analysed using an 
AMNIS ImageStream X MK II, cells positive for F4/80 were assessed for their 
intracellular expression of Ly6G, which was indicative of efferocytosed neutrophils.  
Only a small number of monocyte/macrophages had phagocytosed neutrophils visible 
inside the cell, approximately 2% in wild type and null mice. Detection of very low 
numbers could possibly be due to antigens on phagocytosed neutrophils being 
destroyed before staining occurred and thus substantial differences between 
genotypes could not be determined (Figure 5.6).  
 
Figure 5.6: Efferocytosis of neutrophils by monocyte/macrophages at 96 hours post zymosan 
peritonitis. Mice were injected with 1mg zymosan ip and following 96 hours peritoneal lavages were 
performed to collect leukocytes. Monocyte/macrophages were specifically labelled with F4/80 and 
then fixed and permeabilised before labelling with Ly6G for intracellular neutrophils. The 
internalisation of neutrophils by monocyte/macrophages was assessed using an AMNIS 
ImageStream X MK II. Data are expressed as mean ± SEM, n = 4 per group and analysed by two 
tailed T test.  
5.1.2 Localisation of Galectin-3 in Murine Neutrophils 
Following Recruitment to the Peritoneal Cavity 
Galectin-3 is expressed throughout all cellular compartments and its localisation 
determines its function. When bound to the cell surface of neutrophils it is able to 
induce the exposure of phosphatidylserine without inducing apoptosis and also 
increases the production of reactive oxygen species and degranulation (Stowell et al., 
2008b, Yamaoka et al., 1995). When expressed intracellularly in Jurkat T cells galectin-
3 is able to bind Bcl-2 proteins and inhibit the apoptosis of the cells (Akahani et al., 
1997). The actions of intracellular galectin-3 in neutrophils has not been elucidated 
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primarily because it is believed to be expressed at low levels in these cells, however as 
neutrophils also express Bcl-2 proteins this is a potential mechanism of action for 
galectin-3 within murine neutrophils (Moulding et al., 2001).  
Murine leukocytes were collected from the peritoneal cavity of 6-week old C57BL/6 
mice at 4, 24 and 48 hours post zymosan administration (peak neutrophil time points) 
and Ly6G was used as a specific marker for identifying neutrophils. Leukocytes were 
double-stained for the expression of galectin-3 and Ly6G on the cell surface or were 
permeabilised and the intracellular expression of galectin-3 assessed. The cytosolic 
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The localisation of galectin-3 was modulated in neutrophils over the course of the 
inflammatory response. At 4 hours galectin-3 was predominantly expressed in the cell 
cytosol (488.5  10.243 vs 17.125  0.491, P = 0.00001). At 24 hours post zymosan, 
galectin-3 was expressed on both the neutrophil surface and in the cytosol at equal 
levels (459.209  76.538 vs 402.667  34.801). At 48 hours post zymosan galectin-3 
was once again expressed predominantly in the cytosol of the neutrophil (367.571  
33.788 vs 11.237  3.741, P = 0.00001) Figure 5.7.   
 
Figure 5.7: Cytosolic and cell surface expression of galectin-3 in murine neutrophils taken from the 
peritoneal exudate at 4, 24 and 48 hours post zymosan ip. Mice were injected with 1mg zymosan ip. 
and peritoneal exudates were collected at 4, 24 and 48. Leukocytes were double stained with anti-
Ly6G (clone – 1A8) and anti-galectin-3 (clone – M3/38) on the cell surface and following 
permeabilisation to give total expression. The expression of galectin-3 was assessed using Flow 
Cytometry and the cytosolic galectin-3 expression calculated by subtracting the cell surface 
expression from the total expression. Data are expressed as mean  SEM, n = 4 per group. *** P < 
0.001 vs cytosol at same time point as analysed by two-way ANOVA with Bonferroni post hoc test.  
5.1.3 Do Murine Neutrophils Produce Galectin-3? 
Murine neutrophils expressed high levels of galectin-3 following extravasation to the 
peritoneal cavity (Figure 4.16), which was located inside the cell at 4 hours post 
zymosan suggesting the cells are capable of producing the lectin upon 
activation/transmigration.  
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To determine whether neutrophils express mRNA for galectin-3 a pure population of 
neutrophils was required. Macrophages and monocytes produce high levels of 
galectin-3 and thus express lgals3 and would contaminate the sample even at low 
numbers. In order to obtain a pure population of neutrophils leukocytes were isolated 
from the peritoneal cavity and bone marrow of male 6-week old C57BL/6 mice as 
previously described (section 2.3.4.1) following 4-hour zymosan-induced peritonitis; 
the leukocyte suspensions were then subjected to negative selection for neutrophils. 
An aliquot of isolated neutrophils (200L) was taken for purity assessment using Ly6G 
and Flow Cytometry; this demonstrated that approximately 80% purity could be 
reached for peritoneal leukocytes and 23% for bone marrow leukocytes as shown in 
Figure 5.8; therefore this isolation method was not suitable for collection of a pure 
population of murine neutrophils (Figure 5.8).  
 
Figure 5.8: Neutrophil population purity following negative selection. Leukocytes were collected from 
peritoneal exudate and bone marrow following 4-hour zymosan-induced peritonitis. Leukocytes were 
negatively selected for neutrophils and an aliquot of the remaining neutrophil-rich sample was 
assessed for purity using a Ly6G antibody by Flow Cytometry. Bar shows percentage of sample 
positive for Ly6G.  
Positive selection of neutrophils was then attempted using Dynabeads, again on 
leukocytes collected from the peritoneal cavity and bone marrow following 4-hour 
zymosan-induced peritonitis on male 6-week old C57BL/6 mice. As the beads remain 
attached to the neutrophils it was not possible to assess the purity by Flow Cytometry 
as with the negative selection and thus PCR was used to assess purity as well as 
determine mRNA levels of lgals3. RNA was extracted using the RNeasy kit and the 
levels and purity were quantified using a Nanodrop as described in section 2.3.10. 
From this cDNA was synthesised and PCR performed using primers for Ly6g, cd68 
and lgals9 for neutrophils, monocytes and eosinophil contamination respectively, rpl32 
CHAPTER 5: RESULTS (3) 
173 
was used as a housekeeping gene and lgals3 levels were determined. This data 
showed that all samples were contaminated with monocytes and eosinophils (Figure 
5.9) and thus a pure population of neutrophils could not be isolated using positive 
selection. 
 
Figure 5.9: Neutrophil population purity following positive selection. Leukocytes were collected from 
peritoneal exudate following 4-hour zymosan-induced peritonitis. Leukocytes were positively selected 
for neutrophils and the neutrophil-rich sample was assessed for purity using PCR. Primers for ly6g, 
cd68 and lgals9 were used to determine levels of neutrophil, monocyte and eosinophils in the 
sample respectively. Lgals3 was used to assess galectin-3 levels and rpl32 was used as a 
housekeeping gene.  
5.1.4 Do Murine Neutrophils Bind Galectin-3 Following its 
Release From Other Sources? 
As it was not possible to isolate a pure population of murine neutrophils without 
monocyte contamination it could not be confidently determined that murine neutrophils 
produce galectin-3 however the lectin was detectable inside exudated neutrophils at 4 
hours. If the galectin-3 was derived from other cell types and being bound by murine 
neutrophils upon their transmigration to the peritoneal cavity the lectin must be 
internalised by the cells and this was assessed using human neutrophils due to the 
difficulties in obtaining large numbers of peripheral blood neutrophils from mice.  
Human PMN were incubated with either 10nM recombinant galectin-3, a concentration 
which is detected under pathophysiological conditions (Iurisci et al., 2000), or 1M as a 
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positive control for 2 hours at either 37C allowing  cellular processes to occur or 4C 
inhibiting them; the PMN were then washed with lactose to remove all surface bound 
lectin. The intracellular expression of galectin-3 was analysed using Flow Cytometry 
compared to vehicle-treated cells.  
At concentrations close to that seen pathophysiologically (10nM) human neutrophils 
were unable to internalise galectin-3, as demonstrated by no change in the intracellular 
expression following incubation at 37°C compared to 4°C, however when an excess of 
galectin-3 was added the neutrophils internalised the lectin as shown in Figure 5.10.  
 
Figure 5.10: Internalisation of galectin-3 by activated human neutrophils. Human neutrophils were 
isolated from healthy volunteers using dextran sedimentation and then incubated with recombinant 
galectin-3 (10nM or 1M) for 2 hours at either 4C or 37C, following this cells were washed with 
lactose to remove any surface bound galectin and then fixed overnight at 4C. Fixed cells were 
permeabilised and labelled with antibodies for galectin-3 and the expression assessed by Flow 
Cytometry. Data are expressed as mean  SEM, n = 3 per group, *** P < 0.001 vs all other 
treatments as analysed by two-way ANOVA with Bonferroni post hoc test.  
An adoptive transfer model was used to determine whether murine neutrophils were 
able to bind or produce galectin-3. Bone marrow neutrophils were isolated from 
C57BL/6 mice using negative selection and labelled with CFSE, these cells were then 
injected into galectin-3 knock out mice via tail vein injection and 15 minutes later 
peritonitis was induced with 1mg zymosan i.p. Four hours later the peritoneal cavities 
were lavaged and the leukocytes obtained fixed in 1% PFA overnight; the following day 
the leukocytes were permeabilised and labelled with galectin-3 antibodies. Cells which 
were positive for CFSE were assessed for their expression of galectin-3. 
Murine bone marrow neutrophils express low levels of galectin-3 compared to those 
that extravasate to the peritoneal cavity in response to zymosan-induced peritonitis. 
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When comparing galectin-3 expression levels from bone marrow neutrophils and 
CFSE-positive neutrophils collected from the peritoneal cavity of galectin-3 null mice 
following adoptive transfer a decrease was observed (Figure 5.11). This decrease can 
be explained by secretion of the lectin into the surrounding tissues during trafficking to 
the peritoneal cavity.  
 
Figure 5.11: Galectin-3 expression in murine neutrophils following adoptive transfer of C57BL/6 
neutrophils to galectin-3 null mice. Bone marrow neutrophils were isolated from male 10-week old 
C57BL/6 mice using negative selection and labeled with CFSE; these cells were transferred into 
galectin-3 null mice using i.v. tail vein injection and 15 minutes later peritonitis was induced using 
1mg zymosan. Four hours later peritoneal lavages were performed and the collected leukocytes 
were fixed, permeabilised and assessed for their intracellular expression of galectin-3. Figure shows 
CFSE-positive cells as analysed by Flow Cytometry and graph comparing bone marrow neutrophils to 
adoptively-transferred neutrophils galectin-3 expression. Data are expressed as mean ± SEM, n = 4-
6 per group, ** P < 0.01 vs bone marrow neutrophils as determined by two-tailed T-test.  
This data strongly suggests that murine neutrophils do not produce galectin-3 but 
rather bind it following its release from other cellular sources. In order to determine the 
source of the galectin-3 an air pouch model of inflammation was used. The murine 
dorsal air pouch model is a manufactured cavity induced by injection of sterile air 
subcutaneously into the dorsal flank of the mouse; this cavity is absent of resident 
macrophages and thus a useful model removing a major source of galectin-3 that could 
bind to exudated neutrophils. Briefly 3mL sterile filtered air was injected 
subcutaneously into the back at day 0 and again at day 3, at day 6 zymosan 
(1mg/mouse) was injected into the pouch and following 4 and 24 hours the mice were 
sacrificed and the pouches lavaged. Collected leukocytes were labeled with Ly6G 
(clone 1A8) to identify neutrophils and then fixed and permeabilised to assess the 
intracellular expression of galectin-3 in these neutrophils.  
CHAPTER 5: RESULTS (3) 
176 
Initially a differential leukocyte count was performed using Ly6G and F4/80  antibodies, 
this demonstrated that, similar to the peritonitis assay, neutrophils were the 
predominant leukocyte type at 4 and 24 hours post zymosan administration (Figure 
5.12).  
 
Figure 5.12: Differential leukocyte count for air pouch exudate at 4 and 24 hours post zymosan 
administration. An air pouch was established by injection of 3mL sterile, filtered air at days 0 and 3, 
at day 6 zymosan (1mg/mouse) was injected into the pouch and after 4 and 24 hours the mice were 
sacrificed and the air pouches lavaged. The collected leukocytes were labelled with Ly6G and F4/80 
to determine numbers of neutrophils and monocyte/macrophages respectively. Data are expressed 
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The intracellular expression of galectin-3 was assessed by labelling fixed and 
permeabilised cells with galectin-3 antibodies. Galectin-3 levels in murine neutrophils 
collected from the air pouch were similar to the peritonitis model of inflammation with 
high levels of galectin-3 expressed at 4 hours post zymosan administration, which 
increased at 24 hours as shown in Figure 5.13. 
 
Figure 5.13: Galectin-3 expression in neutrophils recruited to the murine dorsal air pouch in 
response to 1mg zymosan over 4 and 24 hours. An air pouch was established by injection of 3mL 
sterile, filtered air at days 0 and 3, at day 6 zymosan (1mg/mouse) was injected into the pouch and 
after 4 and 24 hours the mice were sacrificed and the air pouches lavaged. The collected leukocytes 
were labelled with Ly6G and then fixed and permeabilised prior to labelling with galectin-3 
antibodies. The intracellular expression of galectin-3 was determined by Flow Cytometry. Data are 
expressed as mean ± SEM, n =4 per group, *** P < 0.001 vs 4 hour as analysed by two-tailed T-
test.   
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5.3 Discussion 
Using a resolving model of inflammation, a difference in leukocyte recruitment was 
evident between control C57BL/6 and galectin-3 null mice with the latter demonstrating 
higher neutrophil and lower non-classical monocyte/macrophage percentages in the 
peritoneal cavity during the resolution phase. This difference in neutrophil number 
could not be explained by a deficiency in phosphatidylserine exposure. Imagestream 
analysis was utilised to identify whether efferocytosis levels were different between 
genotypes, however only low percentages of monocyte/macrophages contained 
neutrophils (approximately 2% in both genotypes) potentially due to antigen loss as a 
result of efferocytosis.  
It is clear that neutrophils express galectin-3 intracellularly at 4 hours post zymosan 
injection and therefore neutrophils must either produce the lectin or internalise it 
following binding to the neutrophil surface. Unfortunately a pure population of 
neutrophils could not be obtained using either negative or positive selection in order to 
assess mRNA expression and therefore it was important to see if galectin-3 could be 
bound by cells following release from other cellular sources.  
An adoptive transfer model demonstrated that in the absence of galectin-3 from other 
cellular sources (using null recipient mice), wild-type bone marrow neutrophils 
exhibited lower galectin-3 levels following extravasation into the peritoneal cavity. This 
is in contrast to the higher expression levels observed in peritonitis experiments using 
wild-type mice adding support to the hypothesis that galectin-3 is released from other 
sources that subsequently neutrophils can bind. Resident macrophages were unlikely 
to be the source of this galectin-3 as increased expression is still seen in neutrophils 
recruited to a manufactured air pouch that lacks resident macrophages. 
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6 Discussion 
Galectins-1, -3 and -9 play important roles in inflammation via interactions with 
leukocytes. Various animal models of inflammation have demonstrated roles for 
galectins-1 and -9 in the attenuation of inflammation due to reduced leukocyte 
recruitment (Cooper et al., 2012, La et al., 2003, Sakai et al., 2011, He et al., 2009); 
while others show that a genetic knockdown of galectin-3 leads to decreased leukocyte 
recruitment, demonstrating a role for this lectin in perpetuating inflammatory responses 
(Colnot et al., 1998b, Hsu et al., 2000).  
As myeloid cells are able to bind galectins-1, -3 and -9, yet these galectins may have 
opposing effects, it can be hypothesised that mechanisms are in place to allow specific 
galectins to be dominant dependent on the environment at a given point in time. Such 
mechanisms may include modulation of the cellular glycophenotype in response to the 
inflammatory milieu or specific cell-cell interactions leading to modifications of the 
binding permissibility for particular galectins, as they exhibit different affinities for 
different carbohydrate residues. This can be seen with naïve thymocytes which are 
unable to bind galectin-1 until treated with neuraminidase due to the presence of an 
α2,6-linked sialic acid capping structure on a galectin-1 receptor (Earl et al., 2010). 
Another possibility may be a modulation of the expression of galectins by the cells 
pertinent to the inflammatory response over the course of inflammation. This is seen 
with endothelial cells, which express increased levels of galectins-1 and -9 in response 
to activation while levels of galectin-3 are not affected (Thijssen et al., 2008). 
The major aims of this thesis were to assess the PMN glycophenotype in response to 
transendothelial migration and activation along with the binding profile of galectins-1, -3 
and -9. The galectin expression profile was also assessed in an in vivo resolving model 
of inflammation to determine the spatio-temporal expression of each of the galectins 
within myeloid cells. Finally an investigation into the cellular localisation and potential 
role of galectin-3 in the resolution process was performed.  
It was demonstrated that the PMN glycophenotype is modulated by transendothelial 
migration; this modification occurs as a direct consequence of trafficking through the 
endothelium as it could not be mimicked by neutrophil activation or treatment of the 
neutrophils with conditioned medium from activated HUVECs. Secondly it was 
demonstrated that although lectin binding can estimate galectin binding permissibility 
for neutrophils it wasn’t accurate enough to confidently determine binding, although this 
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has been previously demonstrated for T cells and endothelial cells (Toscano et al., 
2007, Mercer et al., 2009, Croci et al., 2014). It can be hypothesised that neutrophil 
glycophenotypic changes are a result of a modulation of the glycoproteins expressed at 
the cell surface upon activation and not due to the actions of glycosylation enzymes 
within the cell. This discrepancy with T cells may be due to the shorter lifespan of the 
neutrophil or the more limited functionality of the neutrophils compared to T cells, which 
can differentiate into Th1 or Th2 cells depending on the extracellular milieu and thus 
may require more glycophenotypic modulation. It was found that the expressions of 
galectins-1, -3 and -9 are modulated over the course of a resolving inflammatory 
response allowing different galectins to be dominant at different times in the response. 
Finally a role was determined for galectin-3 in the resolution of inflammation as 
galectin-3 null mice demonstrated a failure to clear neutrophils and an excess of non-
classical monocyte/macrophages at late time points (96 hours) suggesting a 
dysregulated resolution process compared to age- and sex-matched C57BL/6 controls.   
6.1 Glycophenotype and Galectin Binding Profile of 
Neutrophils  
Plant-derived lectins are a useful model for determining the cellular glycophenotype as 
they have well-defined specificities for glycan residues; these can also be used to 
assess lectin binding permissibility. Galectins-1, -3 and -9 exhibit different binding 
preferences for glycan residues and therefore a combination of lectins can be used to 
estimate galectin binding permissibility. Galectins are defined by their ability to bind -
linked galactose and thus RCA120 can be utilised as a marker for the overall 
permissibility for galectin binding (Goldstein et al., 1981, Baenziger and Fiete, 1979). 
Galectin-1 binds mono-LacNAc residues following removal of the 2,6-linked sialic acid 
capping structure and thus an increase in PNA binding and a concurrent decrease in 
SNA binding could be indicative of increased permissibility for galectin-1 binding 
(Stowell et al., 2004, Leppänen et al., 2005, Ahmad et al., 2002). Galectin-3 binds poly-
LacNAc residues and the binding is enhanced by -linked fucose residues and thus 
increased binding of LEL and UEA I could be indicative of increased galectin-3 binding 
permissibility (Rabinovich and Toscano, 2009, Merkle and Cummings, 1987). Galectin-
9 binds poly-LacNAc residues expressed on complex tri- and tetra-antennary N-
glycans following removal of the 2,6-linked sialic acid capping structure and thus 
increased binding of LEL and PHA-L with decreased binding of SNA can be used to 
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indicate an increase in the permissibility for galectin-9 binding (Rabinovich and 
Toscano, 2009, Sato et al., 2002a).  
Studies have been previously published that utilise lectin binding assays to determine 
galectin binding permissibility in T cells and endothelial cells. Rabinovich et al 
demonstrated that Th1 cells have a lower level of sialylation compared to Th2 cells, 
which results in increased binding of galectin-1 to the Th1 cells and increased cell 
death (Toscano et al., 2007). Similar results were seen when an assessment of the 
glycophenotype of human duodenal samples was performed; Th1 and Th17 cells 
within the duodenum bound PNA with an increased affinity compared to Th2 cells while 
these Th2 cells had higher SNA reactivity suggesting increased sialylation of Th2 cells 
and reduced galectin-1 binding (Mercer et al., 2009). Another study demonstrated that 
glycophenotypic changes in the endothelium can impact galectin binding to these cells; 
treatment of the endothelium with immunosuppressive cytokines (TGF-β and IL-10) led 
to an increase in the expression of tri- and tetra-antennary N-glycans and poly-LacNAc 
residues with a concomitant decrease in α2,6-linked sialic acid, which led to an 
increase in the binding permissibility for galectin-1 (Croci et al., 2014). Taken together 
these data indicate that galectin binding permissibility can be extrapolated from 
changes in the cellular glycophenotype for T cells and endothelial cells and thus 
theoretically the binding of galectins to other cell types may also be deduced from 
lectin binding assays.  
As the initial aims of this project were to characterise the glycophenotype and galectin 
binding phenotype of human neutrophils and to determine whether modulation occurs 
upon trafficking a panel of lectins was carefully selected that bind the most common 
terminal residues on glycan chains, particularly those which bind residues that are 
bound by galectins-1, -3 and -9 (Baenziger and Fiete, 1979, Lotan et al., 1975, Merkle 
and Cummings, 1987, Rogerieux et al., 1993, Hormia et al., 1983, Cummings and 
Kornfeld, 1982). Following this freshly isolated PMN were incubated with recombinant 
galectins to determine whether the binding matches the pattern indicated by the lectin 
binding assay.  
It was initially demonstrated in this study that human PMN express a glycophenotype 
characterised by low levels of mono-LacNAc and 1,3-linked fucose residues and high 
expression of -linked galactose residues, poly-LacNAc chains and 2,6-linked sialic 
acid with complex tri- and tetra-antennary N-glycans (Figure 3.1). This correlates with 
the findings of Babu et al in 2009, who showed via mass spectrometry that human 
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neutrophils have predominantly core 2 O-glycans and complex bi-, tri- and tetra-
antennary N-glycans, both with sialylated and fucosylated branches (Babu et al., 2009, 
Haslam et al., 2008). The high level of sialylation present on freshly isolated human 
neutrophils is indicative of a low level of permissibility for galectins-1 and -9 binding 
(Stowell et al., 2004, Leppänen et al., 2005, Ahmad et al., 2002, Rabinovich and 
Toscano, 2009, Sato et al., 2002a). The low level binding of galectin-1 was confirmed 
by recombinant galectin binding assays however the binding of stable, recombinant 
galectin-9 to freshly isolated PMN was higher than indicated in the lectin binding assay. 
This would suggest a receptor for galectin-9 is constitutively expressed on the 
neutrophil cell surface and this corroborates findings from Vega-Carrascal et al who 
demonstrated the expression of Tim-3 on naïve human neutrophils (Vega-Carrascal et 
al., 2014).  
Two populations of PMN were collected from the 6-well adhesion assay; those that had 
not adhered to the endothelial surface following 30 minute incubation and those that 
had. Non-adherent PMN had extremely high RCA120 reactivity and thus β-galactoside 
expression suggesting a high permissibility for galectin binding but no other significant 
modulations from the freshly isolated PMN glycophenotype were seen. This modulation 
is induced by an endothelial cell-derived factor as it is also seen in PMN that are in co-
culture, but isolated from direct cell-cell contact with HUVECs. As the activated 
endothelium is known to be an important source of galectins it is possible that PMN 
that are trafficking PMN bind these more readily than those in the circulation (Thijssen 
et al., 2008). 
The population of PMN that adhered to the endothelial monolayer following 30 minute 
incubation demonstrated significantly less binding of all lectins when compared to 
those that didn’t adhere. The activation of neutrophils is a two-step process in which 
resting neutrophils are primed by a stimulant, including bacterial products, cytokines 
and chemokines; these primed neutrophils are then trafficked to an inflammatory site 
where activation with a secondary stimulant results in full activation (Hallett and Lloyds, 
1995).  
The phenotype of primed neutrophils differs significantly from naïve neutrophils in the 
peripheral circulation due to many factors; granules are mobilised to the surface upon 
priming leading to an increase in specific cell surface molecules including CD11b and 
CD16 (Faurschou and Borregaard, 2003) and the expression of metalloproteinases at 
the cell surface of the neutrophil also increases (i.e. ADAM17) resulting in cleavage of 
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proteins from the cell surface such as L-selectin (Walcheck et al., 2006). As L-selectin 
is a heavily glycosylated protein it can be hypothesised that the loss of this molecule 
and others may result in the overall decrease in glycosylation seen by the neutrophils.  
Binding of galectins-1, -3 and -9 were not modulated by adhesion of the neutrophil to 
an endothelial surface; this was expected from the lectin binding results as although 
SNA reactivity decreased so did PNA and LEL reactivity suggesting that the reduction 
in α2,6-linked sialic acid residues was not exposing underlying mono- or poly-LacNAc 
residues. This somewhat supports the hypothesis that the decreased lectin reactivity in 
adherent compared to non-adherent PMN is due to a removal of cell surface 
glycoproteins and is not a result of glycosylation enzyme activity.  
It is also pertinent to consider the role of plasma proteins in the modulation of the 
neutrophil glycophenotype; studies have shown that plasma proteins such as albumin 
and α1-antitrypsin bind to neutrophils in the circulation, these proteins are heavily 
glycosylated and are also shed from the cell upon activation and transmigration 
(McCarthy et al., 2014). Therefore it can be postulated that the release of these 
glycosylated proteins from the neutrophil cell surface is another cause of the decrease 
in glycosylation seen in the transmigration assay.  
In the transwell transmigration assay two populations of neutrophils were collected 
once again; those that had neither adhered nor transmigrated and those that had 
trafficked through the endothelial monolayer. Although it could be theorised that the 
PMN that didn’t traffic would have a similar glycophenotype to non-adherent cells in the 
6-well assay this was not the case. This was most likely due to the increased length of 
incubation (90 minutes as opposed to 30 minutes) and thus potentially the prolonged 
activity of endothelial cell-derived factors on the PMN. These non-transmigrated PMN 
did not mimic the increase in β-galactoside residues seen in the 6-well assay but an 
increase in SNA reactivity was seen perhaps indicating a capping of newly exposed β-
galactose residues following 90 minute incubation. An increase in fucose expression 
was also demonstrated in these non-transmigrated neutrophils, which was not seen in 
the 6-well assay. Neutrophils require an up-regulation of sialyl Lewis x motifs in order 
to tether and roll on the endothelium as demonstrated by the loss of these functions in 
mice lacking ST3Gal-IV and FucT-VII enzymes (Ellies et al., 2002, Malý et al., 1996); 
thus it can be hypothesised that following 90 minute incubation with activated HUVECs 
glycoproteins have been mobilised to the surface which potentiate trafficking.  
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A more effective way to determine the significance of these changes would be to use a 
single transwell transmigration assay to collect non-adherent, adherent and 
transmigrated PMN and assess thee glycophenotypic changes between the subsets.  
When assessing PMN that had transmigrated through the endothelial monolayer an 
identical pattern was seen to those that had adhered to the HUVECs with all lectin 
reactivity significantly decreased. A similar pattern of decreased glycosylation was 
seen in murine PMN when comparing those in the peripheral circulation to those 
recruited to the peritoneal cavity in response to zymosan.  
PMN that transmigrated through the endothelium demonstrated increased binding of 
recombinant galectin-1 compared to those that didn’t adhere; this is consistent with 
previous reports that demonstrated that primed neutrophils have an increased 
propensity to bind galectin-1 (Almkvist et al., 2002). Transmigrated PMN had a primed 
phenotype characterised by release of secretory vesicles in this study. Transmigrated 
PMN did not demonstrate any increased binding of recombinant galectin-3 compared 
to those that did not transmigrate; galectin-3 is known to bind preferentially to activated 
neutrophils (Karlsson et al., 1998) and thus may explain the lack of reactivity seen in 
this assay as the neutrophils did not become fully activated. The binding of stable, 
recombinant galectin-9 was not changed when comparing PMN that did not 
transmigrate through an endothelial monolayer to those that did.  
An attempt to recapitulate this in a human model of PMN recruitment to an 
inflammatory site using capsaicin-induced neurogenic inflammation gave significantly 
different results from both the in vitro trafficking assays and the in vivo murine assays. 
Fundamental differences can be noted between these assays including that the 
capsaicin-induced inflammation is neurogenic and thus driven by CGRP and substance 
P while both the in vitro and in vivo assays are driven by cytokine-induced inflammation 
(Helme and McKernan, 1985). A difference in the inflammatory site is also important as 
both the in vitro and in vivo studies were performed under sterile conditions while the 
capsaicin-induced inflammation recruited PMN to the buccal cavity, an area highly 
colonised by bacteria. Although no studies have yet been performed to assess the 
variation in neutrophil glycophenotype between sterile and infectious inflammation it 
was postulated that a difference may occur due to the observation in zebrafish 
embryos that neutrophils recruited in response to sterile inflammation have a higher 
propensity for reverse transmigration than those induced in response to infectious 
agents (Mathias et al., 2006, Kolaczkowska and Kubes, 2013).  
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PMN that had transmigrated to an inflammatory site, the buccal cavity in response to 
capsaicin demonstrated an almost complete loss of galectin-1 binding permissibility. As 
galectin-1 has anti-inflammatory effects on neutrophils (Stowell et al., 2009b, Dias-
Baruffi et al., 2010, Cooper et al., 2008, La et al., 2003) it can be postulated that fully 
activated neutrophils lose their reactivity for galectin-1 to prevent these anti-
inflammatory effects inhibiting the actions of the neutrophils. This may also explain the 
failure of resolution in chronic inflammation as anti-inflammatory pro-resolving proteins 
cannot bind to neutrophils as readily. These recruited PMN demonstrated a significant 
increase in the binding of recombinant galectin-3 compared to freshly isolated PMN, as 
galectin-3 is known to bind more readily to activated neutrophils (Karlsson et al., 1998) 
and thus it would be expected that neutrophils at the inflammatory site are more 
permissible for galectin-3 binding. The binding of stable, recombinant galectin-9 to 
neutrophils significantly increased at the inflammatory site compared to those in the 
circulation; high binding of galectin-9 is seen on freshly isolated neutrophils however 
this did not increase during adhesion or trafficking and was only evident at the 
inflammatory site suggesting the presence of additional receptor(s) for galectin-9 that 
are mobilised to the cell surface of the neutrophil upon activation. This may indicate 
that the trafficking process initiates changes in the glycophenotype that are modulated 
further depending on the local inflammatory milieu.  
As a significantly different glycophenotype was seen in trafficked vs freshly isolated 
PMN it was important to delineate the cause of this modulation. PMN in the circulation 
have a naïve phenotype and have yet to release their granules (Borregaard et al., 
1993) however upon activation these follow a specific pattern of granule release 
resulting in a sequential modulation of cell surface proteins to perform specific 
functions. As demonstrated by Figure 3.18 and Figure 3.19 trafficking through an 
endothelial monolayer promotes the release of secretory vesicles and secondary 
granules from the cells while just being in the presence of activated endothelial cells for 
90 minutes is enough to promote the release of the secretory vesicles from the 
neutrophil. Thus the glycophenotypic changes seen during transmigration may be a 
result of granule release from the cell; unfortunately no work has yet been performed 
on the expression of glycosylation enzymes in neutrophil granules however it is known 
that many of the proteins translocated to the cell surface in response to granule release 
are glycosylated and thus may be the source of the modulation (Borregaard et al., 
1993). To test this hypothesis freshly isolated PMN were treated with hrTNF-α or fMLP 
to induce the release of secretory vesicles and secondary granules respectively; no 
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changes were seen in the binding of any of the lectins suggesting granule release is 
insufficient to cause the modulations seen.  
PMN treated with hrTNF-α and fMLP also did not demonstrate modulated binding of 
recombinant galectins-1 and -3 compared to freshly isolated cells suggesting that, as 
with the glycophenotypic changes, this is mediated by transmigration and not merely 
by granule release from the neutrophil. Galectin-9 binding was significantly increased 
upon treatment with fMLP, but not hrTNF-α; this adds evidence to the hypothesis that 
additional galectin-9 receptor(s) are translocated to the cell surface upon activation and 
further demonstrates that the secondary granules are most likely the location of this 
receptor(s).   
It was then hypothesised that the modulations seen in response to trafficking were due 
to the actions of a HUVEC-derived factor on the neutrophil and thus freshly isolated 
PMN were incubated in co-culture with HUVECs but separated from direct cell-cell 
contact by a transwell insert. These conditions failed to modulate the PMN 
glycophenotype to the same extent as trafficking however as a control of unstimulated 
HUVECs co-cultured with freshly isolated PMN was not used it cannot be confidently 
stated that direct cell-cell contact mediates these changes.  
The binding of galectins-1, -3 and -9 are all modulated on human neutrophils under the 
specific conditions analysed however the lectin binding assay was unable to predict 
these changes accurately; this is most likely due to the modulation being a result 
glycoprotein expression changes and not glycosylation enzyme activity. The leukocyte 
adhesion cascade for neutrophil recruitment is well documented and it is known that a 
great number of receptors are upregulated and downregulated from the neutrophil 
surface upon adhesion and transmigration (Wright and Cooper, 2014); as many of 
these are glycosylated and yet not galectin counter-receptors the limitations of using 
whole cell surface lectin binding assays to determine galectin binding permissibility to 
neutrophils become clear. As demonstrated for galectins-1, -3 and -9 the indicated 
permissibility of lectin binding to neutrophils is only an estimate and the results are 
different when galectin binding assays are used.  
6.2 Galectin Expression of Leukocytes 
The expression of galectins-1 and -3 in both human and murine myeloid cells during 
inflammation is well characterised by various groups (Novak et al., 2012, Ho and 
Springer, 1982, Sato and Hughes, 1994, MacKinnon et al., 2008, Gil et al., 2006b, 
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Truong et al., 1993, Farnworth et al., 2008). However the modulation of these proteins 
has not been fully investigated; thus this project aims to determine how their 
expression is modulated following transendothelial migration, inflammatory stimulation 
or recruitment to an inflammatory site. The expression of galectin-9 in human 
neutrophils has not yet been investigated and therefore this study provides novel 
information on the expression of this protein during inflammation.   
Initially isolated human PMN were assessed for their expression of galectins at the cell 
surface and intracellularly and it was determined that galectins-1 and -9 are lowly 
expressed under basal conditions at both locations; this further decreases upon 
transendothelial migration, which correlates with the findings of Gil et al who 
determined that adhesion of human PMN to an endothelial monolayer decreases the 
expression of galectin-1 (Gil et al., 2006b)(Gil et al., 2006b). It has been postulated that 
galectin-9 can compensate for a loss of galectin-1 during inflammation following a 
study that showed increased galectin-9 mRNA in galectin-1 null mice challenged with 
carrageenan paw oedema (Iqbal et al., 2011); thus it can be hypothesised that these 
proteins share many properties and would be expressed at similar times during 
inflammation.  
Galectin-3 is expressed at higher levels than galectins-1 and -9 in neutrophils and the 
expression is predominantly cell surface as determined by comparable levels of protein 
in both cell surface and intracellular flow cytometry assays. Transendothelial migration 
of human PMN did not alter the expression of this lectin. 
In a more pathophysiological model of inflammation PMN were recruited to the buccal 
cavity in response to neurogenic inflammation and the expression of galectins-1, -3 
and -9 compared to that seen in peripheral blood. Contrary to that seen in the 
transendothelial migration assay the levels of galectin-1 were not significantly 
modulated in PMN that had transmigrated to a site of inflammation and this was also 
true for galectin-3. Similar to what is seen during transendothelial migration galectin-9 
levels significantly decrease upon transmigration to the buccal cavity in human 
neutrophils.   
This study on the expression of galectins-1, -3 and -9 on human PMN confirms what is 
known in the literature; that the lectin expressions are modulated by inflammatory 
stimuli, however it is still unclear at which stage of inflammation these are important 
(Liu et al., 1995, Gil et al., 2006b). It can be hypothesised that different galectins are 
expressed predominantly at different stages of the inflammatory process and this 
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allows specificity of their actions. This was therefore investigated further using a model 
of zymosan-induced peritonitis in mice, a model that is well defined and resolves over a 
96-hour time course (Navarro-Xavier et al., 2010, Ajuebor et al., 1999).  
Following confirmation that the model is resolving, ELISAs were performed for 
galectins-1 and -3 to determine the peak expression time points for these lectins in the 
peritoneal cavity. Levels of both galectins were similar in untreated mice however upon 
inflammatory stimulation galectin-1 rapidly decreases while galectin-3 increases 
dramatically suggesting at this time point galectin-3 is dominant in the response. 
Galectin-3 is proposed to be important in leukocyte recruitment while galectin-1 inhibits 
this process therefore it would be expected that galectin-3 be dominant at 4-24 hours 
as this is the peak leukocyte recruitment period  (Nieminen et al., 2008, Norling et al., 
2008). A second peak in the galectin-1 level can be seen at 48 hours, a time point in 
which non-classical monocytes are being recruited and the resolution process has 
begun. This peak in galectin-1 expression at the start of the resolution process was 
also seen in a model of carrageenan-induced paw oedema (Iqbal et al., 2011) and may 
be indicative of a decrease in leukocyte recruitment as resolution begins. As galectin-3 
is considered pro-inflammatory it would be expected to decrease at this stage however 
this did not occur and levels of the lectin remained high until 96 hours when resolution 
had been achieved, possibly suggesting a role for galectin-3 in resolution.  
In this model of inflammation murine neutrophils do not express any galectin-1 or -9 at 
any time point in peritoneal exudate, peripheral blood or bone marrow; galectin-3, on 
the other hand is expressed by all murine neutrophils at relatively low levels except for 
those that have trafficked to the peritoneal cavity where levels are greatly increased. 
This contradicts published work by Sato and colleagues and Farnworth et al who 
suggested that murine neutrophils do not express any galectin-3 (Sato et al., 2002b, 
Farnworth et al., 2008); this may be due to collection methods as this assay kept 
neutrophils on ice until fixed, preventing secretion of the lectin from the cell while Sato 
and Farnworth incubated neutrophils at 37C which would allow secretion. This work 
provides the first confirmation that murine neutrophils do express galectin-3 and that 
this increases as cells are recruited to a site of inflammation.  
Murine monocytes in the bone marrow and peripheral blood express all three galectins 
at low levels and these are all significantly increased in cells that have trafficked to the 
inflammatory site. Due to large variation in the levels of each galectin within a time 
point it was postulated that monocyte/macrophage subtypes may be present that 
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express galectins differentially depending on their function. This would correlate with 
the current literature, as it appears that classical monocyte/macrophages secrete 
galectins-1 and -3 while non-classical monocyte/macrophages do not and thus express 
higher levels of galectins (Novak et al., 2012, MacKinnon et al., 2008, Sato and 
Hughes, 1994, Liu et al., 1995). While the expression levels of galectin-9 have not 
previously been assessed this correlates with the suggested compensation function for 
galectin-1 as these have similar effects (Iqbal et al., 2011).  
It has previously been demonstrated that galectins-1 and -9 are anti-inflammatory 
proteins that act to decrease leukocyte recruitment and promote conversion of murine 
monocytes to a pro-resolving phenotype (Barrionuevo et al., 2007, Rostoker et al., 
2013, Kashio et al., 2003) and thus increased expression of these proteins by non-
classical monocytes/macrophages would be expected as these cells are highly 
implicated in the resolution process. 
This work thus provides the first confirmation that galectin-3 is expressed, or taken up 
by murine neutrophils during inflammation and this is both temporally and spatially 
modulated with recruited neutrophils expressing significantly higher levels of the 
protein. Galectins-1, -3 and -9 are expressed by monocyte/macrophages, also at low 
levels and this is also significantly increased upon transmigration to an inflammatory 
site. It has also confirmed that non-classical monocyte/macrophages express higher 
levels of the galectins compared to classical monocytes possibly due to secretion of 
the galectins by classical monocyte/macrophages.  
6.3 A role for Galectin-3 in Resolution? 
The pro-inflammatory role of galectin-3 has been demonstrated in many models of 
inflammatory diseases; mice lacking this galectin are less susceptible to the 
development of T cell-driven pathologies including experimental autoimmune 
encephalomyelitis, hepatic fibrosis and antigen-induced arthritis (Jiang et al., 2009, 
Henderson et al., 2006, Forsman et al., 2011). This pro-inflammatory role has been 
further characterised in the early stages of an acute inflammatory response where 
galectin-3 null mice exhibit reduced leukocyte recruitment in response to thioglycollate-
induced peritonitis and parasitic protozoan cutaneous infection (Colnot et al., 1998b, 
Hsu et al., 2000, Bhaumik et al., 2013).  
Contrary to these findings other studies have demonstrated that galectin-3 null 
macrophages have defective phagocytic capabilities and alternative macrophage 
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activation; the lectin is also able to induce the exposure of phosphatidylserine and 
subsequent efferocytosis of human neutrophils without a concurrent increase in 
apoptosis and when taken together this suggests that galectin-3 may have a pro-
resolution effect on leukocytes towards the end of an inflammatory response (Karlsson 
et al., 2009, Caberoy et al., 2012, Stowell et al., 2008b).  
Galectin-3 is found at high levels in neutrophils that have been recruited to the 
peritoneal cavity following zymosan-induced peritonitis and while this level peaks 
during the initial stages of the response it remains elevated compared to peripheral 
blood cells until resolution has been reached at 96 hours (Figure 4.16). In 
monocyte/macrophages recruited to the peritoneal cavity the levels are greater than 
that seen in the peripheral blood and this peaks at 72 hours (Figure 4.18). The 
expression of galectin-3 at the later stages of the inflammatory response suggests a 
role for the lectin in the resolution of this response.  
Initially it was essential to confirm that the lectin plays a role in the resolution of 
inflammation; this was assessed by once again utilising the zymosan-induced 
peritonitis mouse model but with galectin-3 null mice, as well as age- and sex-matched 
wild type controls, to determine whether the resolution is impaired in these mice. 
Although no differences could be seen in the number of classical 
monocyte/macrophages when comparing the wild type and the galectin-3 null mice 
(Figure 5.3), it was shown that the knock out mice had reduced numbers of non-
classical monocyte/macrophages at 96 hours (Figure 5.4). This data is in line with 
previous reports showing defective alternative activation of macrophages in galectin-3 
null mice (MacKinnon et al., 2008). Galectin-3 null mice also have increased levels of 
neutrophils at the later stages of inflammation compared to the wild type mice (Figure 
5.2). This is different to what was seen in a model of thioglycollate-induced peritonitis in 
which galectin-3 null mice have fewer granulocytes at day 4 post thioglycollate 
treatment (Colnot et al., 1998b); marked differences are seen in the peritoneal 
inflammatory responses between thioglycollate and zymosan-induced peritonitis with a 
significantly prolonged response in thioglycollate-induced peritonitis thus it can be 
postulated that at day 4 the resolution process has yet to begin and the responses are 
not comparable at this time point (Davies et al., 2013). This data taken together 
confirms a difference in the resolution process when comparing galectin-3 null and wild 
type mice and thus assays were performed to assess the explanation for this 
difference.  
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Galectin-3 is known to function as an opsonin on cells, to prepare them for 
efferocytosis by phagocytes and to promote the exposure of phosphatidylserine (a well 
characterised “eat-me” signal) on activated neutrophils and thus it was important to 
determine whether this was defective in neutrophils from galectin-3 null mice (Sano et 
al., 2003, Karlsson et al., 2009, Stowell et al., 2008b). No difference was seen between 
the strains of mice when assessing the binding of Annexin V, which identifies cells with 
exposed phosphatidylserine or the percentage of F4/80 macrophages containing 
Ly6G-labelled neutrophils suggesting that this mechanism is not defective in these 
mice.  
In order to better characterise the role of galectin-3 on murine neutrophils it was 
important to determine the cellular localisation of this protein. Galectin-3 is known to 
promote the efferocytosis of neutrophils when bound to cell surface receptors by 
inducing the exposure of phosphatidylserine and by acting directly as an opsonin 
(Sano et al., 2003, Stowell et al., 2008b, Karlsson et al., 2009); galectin-3 can also 
inhibit apoptosis when bound intracellularly through interactions with Bcl-2 proteins 
(Akahani et al., 1997). It was therefore important to characterise the location of 
galectin-3 in murine neutrophils at the peak of neutrophil recruitment. At 4 hours 
galectin-3 was predominantly intracellular, by 24 hours this had translocated to the cell 
surface, which may potentially be a mechanism of clearing satiated neutrophils by 
facilitating efferocytosis. This is supported by the fact that at 48 hours galectin-3 was 
localised inside the cell, potentially suggesting that any cells that had cell surface lectin 
were cleared by phagocytes.  
Galectin-3 was expressed intracellularly at 4 hours in the peritoneal cavity; this could 
either be due to production of the lectin by activated neutrophils, or due to binding of 
the lectin to neutrophil cell surface receptors following its release from other cellular 
sources and internalisation. Initially attempts were made to isolate a pure population of 
murine neutrophils from the peritoneal exudate and bone marrow in order to assess 
differences in the mRNA expression for Lgals3, however it was not possible to obtain a 
pure population of neutrophils. Therefore it was essential to determine whether 
galectin-3 can be bound and internalised by activated neutrophils. Human neutrophils 
were isolated from healthy donors as it is easier to obtain a pure population of human 
neutrophils than murine neutrophils. Following activation of these cells with fMLP the 
neutrophils were incubated with a physiologically relevant concentration of galectin-3 
(10nM) and with a non-physiological concentration as a positive control, whilst it 
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appears that galectin-3 can be internalised at 1µM any internalisation at physiological 
concentrations was below the level of detection by Flow Cytometry.  
Although it couldn’t be clearly demonstrated that galectin-3 binds to neutrophils and is 
internalised in vitro it is still a possibility that could occur in vivo and thus it was 
important to determine whether galectin-3 is secreted from other cell types. Murine 
bone marrow neutrophils express low levels of galectin-3 compared to those at the 
inflammatory site and thus these were isolated from wild type mice, fluorescently 
labelled and administered intravenously to galectin-3 null mice. Peritonitis was induced 
in galectin-3 null mice and galectin-3 expression was determined in these fluorescent, 
wild-type neutrophils. If galectin-3 was produced by neutrophils in response to 
inflammation these cells would demonstrate increased galectin-3 levels, however if the 
lectin binds following its release from other cell types there would be no change as 
these mice do not produce galectin-3. The galectin-3 expression of wild type 
neutrophils did not increase in the galectin-3 null mice; this would be expected only if 
the neutrophils generated the lectin, therefore the results support the theory that 
galectin-3 binds following release from other cellular sources.  
The role of resident macrophages in the secretion of galectin-3 was easy to assess 
using a model of murine dorsal air pouch inflammation; a cavity is manufactured in 
which no resident macrophages are located and zymosan is injected into this cavity. 
Upon trafficking of neutrophils to this site of inflammation neutrophil galectin-3 levels 
were assessed and found to be very similar to that seen in the peritoneal cavity.  
Although this assay provided evidence that excluded resident macrophages as the 
source of galectin-3 bound to murine neutrophils it could not discount other cellular 
sources as in both models the neutrophils must pass through endothelial cells and 
stromal cells to reach the site of inflammation, where lots of other inflammatory cells 
are present that are capable of secreting galectin-3 in response to inflammation, for 
example monocytes and endothelial cells.  
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7 Conclusions and Future 
Directions 
In conclusion this study has demonstrated that human and murine neutrophils exhibit a 
modulation of their glycophenotype upon trafficking through an endothelial monolayer, 
however unlike T cells and endothelial cells this does not correspond to changes in the 
galectin binding profile. This is most likely due to the neutrophil cellular glycoprotein 
expression being markedly altered upon trafficking rather than actions of glycosylation 
enzymes as demonstrated in the other cell types. A previous study assessed the 
glycophenotype of naïve neutrophils by mass spectrometry (Babu et al., 2009) and 
thus could be a useful tool for determining the changes seen during transmigration as 
this method determines overall glycosylation changes rather than modulation of the 
terminal residues only, this may help to determine whether the changes seen are due 
to removal of ligands from the surface of the neutrophil or enzymatic activity.  
Galectin binding permissibility is also modulated upon trafficking, with naïve neutrophils 
being more permissive to the binding of anti-inflammatory galectin-1 while activated 
neutrophils at the inflammatory site are more permissive to binding galectin-3 and also 
galectin-9, a novel finding of this study that has yet to be further investigated. The role 
of galectin-9 on human neutrophils has yet to be characterised, this study 
demonstrated that galectin-9 binds to naïve human neutrophils at high levels and this 
increases dramatically upon activation of the cells thus further investigation should take 
place using these two populations of cells including: 
1. Annexin V and PI staining should be performed on naïve and activated human 
neutrophils following treatment with stable, recombinant galectin-9 to determine 
whether this lectin induces apoptosis or the exposure of phosphatidylserine in 
either population of neutrophil 
2. Flow chamber assays should be used to determine the role of galectin-9 on the 
interaction between HUVECs and neutrophils; galectin-9 has been postulated 
to act in compensation for galectin-1 (Iqbal et al., 2011) and as it is known that 
galectin-1 inhibits neutrophil transmigration (Cooper et al., 2008) it can be 
hypothesised that galectin-9 would perform similar roles 
3. The constitutive receptor for galectin-9 on human neutrophils has been 
identified as Tim-3 (Vega-Carrascal et al., 2014), this study demonstrated a 
second receptor for galectin-9 is located in the secondary granules of human 
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neutrophils and thus identification of this receptor would be of great importance 
for the study of galectin-9 on human neutrophils  
The expression of galectins-1, -3 and -9 are spatially and temporally modulated upon 
trafficking of monocytes from bone marrow to peripheral blood to an inflammatory site, 
in this study the peritoneal cavity. These are all expressed at low levels by bone 
marrow and peripheral blood cells but significantly increase upon trafficking to an 
inflammatory site. Higher levels of these proteins were found in non-classical vs 
classical monocytes/macrophages as previously determined in the literature. A recent 
paper demonstrated that the resolution phase of an acute inflammatory response is 
followed by an influx of monocyte-derived macrophages and resident macrophages 
that act to bridge the innate and adaptive immune responses; determination of the 
galectin expression profile of these cells would add a further layer of information to this 
study and help to fully characterise the modulation of galectin expression over a 
resolving inflammatory response (Newson et al., 2014).   
Galectin-3 is found in murine neutrophils, another novel finding of this study, and the 
levels significantly increased as the neutrophils trafficked to an inflammatory site; 
previous studies have designated galectin-3 as a pro-inflammatory lectin however due 
to increased expression during the resolution phase of zymosan-induced peritonitis it 
can be postulated that this protein plays a role in resolution. This was further 
investigated and it was found that the resolution process was dysregulated in galectin-
3 null mice however the exact mechanism of this was not delineated in this study; it 
was demonstrated that neutrophil apoptosis and the exposure of phosphatidylserine 
were unchanged in these mice suggesting no defect in efferocytosis was occurring. 
Secondly it was shown that wild type bone marrow neutrophils adoptively transferred 
into galectin-3 null mice did not demonstrate increased galectin-3 following 
transmigration to the peritoneal cavity; this suggests that the galectin-3 is being bound 
to the neutrophil however does not confirm that murine neutrophils are incapable of 
producing the lectin. Further investigation into the mechanism underlying potential pro-
resolution roles of galectin-3 on murine neutrophils should be performed including: 
1. In situ hybridisation studies or single cell PCR to confidently determine whether 
galectin-3 is produced by murine neutrophils or binds to the cell following 
transmigration to the inflammatory site 
2. The use of other resolving inflammatory models in galectin-3 null mice to 
determine whether the resolution is defective in other models including the 
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K/BxN serum transfer model of arthritis, a model of arthritis in which neutrophils 
are mediators 
3. The determination of galectin-3 expression in neutrophils over the course of a 
chronic inflammatory response such as zymosan-induced peritonitis (10mg 
zymosan/mouse) to determine whether a difference in the expression of 
galectin-3 is seen when resolution does not occur 
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